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Various parameters of the gabavaminergic,ncr-adrenergic and serotonergic c
, cortical innervation were examined during the initiation, development
and eventual resolution of the chronic epileptic focus produced in the
rat by cortical cobalt implant. These parameters included levels of
neurotransmitter, metabolites, synthetic and cat&bolic enzymes, and
E.E.G. correlates. Cobalt levels were assayed in various areas of the
cobalt-implanted rat brains general protein synthesis and certain
aspects of the pharmacology of the serotonergic system in this model
were also investigated.
A hypothesis is offered concerning the possible interactions between
the anterior Raphe nuclei, as a cortical synchronising organ, and
the electrical events in the cortex associated with the epileptic
focus.
The study of the gabbaminergic system was confined to assaying
gamraa-aiaino butyrate transferase (GARAT), as glutamate decarboxylase
(GAD) and GABA had already been examined in this modelj the GABAT
assay was intended as a link between the information already available
and the new data concerning the nor-adrensrgic (KAd) and serotonergic
(5KT) systems. It was found that levels of this enzyme follow a very
similar pattern to the thirty-day cycle as previously established in this
model in the KEG Brain Metabolism Unit, falling during the first four
days after implant and only returning to normal in primary and secondary
focal areas at around day 30* A temporary peak of GABAT at day 9 was
ascribed to the glial reaction that develops at this stage.
Tyrosine hydroxylase f'TOH), mono-nniirin mh d n *r-> (KAC,)}
o-methyl transferase (CQMT) in primary and secondary focal areas also
fell to very low levels during the first few days after implant, but
only returned to normal after 75 - tOO days. This time-course agreed
with the metabolite data. Homovanillie acid (K7A) and 3-methoxy U-
hydroxy phenyl glycol (HMPG) levels were measured in parallel groups
of rats. The changes in TOH were restricted to the NAG nerve-terminals,
as no similar change could be detected in. the cell bodies in locus
coercions. CQMT and MAC peaked shortly before GABAT, and were also
ascribed to the gliosis; the HMPG peak that also developed at this
stage was thought, to bo linked to the altered enzyme levels.
Using atomic absorptiometry, significant amounts of cobalt, were found
in the secondary focus and other cortical areas, and it is suggested
that the secondary focus may not be the biochemically "pure" model
it has previously been assumed to be. The diffusion or other transport
of cobalt from the implant area is discussed in terms of the possible
effects of cobalt poisoning of the enzymes assayed.
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SUMMARY
I The neurological basis of the epileptic condition in one
experimental model, the cobalt-implanted rat has been investigated
with a view to attempting to link the epileptic condition to one or
more of the sub groups of central neurones, as defined in terms of the
neurotransmitter. It was hoped that any evidence of preferential
involvement during the development of epilepsy might serve as a basis
for farther analysis and/or clinical work.
II Many authors have suggested that the seizure threshold in many
models of epilepsy may be related to alterations in the activity of
central monoaminergic systems. Therefore a group of related enzymes,
neurotransmitters and their metabolites were assayed in different
areas of the brain including the primary and secondary foci at a
range of times after the implantation of a cobalt pellet into rat
frontal cortex, a procedure that initiates an epileptic process.
Hie time course of any changes found was compared to the development
of the epileptic state as measured behaviourally and by computer
analysis of the EEC. These studies were a continuation of the
large body of work already carried out in the M.R.C. Brain Metabolism
Unit concerned with monitoring biochemical changes in the cobalt-
implanted rat.
III The basic programme of work for this thesis began very broadly,
employing a wide spectrum of tests as a method of screening as large
a range of parameters as possible; following the first detection of
a second series of tests was
abnormalities/employed to examine more closely the anomalous data,
particularly that related to the serotonergic system. Because of
this method of approach, and also because each tissue sample repres-
2
ented one ret which had been operated on, and subsequently recorded
and observed for periods of up to 100 days, the number of rats sampled
in certain tests, as recorded in the results section, was necessarily
limited. This problem was exacerbated by the operated rats' Increased
susceptibility to respiratory disease and respiratory failure during
the first month after operation.
XV The mechanisms involved in the development of the secondary focus
were investigated. Using fIssueless atomic absorptiometry, it was
shown that cobalt was present in the cortex contralateral to the
implant at 6 days post-implant. Treatment of the animals during
the first week post-implant with acetoxycyclohexlraide was shown to
depress rates of cerebral protein synthesis by 60%, but did not affect
the development of the secondary foveas, as measured in the EEG.
These findings suggested that the formation of the secondary focus
may be influenced by cobalt in the contralateral cortex, and seem
to argue against the theory of a "learning" process contributing to
the developing electrical changes in the secondary focus.
V Gamma aminobutyrlc acid transferase (GABA-T), an enzyme associated
with gabaminergic neurones, was found to be initially reduced in both
primary and secondary epileptic foci, suggesting that gabaminerglc
neurones may be in some way involved in the development of the
epilepsy.
VI Various parameters of the central catecholaainergic nervous
systems were examined. Levels of enzyme activity of tyrosine
hydroxylase (TOH), catecholamine-O-methyltransferase (COOT), monoamine
oxidase (MAO) were also reduced at an early stage in both primary
and secondary focal areas, and with the exception of a temporary
3.
increase in MAO and CC&JT mainly in the area of the primary focus
thought to he <hie to a glial reaction, were still subnormal in
both foci at 30 days post-implant but had returned to normal by
100 days. Changea in cortical protein content were also noted,
the protein/wet weight ratio becoming reduced at 3 days after cobalt
implantation in the primary focus and at 6 days in the secondary,
and remaining low for at least 30 days. The rapidity of the
changes suggested that the changing protein/wet weight ratio was an
indication of the development of cerebral oedema, and all of the above
enzyme data were therefore expressed in relation to total protein
rather than per wet weight of tissue.
VII TOH activity in mid-brain sections containing the locus
coeruleus, the location of the cell bodies of the noradrenergic
neurones, was unaffected in epileptic rats, as were cortical
concentrations of noradrenaline (NAd). Striatal and cortical levels
of 4-ttydroxy-3-raethoxyphenylglycol (IJMPG), a cerebral metabolite of
NAd, showed increases on the lesion and contralateral sides by 8 days
post-implant, but had returned to normal by days 15-20 post-implant.
A cerebral metabolite of DA, homovanillic acid (HVA) in the striatum was
also raised at 4 days, and had still not normalised at 20 days. To
account for the apparently paradoxical situation of low enzyme
activities (T0H, MAO and CGMT) occurring together with raised
metabolite concentrations, a reduction in transport of the metabolites
from the brain is postulated.
VIII The serotonergic (5-hydroxytryptoar;inergic) system was also
examined. Various parameters remained unaffected, including cortical
5-HT (5-hydroxytryptamine) concentrations, and rates of cortical 5-HT
uptake. In the cortex, levels of tryptophan, the amino acid precursor
4.
of 5-HT, were low at 6 days post-implant and elevated to above
normal by 30 days. Concentrations of the 5-IfT metabolite. 5-
hydroxyindole aoetie acid (5-HIAA) fell at 15 days post-implant
around the primary focus and at 20 days in the secondary focus, and
had returned to normal at 100 days. There was evidence of a
transient increase in cortical 5-HIAA at 4 days post-implant, and a
more consistent elevation of striatal 5-HIAA levels, lasting until
24 days* These findings, like thfeoe of increased catecholamine
metabolite concentrations which occurred over a comparable period,
are also suggestive of a block of metabolite transport from the brain.
IX Tryptophan hydroxylase activity in sections of mid-brain contain¬
ing- the raphe nuclei which contain the cell bodies of the serotonergic
neurones was reduced at 20-25 days. In an attempt to analyse further
the reduction in cortical 5-HIAA and mid-brain tryptophan hydroxylase
activity, a group of epileptic rats was given loading doses of trypto¬
phan. The subsequent increases in cortical and striatal 3-HT and
5-HIAA did not differ significantly from control animals.
X A survey of the literature on the relationship between serotonergic
tone and the seizure threshold is presented, and on the basis of this
data and the results detailed in this thesis the hypothesis is put
forward that the serotonergic system responds in a protective manner
to the epileptic condition by reducing turnover of 5-HT; it is also
suggested that the degree of serotonergic activity may be critical
in determining the seizure theshold. This hypothesis has been tested
by examining the effects of drugs, known to act on the serotonergic
system, on the EEC of the cobalt-implanted rats. Preliminary
observations have indicated that increasing cortical 5-HT concentra¬
tions by tryptophan loading aggravates epileptic behaviour, but when
s.
clorgyline, an MAO inhibitor, is given in conjunction with the
tryptophan loading, all epileptic signs were reduced. However the
development of epilepsy in cobalt-implanted rats was found to be
unaffected by a long-lasting central 5-ifT depleting agent, 5,7-
dihydroxytryptamine, and furthermore tolazoline, a drug thought to
include a blocking effect on central 6-HT receptors amongst its actions
was equally ineffective as an antlepileptic. The theory of the
relationship between serotonergic tone Mid the seizure threshold is
re-evaluated in the light of these observations.
6.
MATERIALS
X. All inorganic salts used were of "analytical reagent" grade or
better.
2. Water used was all distilled in all-glass apparatus and deioniaed
using Elgastat equipment.







































































Krebs-Ringer bicarbonate buffer (g/1): NaCl, 6.92; KC'l, 0.35;




























iC toluene, 0.5t triton X-100
4.0 g PPO (2,5, diphenyloxazole)











Appendix 1. Material used in recording unrestrained, conscious rats:




This section contains details of all the methods used in this
thesis. It includes the preparation of the experimental animals, the
subsequent recording of ECoG's, dissection techniques and the method¬
ology of the biochemical assays.
A. Mechanical procedures
I. Method <af cobalt implantation.
II. Recording techniques.
III. Collection and storage of brain tissue samples.
IV. Dissection techniques.
V. General preparation of brain tissue samples for enzyme assay.
B. Enzyme assays
I. Y-aminobutyric acid (GABA) transaminase (GABAT).
II. Tryptophan hydroxylase (Tryp. OH).
III. Tyrosine hydroxylase (TOH).
IV. Catechol-O-methyltransferase (COMT).
V. Monoamine oxidase (MAO).
C. Assays of neurotransmitters, and their precursors and metabolites.
I. Noradrenaline and dopamine (NAd and DA).
II. Homovanillic acid (HVA).
III. 4-hydroxy-3-methoxyphenylglycol (BMPG).
IV. Tryptophan.




Ib. Estimation of rates of cerebral protein synthesis.




The model used in this series of experiments to study the bio¬
chemistry of an epileptic type of brain malfunction consisted of rats
which were given a cobalt implant into the cortex. This implant
induced the formation of an epileptic , focus first on the ipsl-
lateral side and, in due course, on the contralateral side.
Subsequent to the cobalt implantation the development and persistence
of these epileptic foci were monitored by EEC recordings. Changes
in the concentrations of putative central neurotransmitters and of
their synthetic and catabolic enzymes were also monitored, both in
the foci and in other brain areas, with a view to possibly relating
the electrophysiological and biochemical events in some unifying
hypothesis.
I. Method of cobalt implantation into rats' brains with subsequent
recording of electrocortlcogram (ECoC).
The cobalt was implanted as a suspension in solidified gelatine,
prepared according to the method of Fischer et al. (373). Cobalt
powder (5ml, Sigma, mesh 200) was added to 5ml 5% (w/v) aqueous
o
gelatine solution at 56 C. The suspension was thoroughly mixed, and
allowed to settle for 2 mln. Two ml of the supernatant were decanted
to remove fines and the remaining 8m1 suspension poured over horizontal
microscope slides to form a layer approximately 0.75 mm thick. After
cooling, the cobalt gelatine films on the slides were immersed in acetone
for 2h to dehydrate the gelatine, and then placed in a desiccator
containing paraformaldehyde for 2h to allow fixation of the gelatine.
The slides were then steeped in distilled water and finally stored in
80% (v/v) ethanol.
Slides were removed from the alcohol 5-lQm.in.before use, to allow
the alcohol to evaporate from the gelatine film. Discs (1mm diameter)
for implantation in rat cortices were cut as required from the cobalt-
gelatine film with a 1mm punch. The cobalt content of such a disc
was estimated from the dilution of the cobalt powder used to be of the
order of 500-750pg. "Glass implants" were prepared using the identical
procedure, using ground glass (Mesh 175, Sigma) in place of the
metallic cobalt.
Operative technique
The following procedures concerning the operation and subsequent
recording of the EEG from the cobalt-implanted rat are all derived
from work carried out in the MRC Brain Metabolism Unit at Edinburgh
University (References 125, 354 and 567).
All surgical procedures were carried out under aseptic conditions.
Male Piebald Virol Glaxo (PVG) rats (2~ months old, 200-250g) were
anaesthetised with halothane (Fluothane, ICI) in oxygen (2.5 l/ain).
A halothane concentration of 11% was used for Induction and 7-0% for
maintenance of anaesthesia. The scalp was shaved using an electric
hair trimmer, and swabbed with 5% iodine solution in ethanol. A
mid-line incision (l.S-2.5c» long) was made on the scalp, and the
underlying fascia was reflected to expose tits outer surface of the
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skull. After locating the coronal and sagittal sutures, the skull
was trephined, the hole being centred at a point 2 mm from each
suture in the right anterior quadrant. The hole was made with a
dental drill (Renda model RA/21) and a round No. 6 burr (Ash), oare
being taken not to damage the underlying dura. Haemorrhage from the
skull did not constitute a major problem. A cobalt implant was made
into the frontal cortex as follows. At the site of implantation the
dura was split with the tip of a sterile 23-gauge needle. A disc of
cobalt-gelatine was cut from a prepared film using a 1mm diameter
tissue punch fitted with a plunger, and inserted into the superficial
layers of the underlying cortex. The punch wes so tapered that it
protruded a set distance through the standard hole drilled in the
skull with a No. 6 round burr, thus controlling to some extent the
depth of the implant. The hole in the skull was then sealed with
bone wax and the whole operative area was sprayed with antibiotic
(Polybactrin). The incision was closed with Michel clips. The
whole operative procedure took between 10 and IS min.: no special
postoperative care was found to be necessary. The Michel clips
were removed 7 days later when tha wound had completely healed.
in the case of an animal whose REG was to be recorded, the
operation procedure was modified to include the fitting of permanent
electrodes.
1) Using the same equipment and preoperative procedures as above, a
curved cranial incision (2.3 cn, long) was made through the scalp close
to the left eye. The skull was cleared, and the coronal, sagittal
and naso-frontal sutures located and used as landmarks to ensure
consistent placement of the recording electrodes. The skull was
trephined, pairs of holes being centred 2 mm on each aide of the
sagittal and coronal sutures. Cobalt-gelatine implantation into a
frontal cortex was carried out as above, and then the burr-holes
were tapped with an 8 EM tap (or alternatively counter-sunk with a
no. 9 round burr). Specially constructed stainless steel screws
were inserted into the holes, to act as extradural recording:
electrodes (374). It was found necessary to secure the screws to
the bore using cold-curing acrylic resin (Simplex), and to aid this
purpose a groove had been cut round the body of the screw. One of
the electrodes was placed directly over the implant, and one in each
of the other three holes. Fig. l shows the design of the screws
and their placement in the skull. The operation area was then
sprayed with Polybactrin and the skin flap replaced after four holes
had been punched in it so that it fitted over the electrodes and
allowed them to protrude externally. The wound was then closed
with Michel clips. This whole procedure took between 30 and 45 tain;
again, no special post-operative care was found to be necessary.
In general screws have remained! irra in situ for periods of 6 months
or more.
II. Recording Techniques
REG recordings were made from the unrestrained, conscious rat.
Spring-connectors (Amphenol) attached to braided wire (Grass) were fitted
into the hollow electrodes, and brain potentials were recorded on a
Grass Model 7 Polygraph, the controls of which were set as recommended
for the recording of the human EEG. The EEGs were simultaneously
recorded on tape using a Tandberg l.R. series 100 tape recorder, with
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tape speed of 1— inches per s. and input range of 2v. The tapes were
subsequently used for computer analysis and 'spike' counting (507).
Recording sessions were standardised as far as possible, par¬
ticularly with regard to the time of day and the sequence of recording
the individual animals in any group, as there had been reports (52,
576) of diurnal fluctuations in the seizure threshold of various
epilepsy models. To allow time for the dissipation of the stress
induced in the animals by handling and their transfer to the novel
environment of the recording cage, an interim period of 10 min. was
allowed between electrode connection and subsequent recording. The
recording was carried out over the subsequent 10 min. period, the ECoG
of the lesioned and contralateral cortices being recorded simultaneously.
For the purpose of the experiments reported in this thesis, the EEC
recordings were analysed and described in terms of the number of spikes
produced in a given time.
The tape recordings were analysed using a comjngSsr programme
developed by Hill and Townsend (567), which operates by dividing EE&
phenomena into spikes or waves, on the basis of the peak angles of all
the wave forms. This programme has been designed to monitor 10 min.
recordings, and gives a figure for the total spike count over the 10 min.
The values cited in the relevant sections of the thesis are given as
spikes/ain., averaged from a 10 min. recording.
III. Collection and storage of brain samples for biochemical analyses
Groups of experimental animals were stunned and decapitated at set
times, from 5 to 100 days, after cobalt implantation. The brains were
removed immediately, wrapped in aluminium foil, and stored in liquid
nitrogen until all the rats in any one experiment had been sampled.
In practice no tissue sample was left in liquid nitrogen for longer
than 25 days before being used for analysis. In those series containing
15.
"Ions-term" (85-100 days post-implantation) animals, these latter
animals were operated on 2-3 months before the 'short-term' ( 30 days)
animals in the particular expert ent. Generally, one control rat was
killed with each experimental group, ensuring that the control brain
samples were stored over similar lengths of time as experimental brain
samples. 'Control animals' have refers to both unoperated litter-
mates of the experimental animals, and to aliam-operated animals.
These latter were operated on exactly as the experimental animals,
but no cobalt was placed into the cortex. Some of this latter group
were given 'glass-in-gelatine' implants (prepared according to
Fischer (373). The type of control used in each experiment is stated
in the report of the results.
IV. Dissection of brain samples for the biochemical analyses
A) Cortex and Caudate
When the collection of brains from a series of experimental
animals had been completed, the brains were removed one at a time from
the liquid nitrogen and placed cm a 2aa thick glass plate resting on
a mixture of solid CO^ and crushed ice. Tissue samples were cut as
the tissue thawed and became workable. In the case of samples of
tissue containing the site of implant, all visible pieces of cobalt-
gelatine were removed as was any calcified tissue.
Cortical samples were dissected as follows. The brain was
placed on its ventral surface on a glass plate resting on a mixture
of crushed ice and solid CO . The cerebellum was removed, and the
forebrain bisected. The curved tip of a micro-spatula was then
inserted into the lateral ventricle, passed rostrally and caudally
and the cerebral cortex reflected laterally. For some of the less
sensitive assays (generally those depending on fluorimetric methods)
the cortical tissue thus obtained was bisected coronally to give
samples weighing 40-60 tag. For the more sensitive radiometric
assays, scalier samples (15-25fi»g) were obtained using a 4 or 5 am
diameter stainless steel punch to cut discs of tissue centred on the
sites of the primary and secondary lesions in the cortical slabs.
Samples of the caudate nuclei were prepared as follows. After
placing the brain on its ventral surface, the forebrain was cut
through coronally S and 10 sm from the occipital cortical extremity.
The 2 cue thick forebrain section thus obtained was then laid on the
glass surface, and discs of approximately 5mg from the caudate nuclei
were cut out using a 2 mm diameter stainless steel punch
B) Raphe nuclei
The method developed was based on a diagram (Fig. 2) of the
central 5-ITT systems published by Fuxe et_ ajL (552). At predetermined
times after cobalt implantation, a rat was stunned and decapitated.
The brain was rapidly removed and placed on its ventral surface on an
o
aluminium block cooled to 0 C on a bed of crushed ice. The cerebellum
was then gently separated from the cortices, peeled back along the
midbrain and removed. The spinal cord was cut at the level of the
median cerebellar penduncles. A scalpel blade was inserted between
the occipital cortices and the pre-optic tecta, and with this cut the
forebrain removed. The optic and pre-optic tecta were then severed
with a horizontal cut at the level of the third ventricle. Finally
a cut was made along the ventral surface of the midbrain from the
level of the pyramids caudally, removing the ventral third of the
midbrain section. The section remaining contained the rostrally
Fig. 2
Serotonergic systems within the rat brain
C.Cortex . Hippocampus
Cerebellum
N. Caudatus / Stria Terminalis
.fied from Fuze, Hokfelt, Olson, and Ungerstedt Cpl;.
Anteriorly projecting cell groups
Posteriorly projecting cell groups
Area disected.
TABLE J. Tryptophan hydroxylase activity (n.mol. 5-hydroxyindoles/g brain/h)
and 5-ET concentrations (ug 5HT/g brain)in sections of mid-brain.
Using the dissection techicraes described in Methods section A IV, a range of
mid-brain sections were cut as follows:
A Sections of whole mid-brain - that segment remaining after removal of the
cerebellum, section of the spinal cord and removal of the fore-brain.
B As in A, but after removal of the optic and pre-optic tecta.
C The severed optic and pre-oj^tic tecta.
D As in B, after removal of the ventral third of the mid-brain. This section
was used in all succeeding experiments.
Enzyme activity (n,mol. 5-hydroxyindoles produced/g brain/h)
A B C D
1.2 2.3 nil 2.3
1.4 2.7 nil 2.8
1.6 2.1 nil 2.3
.1,6 2.1 nil 2.6
1.45 + 0.16 2.0 nil 2.2
2.24 + 0.24 2.44 + O.22
Amine concentrations (ug 5.KT/g brain)
A. B C D
1.11 1.31 0.29 1.15
0.93 1.53 0.37 1.08
0.87 1.27 O.22 1.21
0.95 1.3 0.28 0.94
0.97 + 0.1 1.64 0.29 + 0.OS 0.92
1.41 + 6.17 1.06 + 0.13
17.
projecting raphe nuclei, and left out the caudally-projecting
nuclei. As all cortical serotonergic innervation derives from the
anterior nufclei, it was thought that any responses in these nuclei
to cortical events would be diluted if all nuclei were included in the
sample for analysis. To check on the accuracy of this dissection,
tryptophan hydroxylase activity (Methods BID was assayed in various
parts of the midbrain. It was established that the method described
above did in fact provide a section of tissue with the highest enzyme
activity/weight ratio (Table 1), suggesting that the anterior raphe
nuclei had been effectively sampled.
The typical weight of this section was 165-185 mg. Dissected
samples were stored in liquid nitrogen until all had been collected
from a series of animals killed at different times after implantation.
Tryptophan hydroxylase assays were then all carried out on the same
day, necessitating a period cf storage, in seme cases, of up to 25
days. As one control animal was killed with every group of experi¬
mental animals and the control group showed in itself little "between
animal" variation, it was assumed that no significant loss of enzyme
activity occurred over this period.
V. Preparation of brain extracts for the estimation of the activity
of various enzymes
The activity of the following enzymes, tyrosine hydroxylase (TC3H),
monoamine oxidase (MAO), catechol-O-methyl transferase (CGMT) and
ganraa-amlnobutyric acid aminotransferase (GABAT), were estimated in
samples of rat brain using radiometric assays. Samples were
prepared for assay as follows.
18.
o
All procedures were carried out at 0-4 C. Weighed samples of
brain, weighing typically between 20 and 30 mg (either freshly
removed or from storage for up to 25 days in liquid nitrogen) were
homogenised in 10 volumes of buffer in an all-glass homogenlser for
2.5 min. at 3,000 r.p.m. The homogenising buffer consisted of
0.1M K^HPO^/NaHgPO^ buffer pH 6.8 containing 1 rag 2-mercaptoethanol/ml,
and made 0.5% v/v with Triton X-100. Homogenates were transferred
to 1.5 ml reaction tubes and centrifuged at 12,000 g for 10 min. at
o
0 C in an Eppendorf Zentrifuge. Samples of the clear supernatant
were used for the radiometric assays of the enzymes mentioned above,
and for protein estimation. This tissue preparation procedure was
a modification of that of Hendry and Iverson (353) in their assay of
tyrosine hydroxylase in rat brain.
B. ENZYME ASSAYS
1. Estimation of ^ -aainobutyric acid (CAM)-transaminase activity
of brain tissue
This assay was based on the method of Hall and Kravltz (574).
The method basically consists of the incubation of a preparation of
14
brain with C-labelled -amlnobutyric acid (GABA under suitable
conditions, in which the amino group of the GABA is catalytically
transferred to an acceptor, a-ketoglutaric acid, by the transaminase
enzyme. For quantification, the unused labelled substrate is removed
by adsorption on a cation exchange Aesin, and the unabsorbed deamlnated
reaction products from the GABA, succinate and succinic semialdehyde,
estimated by scintillation counting. Excess succinate is added to the
incubation mixture to reduce further metabolism of the labelled
succinate formed in the main reaction.
5ftl of the supernatant fraction of samples of brain prepared as
described in Methods section A, part V, were added to an incubation
mixture, total volume 50f*l containing the following:
150 nmol unlabelled CAM, 100 nmol o-ketogluarate, 2 fuaol 2-
mercaptoethanol, 100 nmol NAD, 100 nmol sodium succinate, 20 nmol
14 14
pyridoxal phosphate, 5.0 nmol C-GABA (4-amino-n-(U- C) butyric
acid, sp. act. 150 mCi/mmol, and 5 ptnol potassium glycylglycine,
which last was previously adjusted with 5M K0H to pH 8.5 (glass
electrode). The final pH of the incubation mixture was close to
8.3 (glass electrode).
Incubations were carried out in stoppered 1.5 ml polycarbonate
o
tubes at 37 C for lh. The reaction was stopped by adding 5 pi tri¬
chloroacetic acid (0.4g/ml) and the whole reaction mixture was then
applied with washing with 50|il distilled water to a cation exchange
column, containing Dowex-50x2, 100-200 mesh. The columns, 3cm x
0.5cm dia., were washed with 20 ml 25 mH HC1 before use. A^ter
application of the incubation mixture the resin column was washed
with 5 ml distilled water, and the effluent containing the reaction
products of the incubation, was collected. After mixing, 1 ml was
added to 10 ml Triton scintillant for subsequent counting in a
Hewlett-Packard scintillation counter for 10 min., external ratio
mode. A second 5 ml wash of distilled water of such solumns was
found to contain very little radioactivity (100-150 cpra/ml).
The Dowex column quantitatively retained GABA, as measured by
the very low values of tissue bl&iffika (200-500 cpm), obtained from
incubates prepared by adding the trichloroacetic acid to the tissue
extract before the mixture containing the substrate. All tissue
Fig. 3
GABA transaminase activity in cortical homogenates as a
function of pH of incubation
Enzyme activity expressed as percentage of mean activity at
pH 7 (330 +13.3 (6) n.mol. GABA transaminated/g protein/h.).









Linearity of GABA-transaminase activity in relation to enzyme
concentration in cortical homogenates
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1. A fixed volume of each homogenate was added to a standard incubation
mix.
Z. 1/10, 1/20 etc. refers to lmg. tissue in 10, 20, etc. fils homogenising
buffer.
3. All points on graph refer to x + SD1 for groups of 8 replicate samples.
20,
samples giving- counts less than twice those of the "tissue blanks"
were assigned 'nil' values.
14
The specific activity of the C-GABA in the reaction mixture
14
was 4.84 oCi miuol, close to the specific activity of the C-GABA
originally used by Hall and Kravitz (574). As the specific activity
of the i4C-GABA from Amersham was so such higher than the 14C-GABA
they used, a dilution with unlabelled GABA was decided on to make the
assay more economical. The addition of 150 nmol unlabelled GABA
brought the overall concentration of GABA in the reaction mixture to
2.82mM, which Hall and Kravetz suggested ensured enzyme saturation
conditions.
Since both succinic semi-aldehyde and succinate are present in the
column effluent, this nethod is therefore not affected by changes in
the activity of succinic semialdehyde dehydrogenase in the tissues
being analysed. Further degradation of the formed succinate with
14
concomitant loss of C was reduced to a minimum by the presence of
excess added succinate in the incubation mixture. The validity of the
enzyme assay as described was checked by establishing a linear relation¬
ship between enzyme activity and the concentration of the tissue
homogenate (Fig. 4) and by establishing that the pH profile of the
enzyme matched already existing data (Fig. 5).
II. Estimation of tryptophan hydroxylase (EC 1,14.36) activity
in rat brain
The method of estimation was based on that of Bauisgarten at al
(243) which was itself a modification of the procedure reported by
Friedman et al (244). Basically, a homogenate of brain containing
the enzyme tryptophan hydroxylase is incubated with L-tryptophan,
and after the reaction has been terminated 5-HT and 5-HIAA are
21.
estimated fluorimetrically in the incubation mixture using the
method of Bogdanski et al (240).
The estimation procedure detailed here proved sufficiently
sensitive to assay tryptophan hydroxylase activity in the raphe
nuclei, but not in the small cortical samples (15-25 rag) that were
being used in the assays of other enzymes by radiometric techniques.
Thawed samples containing the anterior raphe nuclei dissected as
described in the methods section A, part IV, were weighed (180.5
0.2 rag, x + SD for one series of 10 samples) and homogenised
immediately in all-glass equipment at 2,000 r.p.ra. for 2 rain, in
5 vol. (5 txl/mg tissue) of 33 mM sodium phosphate buffer pH 7.4
containing 2 mraol dlthiothreitol per litre. Portions of the
homogenates were transferred to 1 ml polycarbonate reaction tubes
and centrifuged for 5 min. at 12,000 g using an Eppendorf 'Zentrifuge'.
o
All steps were carried out at 0-4 C. Bsmticate samples, 100 (il, of
the supernatant, were taken for subsequent estimation of enzyme
activity. Each supernatant sample was transferred to a 1 ml reaction
tube, containing a mixture of 1 pi catalase solution (55,000 units activity/
ml), 10 pi 2 mM L-tryptophan and 5 pi 10 mM tetrahydrobiopterin.
The L-tryptophan and tetrahydrobiopterin were dissolved in distilled
water.
The reaction mixture was incubated at 37°C for 2 hr after which
time the reaction was stopped by adding 10 pi 6 M-perchloric acid.
The precipitated protein was removed by centrifugatlon for 2.5 rain,
at 12,000 g. Portions, 100 pi, of the supernatant were removed and
o
stored at -20 C until required for assay of the formad 5-hydroxyindoles.
Immediately prior to fluoroassay, 25 pi conc. HC1 (B.D.H. Aristar)
22.
containing freshly dissolved ascorbic acid (0.5 mg/ml) was mixed
with each thawed sample. The procedure of the fluoroassay was
standardised as far as possible. All samples were kept on ice
until immediately prior to reading, when the addition of the HC1
and subsequent transfer of the solution to the micro-cuvette, and
the fluorimetry were timed to the second, using stop-clocks, as
follows: mixing with HCl, 2 sec., transferral to the micro-cuvette
at 4 sec., and activation scans of samples began at 7 sec. The
conditions of fluoroassay were Identical to those described in the
assay of 3-HT and 5-HIAA.(Methods C,V). The amount of 5-hydroxyindoles
formed was calculated from a standard curve of the fluorescence of
authentic 5-HT added to complete but unincubated reaction mixtures.
Two pairs of duplicate samples were taken from each horaogenate of mid¬
brain. One pair was incubated as above for 2h. For estimation
of the endogenous 5-hydroxyindole levels the other pair was stopped
at incubation time zero, which in practice gave readings of slightly
under half of those of the experimental samples. The amount of 5-
hydroxyindoles in each pair was then calculated, and the endogenous
5-hydroxyindole values were subtracted from the post-incubation values
to give a final figure representing 5-hydroxyindoles formed during
the 2 h. incubation. Although in the original method of Friedman
et al (244) it was suggested that a decarboxylase inhibitor should be
used to prevent further metabolism of the formed 5-hydrojcytryptophan
(5-HTP)? Bauugarten et al (243) found this unnecessary. In their
hands the fluoroassay of total 5-hydroxyindoles (5-HT, 5-HIAA and
5-HTP if aj»y) proved an accurate and relaible index of tryptophan
hydroxylase activity. They also suggested that by not using an MAO
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1. A fixed volume of each homogenate was added to a standard incubation
mix.
a. 1/5, 1/7.5 etc. refers to lmg tissue in 5, 7.5 etc. gls homogenising
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increase in the overall rate of bydroxylation, in accordance with the
principle of Le Chatelier. However, with hindsight I now regret
not having used an MAO inhibitor in view of the different relative
molar fluorescence of the 5-hydroxyindoles (238), and the changes in
MAO activity that develop in the cobalt-implanted rat.
The final substrate concentration of L-tryptophan (200 jxM) was a
compromise. At this concentration of L-tryptophan the sensitivity
of the fluoroassay of 5-HT was diminished 3-fold, by a combination of
an elevated background fluorescence plus a degree of fluorescence
quenching. But substrate concentrations also had to be high enough
initially to provide saturating conditions throughout the 2 h. incub¬
ation. Using previously published data on rates of tryptophan
hydroxylation in mid-brain (18), calculation indicated that in the 2 h.
incubation period insufficient of the added substrate would be
metabolised to produce a sub-saturating condition. This was supported
by finding that the hydroxylation did appear to develop linearly over
the 2 h. of the incubation (Fig. 5). The fluorescence readings at
time zero in this table refer to endogenous mid-brain 5-hydroxyindole
concentrations, approximately 1.5 |ig/g wet weight tissue.
The validity of the enzyme assay as described above was also
checked by establishing a linear relationship between enzyme activity
and the concentration of the tissue homogenate (Fig. 6) and by
establishing that the pH profile of the enzyme as assayed here matched
existing data (Fig. 7).
24.
IX* Unsuccessful assay of tryptophan hydroxylase using a
radiometric method
As indicated in the previous section the method for estimation
of tryptophan hydroxylase activity, involving the fluorimetric
measurement of 5-hydroxyindoles produced from tryptophan, was
insufficiently sensitive to detect enzyme activity in small cortical
samples. The adequacy for this purpose of a radiometric assay
described by Bensinger et al (126) was investigated. The principle
of the method is as follows:
3
When (5- H)-tryptophan is hydroxylated at the S-position, the
3
H is shifted to the 4-position (Guroff et al 573), where it exchanges
"4*
readily with H in acidic solutions. The amount of 5-hydroxylation
3
of (5- H)-tryptophan can therefore be measured by the formation of
trltiated water. The method of Bensinger et al (126) separates the
3
trltiated water from unused ( H)-tryptophan substrate by passing
the incubation mixture through an ion-exchange resin which retains
,3 .
the labelled tryptophan, but not the ( H)-water. The ion-exchange
resin used was Dowex 50 x 8 (Hf); Bensinger et al found that this
resin effectively absorbed tryptophan, and also tryptamine and
3
melatonin. They also found that (4- H)-melatonin did not release
,3 %
enough ( H) on acidification to bias the results of the assay, and
therefore felt confident enough to state that when tryptophan
hydroxylase activity was assayed using this method the tritiated
3
water formed was a product only of the 4- H-5-hydroxyindole metabolites
3
formed from 5- H-tryptophan. The following preliminary experiment
was carried out to examine the method, using the experimental
3
conditions detailed by Bensinger e;t al (126)* 50 pmol of L-(5- H)-
3
tryptophan, containing 1 pCi radioactivity (L-(5 H)-tryptophan,
22 Ci/mmol, Amersham) was added to 500 pi 0.1 mM L-tryptophan in
25.
distilled water. This solution of labelled and cold tryptophan
contained the same amount of the substrate as used by Bensinger in
subsequent enzyme assays. The solution was acidified by the
addition of 50 }il ION HC1 and incubated for 15 min. at room temper¬
ature to permit (3H)-(H ) exchange. The solution was then passed
through a 6 x 0.4 cq dia. column of Dowex 50 x 8 (H+) resin, made
up in a Pasteur pipefete. The resin was washed before use with
20 ml 0.1 If HC1. After the sample had passed into the column, the
column was washed with 2 x 4.00 ml 0.1 M HC1, the combined effluents
being collected in a scintillation vial. 10 ml of Triton
scintillant was added to the vial and samples were counted for 10 min.
(external ratio mode), in a Hewlett-Packard scintillation counter.
3
As all ( H) in the solution was theoretically in the 5-position
of the labelled tryptophan, these column effluents should have
3
contained little radioactivity since 5- H does not readily exchange
with Hi, and both labelled and unlabelled tryptophan should have been retained
on the columns. However, the effluents when counted were found to
4 4
contain 1.0-1.5% (1.5 x 10 - 2.0 x 10 counts/min.) of the amount of
3
the ( H) applied to the column. To determine whether these counts
were due to incomplete retention of tryptophan on the column or to the
3 3
presence of either ( H) water or L-(4- H)-tryptophan in the sample from
Aaersham, the initial acidification and incubation of solutions of
labelled L-tryptophan were repeated, but after incubation the pH of
the solution was altered using 0.5M NaOH to discover the optimal
conditions for retention. The pH of the wash was altered to match,
using different Tris (hydroxymethyl) methylamine buffers, 25 mil.





















































































retention was of the order of 96.14%. The (presumably) optimal
results published by Bensinger et al are an order better than this,
indicating a column retention of 96.92% efficiency; it seemed that
the high reagent blank values obtained here could have been due to
3
incomplete column retention and/or the presence of exchangeable H
s
in the sample from Amersham. This latter factor is probably involved
to some extent as Bensinger reports some degree of non-enzymatic
+ 3
exchange of (H ) with the (5- H). Hie blank values were considered
unacceptably high for the proposed enzyme assays and the method was
therefore not pursued further. A preliminary purification of the
3
H-tryptophan by ion exchange chromatography would have resulted in
excessive dilution of the labelled compound.
III. Estimation of tyrosine-3-hydroxylase (TOH) activity in rat brain
The activity of the enzyme tyrosine 3-hydroxylase (L-tyrosine
tetrahydrobiopteridine: 0^ EC 1.14.16.2) was estimated in samples of
rat brain using the method of Hendry and Iverson (353).
The basis of the reaction Is as follows: an extract of brain
3
is incubated with H-labelled tyrosine in the presence of an inhibitor
of aromatic amino acid decarboxylase. At the end of the incubation
period the amount of tritiated 3:4-dihydroxyphenylalanine (Dopa) forced
is measured. This is proportional to the degree of tyrosine hydroxy¬
lase activity of the tissue extract. The incubation mixture
3 3
containing both H-Dopa and H-tyrosine is passed through an alumina
column. The tyrosine does not adsorb to the alumina and is washed
out with a dilute buffer. The Dopa however is retained until
3
eluted by an acid wash, a sample of which is then taken for H
counting.
3
H-2:3 side chain L-tyrosine (8 fig/ml, sp.act. 20 Ci/mnol,
Amersham) was purified before use by incubation for 30 tain, with
3
alumina, to remove any H-labelled catechol conpounds that may have
o
been present as impurities. This procedure was carried out at 0 C.
3
100 pi of the ( H) L-tyrosine solution was added to a mixture of 100 pi
of alumina slurry (*Neutral'sxade, alumina Woelne, Eschwege:10 rng/100 pi
distilled water) and 200 pi 5nM Tris (Tris-hydroxymethyl methylamine)
buffer, pH 8.6. This mixture was shaken continuously for 30 min.
using a mechanical shaking apparatus with sufficient force to keep the
alumina in suspension. It was then centrifuged at 12,000 g for 1 min.
The supernatant was used as the purified tyrosine substrate in the
tyrosine hydroxylase assays. To produce enough substrate solution
for 1 enzyme incubation 5 pi of the purified tyrosine solution was
added to 5 pi of 0.2 M sodium phosphate buffer pH 6.0, containing
25 nmol tetrahydrobiopterin (Roche), 6.25 mmol mercaptoethanol, and
3.05 nrnol 3-hydroxybenzyloxyamine (NSD-1055, Smith and Nephew) as the
decarboxylase inhibitor. This was a concentration of NSD-1055 that
had previously been found to effect a complete inhibition of aromatic
amino acid decarboxylase activity, as measured using the method of
Fonnum o_t al. (377). The final substrate solution, vol. 10 pi,
3
contained 66 pmol (1 pCi) H-2,3- side-chain L-tyrosine. To this
was added an equal volume (10 pi) of tissue extract, prepared as
described in the methods section A pt.III .The reaction was allowed to
o
proceed for 20 min. at 37 C in a 1.5 ml stoppered Eppendorf reagent
tube, and terminated by adding 200 pi 1 M perchloric acid, containing
1 pg L-Dopa as a carrier. The acid solution was then brought to
approximately pH 8 by the addition of 4.0 ml of a solution made up of
0.1 M Tris-(hydroxymethyl) methylamine, 0.005 M Na Edetate, and 0.075 M
28.
NaGH. The solution was then passed through a 5 x 0.25 cm (dla.) column
of 'neutral' alumina, which had been previously washed through with
15 ml of S rM Trie buffer, pH 8.6. The unabsorbed unreacted
tyrosine was washed out of the column by the passage of 40 el 5 wM
3
Tris buffer pH 8.6, over 10-15 tain. The H-Dopa was subsequently
eluted from the column using 3.0 ml 1.0 M-acetic acid, and a sample
(1.0 ml) of the 3.0 ml eluate was added to 10 ml Triton scintlllant
(made up as specified in 'Materials'). The radioactivity
of the samples was estimated in a Hewlett-Packard scintillation
counter, (external ratio mode) the number of counts over 10 min. being
recorded. The recovery of dope through the whole procedure was
measured as follows. 0.05 nmol l4C-L-Dopa was added to a tissue
3
hooogenate (containing no H-tyrosine) and then processed through the
method,and the same amount of **C-Dopa was added directly to the
effluent of a delicate tissue sample processed through the method.
The ratio of counts thus obtained gave a figure of around 75%.
(Actual data, 73% + 6.6% (10)). Tissue blanks were prepared in
parallel with the samples of brain tissue, prepared by adding the
perchloric acid to the tissue extract before adding the substrate
solution. They gave counts of between 500-1,000 cpa. Nil values
were assigned to all tissue samples with tyrosine hydroxylase
activity less than 0.12 nmol dopa produced/# proteln/h, or less than
double the counts produced by tissue blanks.
A sub-saturating concentration of tyrosine was used (8 pM), as it
has been found that, probably because of certain impurities typically
present in the tyrosine, and a degree of non-enzymatic tyrosine
hydroxylation, the sensitivity of the assay can best be increased by
Fig. 9
Tyrosine hydroxylase activity in cortical homogenates as a
function of pH of incubation
Enzyme activity expressed as percentage of mean activity at
pH 6.5 (4.53 0.16 (4) n.mol. Dopa produced/g protein/h.).
Vertical bars show standard deviation of 4 replicate samples at
each pH value.
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1. A fixed volume of each homogenate was added to a standard incubation mix.
2. 1/10, 1/20 etc. refers to Img tissue in 10, 20 etc. fxls homogenising
buffer.
3. All points on graph refer to x ^ SD' for groups of 8 replicate samples
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reducing tissue blank values (353). No significant loss of enzyme
activity was found over periods of up to 25 days when the brain tissue
was stored in liquid nitrogen: control groups of rats, the brains of
which were stored for different lengths of time, showed no greater
variation in levels of enzyme activity than groups of freshly killed
rats. The validity of the enzyme assay as described was checked by
establishing a linear relationship between enzyme activity and the
concentration of the tissue homogenate (Fig. 9), and by establishing
that the pH profile of the enzyme matched already existing data
(Fig. 10).
IV Estimation of catechol-0-icethyl transferase (CCMT) activity
in rat brain
The arthod based on that of Axelrod and Tomchick (351) was as
follows, An extract of brain was incubated with a suitable substrate
for 0-methylation, in this case 3.4-dihydroxyphenylethyleneglycol
14
(DOPEG), in the presence of a C-labelled methyl donor, S-adenosyl-L-
14
methyl- C-methionine (SAM). The amount of methylated substrate
produced in a standard time was a measure of the OCBiT activity in the
14
tissue extract. The C-methyl labelled metabolite, 4 hydroxy-3-
iuethoxyphenylethylene glycol (HtiPG) was separated from the unused
14
. C-SAM, by a process of phase partitioning, and a sample of the phase
containing the HMPG was then taken for counting of the radioactivity
as a measure of the amount of metabolite formed.
Stock solutions were prepared in distilled water immediately
before beginning the assays. The contained DOPEG (2 mg/ml), MgCl^,
Ciy) (5 mg/ml), 0.5 M NaH2PO4/K2HP04 buffer pH 7.8, and 5-adenosyl-L-
(methyl-C14) methionine, 125 nmol/ml, S.A. 40 mCi/mmol, (Araershatn) -
stock solution.
The incubations were carried out in 1.3 ml stoppered polycarbonate
reaction tubes. The total volume of each Incubation (54 pi), was
made up of 10 pi DOFEG solution, 20 pi solution, 10 pi Na/K
phosphate buffer, 10 pi of a ten-fold dilution in water of the stock
SAM solution and 4 pi of a brain extract prepared as previously described
Q
(Methods A III). This reaction mixture was incubated at 37 C for
60 min., when the reaction was stopped by the addition of 1 drop conc.
HC1. Solid sodium chloride was then added to saturation followed by
500 pi water-saturated ethyl acetate (chromatography grade). The
reaction tubes were shaken vigorously by hand for 3 min. and then
centrifuged for 2 min. at 12,000 g in an Eppendorf centrifuge. A
sample, 400 pi, of the organic phase containing the HMPG, was added
to 200 pi 0.1 U HC1 in a 1 ml polycarbonate reaction tube and the
mixture shaken and centrifuged as before; this washing procedure was
14
included in the method to ensure complete removal of the C-SAM in
an attempt to lower tissue blank values. A sample, 250 pi, was taken
from the upper organic phase and added to a scintillation vial
containing 10 ml Triton scintillant. All counting was done on a Hewlett-
Packard scintillation saunter for 10 min. external mode. Tissue blanks,
prepared with every series of assays, were of the order of 200-500 c.p.m.
and represented from l%-5% of the range of control enzyme values. They
were prepared by adding the conc. HC1 to the brain extract before the
incubation mixture, followed by the otherwise normal assay procedure.
'Nil* values for the enzyme activity were assigned to samples of tissue
with carr activity of less than 14 nmol HMPG formed/g proteln/h,
equivalent to twice the 'tissue blank' counts. The validity of the
enzyme assay as described was checked by establishing a linear
rxg. xx
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Linearity of COMT activity in relation to enzyme concentration in cortical homogenates
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relationship between enzyme activity and the concentration of the
tissue homogenate (Fig. 11), and by establishing that the pH profile
of the enzyme matched already published data (Fig. 12).
V. Estimation of monoamine oxidase activity in rat brain
The method used was an unpublished modification by ftuaon of the
method of McCaman and McCaman (352).
The basis of the assay is as follows. An extract of brain is
14
incubated with C-tyramine, and after a standard incubation period
14
the unused substrate is removed into an organic phase. The C-
labelled metabolite, p-hydroxyphenylacetic acid, is measured in a
sample of the aqueous phage to give an index of the amount of mono-
14
amine ocidase activity. 1 Kg 1C-tyramine hydrochloride in
10 {Al 0.1N HC1 (317 pCi/mg, 55 mCi/mmol) was made up in 1.0 ml of
distilled water containing 1 mg ascorbic acid. Equal volumes of
this and 0.4 M sodium phosphate buffer pH 7.8 constituted the
reaction medium.
3
2 |*1 of the reaction medium containing 4.3 x 1C c.p.m. was
added to 2 pi of the brain extract (prepared as in Alii) in glass
o
micro-tubes, and the mixture was Incubated for 13 lain. at 37 C. The
reaction was stopped by placing the micro-tubes in ice-water. The
contents of each tube was washed out into a 10 ml test-tube with
2.0 ml 10 phosphate buffer pH 7.0. To this solution was added 1 ml
of a reagent consisting of 15 mg sodium tetraphenylborate/ml ethyl
butyl ketone. The unused tyramine substrate was extracted into the
organic phase by shaking gently the mixture in the stoppered glass
tube for 5 rain., followed by centrifuging at 2,000 g for 5 min. A


















































Linearity of MAO activity in relation to enzyme concentration in cortical homogenates
1/10 1/20 1/100
Homogenate dilution
fixed volume of each homogenate was added to a standard incubation mix.
'10, 1/20 etc. refers to lmg in 10, 20 etc. gls homogenising buffer.
.1 points on graph refer to x + SD' for groups of 9 replicate samples.
D
V
from the lower aqueous phase. As the tip of the pipette was lowered
through the upper organic phase, air was gently expelled from the
pipette to prevent any of the organic phase front entering the tip.
The sample of the aqueous phase was then added to 10.0 ml Triton
scintillant and counted in a Hewlett-Packard scintillation counter,
for 10 min., external mode. Tissue blanks were prepared by adding
brain extract to incubation medium as above, but leaving the mixture
in ice-water for 15 min. before processing as for other samples.
The tissue blanks gave counts so low (300-000 cpm) as to suggest a
nearly total transfer of unused tyramino to the organic phase -
that is, better than 99.0%. Nil values were assigned to samples with
MAO activity less than 0.4 pmol tyramine oxldlsed/g protein/h,
equivalent to sample counts less than twice the *tissue blank* counts.
The validity of the enzyme assay as described was checked by
establishing a linear relationship between enzyme activity and the
concentration of the tissue homogenate, and by showing that the pH
profile of the enzyme matched already published data (Figs. 13 & 14).
C. ASSAYS OF NEUROTRANSMITTERS. EfiECURSOKS AND METABOLITES
I. Estimation of noradrenaline (NAd) and dopamine (DA) in rat brain
This jrocedure was based on the method of Schlumpf e_t al (24).
o
All the following steps were carried out at 0-4 C. Sections of
brain, 20-25 mg, were weighed and homogenised (1 mg in 10 pi) in
HCl-butanol (850 pi cone. HC1, BDH 'Aristar* in 1 litre n-butanol,
spectroscopy grade), for 1 min. in an all-glass homogeniser, working
capacity 500 pi. The homogenate was transferred to a 1.5 ml
Eppendorf reagent tube and centrifuged for 3 min. at 12,000 g. A












































































to 400 pi heptane (BDH, spectroscopy grade), and 90 pi 0.1 M HC1, in a
1.9 ml polycarbonate reagent tube. The mixture was shaken vigorously
by hand for 10 mln. and then centrifuged as before to separate the two
phases. The upper organic phase was carefully removed, and a portion
of the aqueous phase (40 pi) taken for either NAd/DA estimation (below)
or for 5—HT estimation (cv).
To 40 pi of the aqueous phase in a 1.9 ml polycarbonate reaction
tube was added 10 pi 0.4M HC1 and 20 pi EETA/sodiu® acetate (4>» sodium
acetate, 5 mM Na Edetate, pH 6.9), followed by 20 pi iodine solution
(0.1M in ethanol) for oxidation. The reaction was stopped after
120 sec. by the addition of 20 pi of a solution of sodium sulphite
in NaOH (0.9g Na-SQ,.7H_0 in 2ml HO + 18 ml 9M NaOH), and after a
* a 2 2
further 90 sec. 20 pi 10 M acetic acid was added. The solution
o
was heated, in the sealed reaction tube, at 100 C for 13 min.,
conditions which were found to be the optimal compromise for the
simultaneous development of both the NAd and the DA fluorophore
(Fig. 19). Samples were then rapidly cooled to room temperature,
and each transferred to a microcuvette (capacity 200 pi) for
fluorimetry in a Perkin-Elmer spectrofluor^veter, MPF-2A. The
excitation (and occasionally the emission) spectrum was recorded from
each sample: excitation and emission wavelength maxima were respec¬
tively 399nm and 483nm for the NAd fluorphore and 330nm and 379nm for
and X = 3^5 nm
that from DA. The excitation spectrum was recorded between X = 439 nm
for NAd, and between X = 280nm and X = 380nm for DA. Various
primary and secondary filters were tried, but none were found to have
any significant effect on the method. The slit widths of both
excitation and emission monochromators were generally set at 9 nm.
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These figures all refer to uncorrected instrument values.
Using the above conditions the excitation spectra showed no
evidence of any cross-interference. Flurophore-containing solutions
derived from pure samples of NAd gave nil readings when the recording
conditions were set for DA, and vice versa. Quantification was by
comparison with standard curves obtained by processing aqueous
solutions of the two amines through the method, and further corrected
using a method recovery estimate, obtained as follows. Identical
amounts of NAd and DA (50 ng of each) were added to a control
homogenate and then processed through the method. The same amounts
were also added directly to the final 40 pi acidic phase from a
duplicate tissue sample. When the fluorescence readings due to
endogenous amines had been subtracted from each 'total' fluorescence
value (including endogenous and the exogenous amine) this gave a
figure for recovery of the amines through the method of 51% + 7% (DA)
and 42% +5.5% (NAd) from a series of 8 duplicate samples. This
correction was used when referring fluorescence readings in tissue
samples to the standard curves. The amount of each amine used (50 ng) had
previously been found to occur within the linear amine concentration/
fluorescence intensity range.
The sensitivity of the fluor©assay (arbitrarily assessed as that
amount of the amine which produces a fluorescence equal in size to that
of the tissue blank) was approximately 15 ng of either amine; the
degree of fluorescence attributable to this amount of exogenous amine,
when added to a control homogenate of 25 mg cortex, was approximately
double that of 'tissue blanks'. 'Tissue blanks' were obtained by
adding the acetic acid to the amine-containlng extract before the
sodium sulphite, and adding the iodine last of all.
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II. Estimation of homovanllllc acid (HVA) in rat brain
The method is based on those of Whiter and Eccleston (562) and
of R>os (211). The extraction procedure described in this method is
also suitable for use in conjunction with the fluoroassay of 3HIAA,
which is extracted like the HVA into the 0.15 II sodium borate buffer
(below). This method was used for one series of 5HIAA assays mainly
to verify data generated using a different extraction technique
(Methods C, section V). The particular analytic method employed la
noted with each series of estimates cited in the results section.
Samples of brain tissue were processed as follows. After
weighing, the samples (20-35 mg) were homogenised at below 5°C in 2.5
ml 0.4 M-perchloric acid in an all-glass apparatus. The homogenate
was transferred to a 5 ml glass test-tube with one wash of 0.5 ml
0.4 M-perchloric acid. The combined homogenate and wash was then
o
centrifuged at 10,000 g for 15 min. at 0 C. The supernatant was
removed and adjusted to pH 4-5 (glass electrode) with 3 M-K0U. After
o
15 min. at 5 C, to obtain maximal precipitation of the potassium
perchlorate, the sample was centrifuged at 3,000g for 10 min, and the
supernatant was transferred to a C24 ml glass test-tube containing
50 fil of a freshly prepared 2 mg/ml solution of ascorbic acid. The
sample as adjusted to pH 2.5 (glass electrode) using 2 N HC1, then
saturated with NaCl. The phenolic aclda were extracted into butyl
acetate (B.D.H. redistilled and water-saturated) by shaking the
sample twice for 5 min, eachtlme with 10 ml of the solvent. The
butyl acetate extracts, 9 ml and 10 ml respectively, were combined
after separation from the aqueous phase by centrifugatlon at 2,000 g
for 5 min.
The phenolic acids were returned to aqueous solution by shaking
the pooled butyl acetate extract for 5 Bin. with 1.4 ml 0.15 M sodium
borate buffer, pH 8.6. After centrifugation at 2,000 g for 5 min, the
upper organic layer was aspirated off and a 500 pi portion of the
aqueous phase was placed in a 1.5 ml poly reaction tube containing
200 pi of an alkaline potassium ferrlcyanide reagent. This reagent
made up Immediately before use, consisted of 25 ml 9 M ammonium
hydroxide solution to which was added 100 pi of a stock solution
of potassium ferricyanide of 11 rag/ml. After 4.0 min. the oxidation
was terminated by the addition of 50 pi of a freshly prepared 1.75 mg/ml
solution of cysteine.
The fluorophore thus obtained from HVA was stable for several
hours, and has a maximum activation wavelength of 320 nm and a maximum
fluorescence wavelength of 425 nm. (uncorrected instrisaent settings)
For each sample, activation spectra were recorded from 260 nm to 360 nm,
using a Perkin-Elmer spectrofluorimeter model MPF-2A with the slit
widths on both monochromators set at 8 nm, and the emission nonochromator
set at 425 nm. The fluorescence intensity at peak fluorescence
( X = 320 nm) was used as a measure of the fluorophore content, in
relation to those of aqueous standards (10-200 ng), processed through
the method. These amounts of HVA all fell within the linear range of
the HVA concentration/fluorescence intensity curve.
Tissue blanks, obtained by mixing the fluorophore-developing
reagents (the cysteine and ferricyanide solutions) together Mfore
adding them to the HVA-containing fraction, were as low as reagent
blanks. The recovery of HVA through the method was derived as
follows: 40 ng of HVA was added to a control homogenate of 25 mg
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cortex, and also directly to the final 500 pi aqueous sample derived
from a duplicate cortical sample. The recovery of HVA through the
method was derived from the ratio of the fluorescence attributable
to the exogenous HVA when added either to the homogenate or to the
500 pi aqueous sample. The figure was 25.8% _+ 7.25 (8). The sen¬
sitivity of the assay, arbitrarily assessed as that amount of
exogenous HVA, which when added to a control homogenate of 25 mg
brain and processed through the method produced a fluorescence equal
in size to that of a tissue blank, was of the order of 40 ng.
III. Estimation of 4-hydroxy-3-methoxyphenylethylene glycol (IR1PG)
in rat brain
The method of estimation was based on that described by Walter
and Eccleston (562). Weighed samples of brain (10-20 mg) were homo-
o
genised at 5 C in 2.5 ml 0.4 M perchloric acid, in an all-glass
homogeniser. The hosaogenate was transferred to a 5 ml centrifuge
tube with washing with a further 0.5 ml 0.4 M perchloric acid,
and the combined homogenate and washings centrifuged at 10,000 g for
15 min. The pH of the supernatant was adjusted to between pH 4-5
(glass electrode) with 5 M-KQSI and the sample was kept for a further
o
15 min. at 5 C to obtain maximum precipitation of the potassium
perchlorate. The sample was centrifuged at 3,000 g for 10 min. St
o
5 C, and portions of the clear supernatant were taken for HlPG assay.
HMPG exists in the brain both as the free compound and as its
sulphate ester (Scbanberg et si. 578). The brain extract was
treated therefore to hydrolyse the sulphate conjugate prior to
assaying total HMPC- content. A 3 ml sample of the clear supernatant
from the homogenisation stage was adjusted to pH 5.0 using 206 pi
1.0 M sodium acetate buffer pH 5.0, and incubated at 37°C for 16 h in
a stoppered 1.5 ml polycarbonate reaction tube with 100 pi of a
50 mg/rnl solution of the sulphataso-containing enzyme preparation
"Ifelicase" (Industrie Biologique Francais). The H^PG was extracted
into ethyl acetate (Reeve Angel Scientific Ltd., C.T. grade) by
shaking the sample twice for 5 tain, each time, with 8.0 ml and then
5.0 ml of the solvent. The ethyl acetate extracts, 7.0 ml and 5.0 ml
respectively, were combined in a 100 ml round-bottomed flask, after
separation from the aqueous phase had been aided by centrifugation
at 2,000 g for 5 min. and were reduced to a small volume (1-2 ml) by
o
evaporation at 50 C under reduced pressure. The extract was
transferred to a 5 ralglass test-tube and reduced to dryness at 56°C
under a stream of dry JC. The residue was dissolved in 0.4 ml distilled
water, and the IftlPG was acetylated (Sharraan, (563)) by the addition
of 50 pi redistilled acetic anhydride (Sigma) and 0.6 ml of a 16.5%
solution of potassium bicarbonate (Walter, personal communication).
The reaction was allowed to continue with occasional gentle shaking
for 30 min. and the acetyl-HMPG extracted from the aqueous solution
by shaking for 1 ruin. with 1.6 ml l:2-dichloroethane (BDH laboratory
reagent, redistilled). After centrifugation at 2,000 g for 5 min.,
1.3 ml of the bottom organic layer was transferred to a 5 ml glass
stoppered test-tube containing a small quantity of anhydrous sodium
sulphate and shaken to remove residual traces of water. After
cent*ifugation at 10,000 g for 2 min. the 1:2 dichloroethane extract
was decanted into a 2 ml borosilicate test-tube and reduced to dryness
under a stream of N2» at 50°C. The acetyl-HMPG was converted to the
trifluoroacetylated form (Bond, 564) by dissolving the residue in 0.6 ml
"N
of a mixture of 1 vol. redistilled trifluoracetic anhydride (Sigma)
o
and 5 vol. ethyl acetate. The tube was stoppered and heated at 56 C for
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15 itiln. The solution was then blown to dryness under a very gentle
stream of at room temperature, and the residue dissolved in 0.2 oil
ethyl acetate containing 30 ng/nil hexachlorocyclohexane as a marker
to enable variations in final injection volume (into the GLC apparatus)
to be allowed for (Sherman 563). As the injection volume could not be
completely standardised, measuring the HMPG/hexachlorocyclohexane peak
height ratio instead of HMPG peak height alone enabled samples to be
compared directly. Analysis of the sample was carried out on a Perkin-
Elmer 900 gas chromatograph with a 6 ft. column, internal diameter 4 mis.
The stationary phase was 2.5% silicone gum rubber E301 on a support of
Chromosorb GAW L&'CS, 80-100 mesh. The carrier gas was an argon/methane
mixture (90%/10% v/v) with a flow rate through the column of 40 ml/min.
63
Detection was by means of Ni electron capture detector. Polarising
voltage was in the pulse mode with a negative amplitude of 50v and
1 m sec pulse duration. Instrument ovens were set at the following
o o o
temperatures - injection, 270 C; column, 170 C; manifold, 270 C;
o
electron capture detector, 280 C.
Under these conditions the retention time of trifluoroacetyl-
HMPG (7 rain) was half that of the hexachlorocyclohexane marker.
Quantitative analysis was performed by comparison with a standard
curve obtained by processing 1EJPG through the method, adding
standard amounts (10-100 ng) of IfifFG to duplicate samples of cortical
homogenate. Recovery of HMPG through the extraction and derivative
formation was found to be of the order of 30% (35.1/ +3.3 (10)), for 100
of added I&PG. The relationship between the amount of UMPG added to a
standard hotuogenate of brain, and the subsequent peak height on the
G.L.C. was found to be linear over the range 50-150 ng.
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IV. Estimation of tryptophan in rat brain
This procedure was based on the method of liege and Udenfriend
(242) in which the fluorescent norharinan, derived from tryptophan,
is ieasured. Weighed samples of cortex (20-30 sag) were homogenised
in distilled water, 10 pl/mg, at 100 r.p.m. for 2.5 sain. After
centrifugation at 10,000 g for 5 min. 1.00 pi portions of the super¬
natant were added to 1.0 ml trichloroacetic acid (50 g/1) in a 2.0 ml glass
test-tube.
Ten min. after thorough mixing, the contents of the tubes were
centrifuged for 2.5 min. at 2,000 g. 400 pi portions of the super¬
natant were removed and added to 100 pi 0.25 M-H SO and 100 pi
formaldehyde (40g/l) in 1.5 ml polycarbonate reaction tubes. The
o _
tubes were stoppered and heated to 90 C for 20 min., when 100 pi 1.2%
w/v was added. The hydrogen peroxide solution was made up
immediately prior to use by diluting a stock 6% w/v BOS preparation.
Heating was then continued for a further 20 min. After cooling in
ice the reaction mixture was transferred to a cuvette in a Perkin-
Elmer spectrofluorimeter, model MPF-2A for fluorimetry. Excitation
scans were recorded from = 320 nm to = 420 nm with the emission
monochromator set at = 450 nm (the wavelength of maximum fluorescence).
fconochromator slit widths were both 10 nm. The figures quoted refer
to uncorrected instrument settings. The sensitivity of the method
was such that the fluorescence attributable to 15 ng L-tryptophan,
added to a homogenate of 25 mg cortex and processed through the method,
was at least double the fluorescence of "tissue blanks". The "tissue
blanks" were obtained by adding distilled water in place of hydrogen
peroxide to the tissue extracts.
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Background fluorescence could be allowed for by measuring the
norbarnaan-spec if 1c fluorescence in terms of the distance 'h% as in
Fig. 20. This procedure of course assumes that the baseline
fluorescence does not alter over the wavelengths recorded, or, if
there is an alteration, that this remains constant with every sample.
Although this cannot be directly examined, the baseline fluorescence
in the 'tissue blanks' was found to be stable over the critical
wavelengths. Data were also corrected using a recovery factor
obtained by comparing the fluorescence attributable to 50 ng L-
tryptophan when added either to distilled water, or to a homogenate
of 25 mg brain and processed through the method. This recovery factor
was of the order of 80%. (Actual values as used in the assay of
cortical tryptophan, 78% + 7%, (10)).
V. Estimation of 5-hydroxytryptamine (5-HTT) and S-hydroxyindoleacetic
Acid (S-H1AA) in small areas of rat brain
The simultaneous assay of S-IfT and 5-HIAA in small areas of rat
brain is currently generally carried out using one of two types of
fluoroassay. The first of these two types is based on the measure¬
ment of the fluorescence with characteristics specific to the
5-hydroxyindoles which develops at acid pH, and the second type is
based on the reaction between these compounds and o-phthal dlaldehyde (OPT)
with the resulting formation of highly fluorescent complexes (441).
Of the first type, the methods of Giacolone and Valzelli (438),
Welch and Welch (439) and Jonson and Lewander (440) all required
several hundred mg of tissue, necessitating therefore the pooling
of samples from groups of rats. These methods have been superseded
very recently by a fluorimetric method published by Schlumpf et al, (24),
42.
utilising the extraction procedures originally described by Chang (238)
and Maickel et al (239). This new method can assay the two compounds
in nieces of tissue only 2-3 mg in weight. The OPT-based double
and the two types of assay procedures were therefore examined so that
the more roliable could be used for the later experiments.
All brain samples used were taken from rats killed between
10.30 and 11.30 am, to minimise the effect on the assays of the
circadian rhythms of central levels of 5-HT and 5-HIAA (52).
20-30 mg samples of freshly removed or deep-frozen (in liquid N^)
rat cerebral cortex were homogenised in 10 volumes HCl/butanol
(85 pi 37% HC1 B.D.H. Aristar in 100 ml n-butanol, B.D.H. spectroscopy
grade). The homogenisation das carried out in all-glass apparatus,
1.5 minutes at 2,000 rpm. The homogenate was then transferred to
1.5 ml polycarbonate reaction tubes and centrifuged for 2.5.min at
12,000g. A portion of the supernatant (160 pi) was added to 400 pi
heptane (B.D.H. spectroscopy grade) and 50 pi 0.1M HC1 in 1.5 ml
polycarbonate reaction tubes. The tubes were then stoppered and
shaken vigorously by hand for 10 min. The phases were separated by
centrifugation for 2.5 min. at 12,000g and the lower aqueous phase was
used for the estimation of 5-HT (see below). A 500 pi portion of the
upper organic phase, containing the 5-HIAA, was added to 60 pi 0.15 M
of the aqueous phase taken for 5-HIAA estimation. At this stage the
remaining small volume of heptane/butanol was aspirated off from the
(442) was reported to be equally
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aqueous extract containing the 5-HT, and a 40 (*1 portion taken for the
assay.
ASSAY BY THE 1101 METHOD
To each SO |il '5-HIAA' samples or 40 f*l ' 5-HT' samples was added
20 pi concentrated HC1 (B.D.H. Aristar) containing 0.6 nsg/ml ascorbic
acid, the solution being prepared immediately before use for a series
of estimations. Each sample was mixed thoroughly and transferred
immediately to a micro-cuvette in a Perkin-Elmer spectrofluorimeter
model MPF—4. The fluorescence spectrum of the sample was recorded
with the emission monochromator set at /• = 640 nm while the excitation
light was continuously altered from / = 240 nm to X = 340 nm (excitation
scans). Slit widths of 8 nm were used in both the excitation and the
emission monochromators, and a filter (UV - 39) cutting off light
below A « -360 nm was interposed in the emitted light beam between the
micro-cuvette and the emission monochrooator so that none of the
activation light or harmonics thereof would reach the phototube.
All quoted figures are uncorrected instrument settings. Emission
scans were not used: one criticism of this method is that direct
comparison between excitation and emission curves was not possible,
as the emission scan did not show a definite peak at the appropriate
5-hydroxyindole wavelength. The appearance of a typical excitation
spectrum for 5-HT or 5-HIAA is shown in Fig. 16. The excitation
i —-
maximum occurs close to 300 nm, and all readings were corrected for
j
background fluorescence by assaying the indoles in terms of the dlstanee
*d'. This method assumes that baseline fluorescence remains unchanged
over the wavelengths measured; in fact, there is a minor peak of
fluorescence associated with the HC1 at these wavelengths, as shown
in reagent blanks, but this appears to make a fairly constant
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contribution, and therefore cannot affect assay results. The
fluorescence attributable to 10 ng of either 5-HT or 5-HIAA when
added to a homogenate of 25 mg cortex and processed through the
raethod was equal to or slightly greater than the fluorescence of a
reagent blank. Whenever samples were processed, a series of aqueous
standards were also assayed. This was done fcy shaking 26 pi distilled
water containing known amounts of 5-HT or 5-HIAA (5-100 ng) with
250 pi HCl/butanol, and then treating the standards as the other
samples. Recovery factors were also estimated on each occasion,
comparing the fluorescence attributable to 100 ng of either 5-HT or
5-HIAA when added directly to BCl/ascorbic acid and when added to
samples of brain homogenate. For the three major experiments
involving the assay of the 5-hydroxyindoles, the recovery values from
brain homogenates were as follows:
5-HT - 63%, 65%, 63%
5-HIAA - 84%, 75%, 82.6%
B. 5-HYDROXYINDOLE ESTIMATION BY FLUORIMKTRY OF THE REACTION PRODUCT
FORMED WITH O-PHTHALDIALDEHYDK (OPT)
This method, based on that of Maickel et al (442) was examined
as a possibly more sensitive alternative to that described above.
Both methods involve the same extraction procedure, beginning with the
brain tissue being homogenised in 10 vol. HCl/butanol, and ending with
5-hydroxyindoles in aqueous solution (6-HT in 0.1 M BC1 ami 5-HIAA
in 0.15 M sodium borate buffer respectively).
Samples were taken of the 5-HT-containing 0.1 M HC1 phase (40 pi)
and of the 5-11 IAA-containing 0.15 M borate buffer (50 pi), and to either
of these was added 50 pi of the OFT reagent (0.2 mg o-phthaldialdehyde
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100°C for 10 min. in a stoppered 1.5 ml polycarbonate reaction tube.
The samples were then rapidly cooled by immersion in ice-water.
The O-hydroxyindole-containing samples were transferred to a micro-cuvette
(capacity 200 pi); and analysed in a spectrofluorimeter, the Perkin-
Elmer model MPF-4A.
The excitation maximum occurred at X = 300 nm, the emission
maximum at A = 470 nau Excitation spectra were recorded from
A = 300 nm to A = 420 nm and the slits of both monochromators were
set at a width of 5 nm. A filter cutting- off light below A = 420nm
was inserted in the light beam between the micro-cuvette and the
emission laonochrosiator. The quoted instrument settings are uncorrected.
Quantification was by comparison with • series of aqueous standards
containing 10-150 ng of 5-HI' or 5-HIAA. Typically, the fluorescence
attributable to 15 ng of either 5-hydroxyindole when added to a
homogenate of 25 mg brain and processed through the method was
approximately twice the fluorescence of "tissue blanks", which were
obtained by processing control tissue samples through the method, but
treating tfem finally with pure HC1 only, containing no OFT.
To compose the two methods, duplicate samples from control
cortical homogenates were processed by the two different methods
(Fig. 17 & 18). In fact the HC1 method gave results for the control
brain samples that agreed very closely with published data, while
the apparently greater 5-hydroxyindole concentrations as measured
using the OPT method may have been due to the formation of OPT-
fluorophores with other compounds (441, 442, 443). It was therefore
decided to use the HC1 method.
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D. OTHER METHODS
la. Estimation of protein in rat brain samples
In order to avoid problems in the quantification of various
biochemical parameters in brain tissue associated with possible
alterations in the water content of the samples due to oedema, the
concentrations of the variables have usually been recorded in terms
of protein concentrations. Protein estimations were made on portions
of the brain extracts used in the biochemical assays. The Waddell
method of protein estimation was use^In^preference to that of lowry
(584), as it was found (466) that cobalt salts interfered with the
Folin phenol method of Lowry.
Samples of 50 pi were taken from the clear supernatant obtained
from brain samples extracted as described in Methods A, part V.
These were diluted 1 in 25 in sodium chloride solution, 9 g/1.
Using a Pye Unicam spectrophotometer, model SP 500 series 2, the
absorbance of each diluted extract was measured at 215 mn and
225 nm, and the latter value subtracted from the former; the value
thus obtained was converted to a protein concentration by comparison
with a standard curve, obtained by processing known amounts of bovine
serum albumin (Sigma) through the method. Reagent blanks were
obtained by using a saline dilution of the homogenising buffer used
in the preparation of the brain extracts, as on p6a.
The rationale of this method is af follows. The absorption at
these low wavelengths is due principally to the peptide bond — unlike
the absorption maximum at X = 280 nm which is due to aromatic amino
acid moieties. The latter absorption factor obviously differs far
more between proteins than the former. Waddell found that
absorption concentration curves of different proteins at the lower
wavelength are so similar that the same standard curve could be used
to calculate the concentration of either human serum albumin or
globulin, without significant error. With this method Waddel found
that in almost all biological specimens the concentration of protein
is so high, relative to possible interfering materials, that the
method is essentially specific. The presence of nucleic acids, which
can seriously interfere with determination of protein when abaorption
at 280 mi is measured, does not affect this method.
Ib. Estimation of cerebral protein synthesis
The method used was based on that of Barondes and Cohen (595).
48 h. after the intracerebral injection of 20 pg acotoxycyclohexisid©
in 10 pi Krebs* Ringer's solution into the frontal cortex, the
experimental rats were given a subcutaneous injection of 1 pCi of a
14
C-labelled protein hydrolyaate, made up in 0.3 ml 0.9% NaCl
14
([U- CJ Protein hydrolysate, a.a. 45 raCi/miIliatorn of carbon, Amershaa).
One hour later, the rats were stunned, decapitated and the cortex from
both cerebral hemispheres was removed and homogenised in 0.1 N NaOH,
1 ml/25 mg. 3.0 ml of cold 12% trichloroacetic acid (TCA) was added to
1.0 ml of the homogenate and this was then left for 10 min. at 0-4°C.
The suspension was centrifuged at 10,000 g for 2.5 min. and aliquots
of the supernatant (250 pi) were added to 10 ml Triton scintillant
(TCA-soluble fraction). The protein-containing sediment was re-suspended
and re-centrifuged twice in 10% TCA. After the last centrifugalion
the TCA was allowed to drain off and the insoluble pellet was
solubilised in 1 ml 0.1 N NaOH. This was then also added to 10 ml
Triton scintillant (TCA-insoluble fraction). Each tissue sample was
then assigned a value corresponding to the ratio between the counts
in the TCA-insoluble and TCA-soluble fractions, the ratio being directly
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proportional to the degree of protein synthesis. All counting was
done over a period of 10 min., external ratio mode, on a Hewlett-
Packard scintillation counter.
II. Measurement of 5-hydroxytryptamlne (SOT) uptake by rat cortex
The method used was based on that of Bjorklund et al. (304).
Male Piebald Virol Glaxo strain rats. 10 weeks old and weighing from
200-230 g were operated on and given cobalt implants as previously
described. Twenty days after the operation these experimental
animals and * glass-implanted' controls were stunned and decapitated.
The brains were removed and immediately washed in ice-cold Krebs-
Ringer bicarbonate buffer (pH 7.4) (for composition see 'Materials')•
After immersion for 1 min. each brain was removed from the buffer and
o
placed on an aluminium block chilled at 0 C on ice. The cerebellum
was removed, and the cortical hemispheres separated. A Perapex
microscope slide with a central trough 1 mm deep, 20 mm wide, was
pressed down gently over the superior surface of each cortical
hemisphere. A scalpel blade was then passed slowly with a sawing
motion along the inferior surface of the slide. In this manner
cortical slices of a standard 1 mm depth were obtained. From theme
slices circular tissue sections were cut using a thin-walled
stainless steel tube with an internal diameter of 3 ma.
Each cortical disc was then placed in a numbered scintillation
vial containing 2.0 ml of ice-cold Krebs-Ringer buffer solution (made
up M in 'Uat.ri.1.'). Thl. «. pr.-..tur.t.d ,1th 95% »s and 9*
COg and had a final pH of 7.4.1 Sections from the experimental and
control animals were then pre-lncubated in the buffer solution for
o
10 sain at 37 C« In order to give a measure of 5-HT uptake attributable
to simple diffusion, other sections from control animals were
incubated throughout at 0°C. To each vial was now added, using a
Pederson pipette, 1 pi of a tritlated 5-HT solution (1,2-3H 5-HT
binoxalate, 5.7 Ci/wmol, New England Nuclear). This gave a final
q
concentration of 5 x 10 mol/1 in the incubation medium. The
incubation was allowed to continue for 10 min. The reactions were
then stopped by placing the scintillation vials in ice-water. Two
10 pi samples were taken from the incubation medium in each vial, for
duplicate determination of the free 5-HT and metabolites. lite
samples were added to 10 ml Triton sclntillant ^'Materials') and the
counts obtained hereafter referred to as the "Medium count". Each
tissue section was aspirated from the scintillation vial into the
barrel of a clean Pasteur pipette, and placed on a Milllpore filter
(Fore size 0.45 p). The sections were then washed vapidly with 10.0ml
of 0.9% NaCl under suction. After washing, each filter was removed
(with the tissue section) from the Milllpore filter holder, and
placed in a scintillation vial containing 1.0 ml distilled water.
Ten ml of Triton scintillant (made up as in 'Materials*) was added
to each vial, and the vial was then agitated for 15 min. in a shaker.
The tissue disc disintegrated after approximately 5 min. but at this
stage a slight opacity might still be detected in the scintillant
solution. After fifteen min. the scistillant mixture became
completely clear, indicating effective dissolution of the tissue.
Counts obtained from such samples are referred to as "Tissue counts".
All samples were counted for 10 min. external ratio mode, on a
Hewlett-Packard scintillation counter. Each tissue section was
assigned a value determined by the ratio of tissue counts to medium
o
counts, from which was subtracted the 0 C control ratio, this latter
factor representing the degree of passive diffusion of 5-HT into the
brain slices. This gave a final tissue counts/medium counts ratio
which referred only to the degree of 5-HT taken up actively by the brain
slices. No monoamine oxidase inhibitor was used (as in the original
method, 304). This meant that the tissue and the medium counts
probably included not only 3H as (3H)5-HT but also (3H)5-HIAA. The
degree of 5-HT oxidation in these sections is not known exactly; but
if 5-HIAA is more easily lost from brain sections than 5-HT, then a
reduced MAO activity might cause an artificially high tissue/medium
counts ratio. This potential weakness in the method is discussed in
the results section.
111. Estimation of cobalt in rat brain
The estimation was carried out by flameless atomic absorptiometry
(Slavin and Femandex, 575), using a Parkin-Elmer Atomic Absorptiometer
model HGA-360 with a graphite furnace attachment. Essentially the
apparatus consists of a graphite tube, through the long axis of which
is passed light of a wavelength that will be absorbed by the atoms of
the element to be measured, the degree of absorption being monitored
by the output from a photomultiplier tube. In order to measure trace
elements present in biological material, a small volume of a suitable
extract of the material is injected into the graphite tube. Suitable
setting of the instrument allows controlled heating of the graphite
tube to temperatures suitable for evaporation and then ashing of the
sample, and eventual atomlaatlon of the element of interest.
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The following method was developed for the estimation of cobalt
in brain tissue. Preliminary experiments were conducted to select
a suitable programme for the instrument. Normal brain tissue was
digested in conc. nitric acid (BDH Analar), 2 pl/rag tissue, for 2 h
at 70°C in a stoppered 1.5 ml polycarbonate reaction tube. To the
digest was added 13 pl/mg tissue of a standard solution of cobaltous
chloride, 1 |tg Co /ml. Of this mixture, 20 |il samples containing
18 ng cobalt were introduced into the instrument. Suitable conditions
were found to be 00 sec. at 80°C, (for evaporation), followed by a
o
controlled increase in temperature, over the next 90 sec. to 1,050 C,
this temperature being maintained for 10 sec. (ashing stage); the tem-
o
perature was then raised to 2,760 C for 10 sec. to atomise the sample.
Lengthy experimentation involving adjustment of durations and temper¬
atures of the first two stages was required to define conditions so that
the on-line absorptiometer Just gave nil readings until the third
stage, controlling atomisatlon, was activated. In follow-up experi¬
ments with samples containing 00 ng cobalt 'nil* readings were
obtained during the first two stages, indicating no loss from this
relatively large amount of cobalt during the evaporation and ashing
stages. A cathode-less light tube with a primary wavelength of
240.7 nm was used as the light source. (These lamps are supplied by
Parkin-Elmer for use in conjunction with the atomic absorptiometer.)
For the estimation of cobalt in brain tissue from experimental
animals, weighed pieces of brain (15-20 mg) were digested in cone. HN0„
as described above. Portions of the clear digest were diluted 20-fold
with deioniaed distilled water, and 20 |xl portions of the dilution
used for analysis. No cobalt (< 1 ng) was detected in blank digests,
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with no brain tissue, nor in samples of brain from control animals,
indicating no contamination from the nitric acid, deionised water or
reaction tubes, and the absence of measurable endogenous cobalt.
The smallest amount of cobalt that could reliably be detected in a
15 mg sample of control brain was 1.5 ng.
In the case of tissue samples of ipsilateral cortex from cobalt-
implanted animals, the glial capsule and any calcified tissue was
rejected, as were any visible traces of gelatine-cobalt.
CALIBRATION OF THE ATOMIC ABSORPTIOMETER
A series of aqueous standards of cobaltous chloride was processed
through the cobalt assay method, and it became apparent that the
relationship between the amount of cobalt present and the cobalt
related light absorption was non-linear. Assuming a curvilinear
relationship, and force-fitting the curve through x = y = 0, an
equation was derived using the method of least squares analysis.
2
The curve thus derived obeyed the equation y = 2.683x - 0.052x , and
is shown in Figure 19, together with the experimental data. The
fact that the cobalt standards of 5 and 10 ng do not fit the curve as
accuaa*ely as the other standards may be explained by either postulating
a dilution error committed during the preparation of the standard
3
solutions, or by adding an x and log.x factor to the equation
2
y = ax + bx . This letter alternative however does not agree with
the data published by Slavin and Femandex (575) who found a simple
2
y = ax + bx curve adequate. The possibility of a consistent (in vidw
of the results) error in the preparation of the standards, perhaps due
















The curve as described by the equation y = 2.683x - 0.032x
accounted for 90.3% of the variation in y.
IV. The technique of tryptophan loading (as used in the Pharmacology
section)
Tryptophan was prepared for injection by the method of Aahcroft
et al. (180 ). A known amount of L-tryptophan (200-500 nig) was
placed in a mortar and ground with a few drops of Tween 80, and
then 0.0% NaCl was added drop by drop with further grinding until a
suspension of 150 mg L-tryptophan/ml was obtainod. Each rat was
then weighed and given an i.p. injection of the suspension of a
volume calculated to give a dose of 400 mg/kg. A wide—bore needle
was used to minimise the risk of the suspension clogging the needle.
Rats were killed 2 hours after injection, and samples of brain




GENERAL INTRODUCTION TO THE BIOCHEMISTRY OF EPILEPSY
Various studies have demonstrated d disturbances of cerebral
netabollsa associated with idiopathic epilepsy. Amongst the
metabolic changes usually referred to are reports of a reduced
aotivity of cholinergic metabolism (390, 451, 452, 453), an inhib¬
ition of glucose metabolism, and alterations of amino acid metabolism
(453, 452, 451, 390). It has not been possible to classify these
changes as aetiologlcal or associative, and there are currently no
anticonvulsants in use which could be said to have been developed on
the basis of these findings. More recently, interest has been
focussed on the postulated central neurotransmitters, primarily gamma*
aminobutyric acid (GABA) and the monoamines noradrenaline(NAd)
dopamine (DA) and serotonin (5-OT).
There is a need for drugs that will interfere with the circuitry
involved in the initiation and spread of opileptic be aviour, while
leaving normal neuronal function undisturbed. If any one class of
neurone could be shown to be specifically involved in the epileptic
process, this would then serve as a pharmacological focus around which
the search for specific antl-convulsants could be based. The most
readily available methods of classifying distinct sub-groups of
neurones, and manipulating such sub-groups, refer to the metabolism
and function of the different neuro-transmitters; and there is
already available a large body of information concerning the relation¬
ships between various parameters of one or other of the biochemically
classifiable sub-groups and the tendency to the development of
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epileptic symptoms, in a wide range of animal models and in the
clinical situation. This area of research, into which the body of
the work referred to in this thesis falls, is reviewed in the
introductions to the relevant sections on neurotransmitter metabolism
In one animal model of epilepsy, the cobalt-implanted rat.
GENERAL PHYSIOLOGY OF EPILEPSY
A large volume of research has also centred around the physiol¬
ogical responses associated with epileptic behaviour in various models.
These appear to be widespread (occurring in and also outwith the
focal areas) and complex, varying not only from model to model but
also in time, different responses being associated with different
stages in the initiation and development of the epileptic focus.
Much of the data reported on below was assembled from the study of
the consequences of clinical and experimental cranial trauma.
During the first minutes or hours after injury, humoral mechanisms
may be important: Borastein (369) demonstrated that experimental
head trauma resulted in a release of acetylcholine (ACh) into the C3F;
and Tower and McEachern (390) showed that in clinical cases of head
injury there was also an increased efflux of ACh into the CSF.
Significantly, ACh not only has a direct excitatory effect on
cortical neurones (391), but has also been reported to activate human
epileptic foci after topical application (392).
At later stages, for example after the recovery of consciousness,
a different contributory factor has been suggested by Dempsey and
Morrison (393). They suggested that injury could, by temporarily
reducing the inhibitory tone of the mesencephalic reticular system
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cm ventro-lateral thalamic nuclei and diencephalic nuclei, release
a cortical recruiting response that generally increases cortical
excitability. Later again in the syndrome physiological factors
related to the displacement and disorganisation of the nervous
tissue may become important; venous sinus thromboses with consequent
stasis and anoxia, the pressure increase following sub-dural
haemorrhage, and the nervous irritation caused by the presence of sub-
pial extra-vascular blood would all increase the tendency to the
development of fits (304, 395). The final pathology may be
contributed to by scar formation associated with alterations in
local blood supply (397), and also denervation hypersensitivity
phenomena (396). Finger et al. (582) suggested that the reinnerv¬
ation of damaged areas of CN3 by the sprouting of neighbouring,
undamaged cells could introduce 'noise* and disrupt normal activity.
This may also become important in later stages of an epileptic focus.
The physiological responses associated with the epileptic condition
precipitated by frank neuronal damage can then be described as an
overlapping sequence of adjustments to the original trauma. Similarly,
seizure behaviour as a consequence of cerebral trauma, and probably
in other epilepsy models, may be influenced by different contributing
factors at different stages after the injury. One might also
hypothesize that the epileptic behaviour accompanying the early, more
rapidly developing, responses to injury should be less likely to
persist than those associated with the long-term resolution of the
injury.
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REASONS FOR CHOICE OF MODEL
The different models that have been used in the investigation of
epilepsy all have their own unique advantages and disadvantages*
Eany types display epileptio behaviour only for a very short time,
and into this category fall most of the epilepsies precipitated by
syatemically administered convulsants, and also the epileptic states
precipitated by those substances which are effective convulsants when
applied directly to the brain tissue, such as the penicillins and
oestrogens. These models would not have been suitable for my purpose,
as the intention was to examine neuronal changes in a chronic epileptic
focus such as is found clinically. The longer term models available
include the freeze lesion, audlosensitlve and photosensitive epilepsies
(the reflex epilepsies), and the metal lesions; in the event it was
decided to investigate the metal lesion, specifically the cobalt
lesion. This model is relatively cheap, and simple to reproduce, and
furthermore work had already been done in the department on various
aspects of the biochemistry, histochemistry and pharmacology of this
model so that there already existed a framework of data against which
the findings of mono amlnergic involvement could be contrasted and
compared. This study then, was an attempt to uncover correlations
between changes in various parameters of specific types of neurone
and changes in the electrical behaviour of the cortex as measured
in the EEG associated with the initiation, development and eventual
resolution of the cobalt epileptic focus.
It is impossible to say exactly how valid this particular model
is but there is a body of information that suggests that the cobalt-
implanted rat behaves in a somewhat similar way to certain cases of
human epilepsy. In an extensive study on the patterns of EKG
behaviour of cobalt-treated rats, Dow et al. (456) suggested that
the abnormal hypersynchronous focal epileptic activity characteristic
of this model approximated very closely to the epileptic EEG patterns
of some human epilepsies; this was supported by two later studies,
by Dawson and Iioliaes (457), and Chocholova and Rodel-Weiss (458).
Ashcroft et al. (354) have found that ethosuxiraide, an anticonvulsant
used in the treatment of petit mal epilepsy, is also successful in
reducing epileptic signs in the cobalt-implanted rat, while pheno-
barbitone and diphenylhydantoin, the two major daugs of choice in the
treatment of grand ml, are not effective in this model. This pattern
of response to anticonvulsant drugs plus the fact that the cobalt-
implanted rats display fore-limb and whisker twitch but only very
rarely develop generalised convulsions, suggests that the model may
be more suitable as an analogy for petit ual or myoclonic epilepsy.
The fact that one at least of the clinically used *afe£ti-convulsants
is effective in this model also suggests that, even if the initial
epileptogenic stimuli are different, the information concerning the
development of the EEG epileptic behaviour in the rat may well be of
relevance to the clinical situation. The fact that the cobalt-
implanted rat only displays myoclonic behaviour may well be an
advantage from the point of view of a biochemical analysis of the
model, as the pathological situation and biochemistry are not
compounded by the effects of generalised convulsions (466, 577).
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THE COBALT MODEL - POSSIBLE MECHANISMS
The direct application of epileptogenic agents to the plal
surface of the brain is a common experimental method of producing
seizure discharges. The oestrogen and penicillin convulsants are
applied in this way (291, 292) but these epilepsies, as already
mentioned, are of too short duration to be of use in the study of
the chronic epileptic focus.
Chronic focal epilepsy can be produced in the rat and in a
number of other species by the application of a gelatine suspension
of metallic cobalt in powder form to the cerebral cortex. Cobalt
wire and cobalt metal powder alone have also been used (371, 372,
373, 374). Hie animals develop epileptiform EEC abnormalities
associated with myoclonic whisker and limb twitches and a lowered
threshold to systemic convulsants (375) within about a week after
implant. These models present with substantial cell damage
involving a focal area of leptomeningeal inflammation (376) and a
cortical necrosis characterised by neuronal degeneration, gliosis
and ingrowth of new blood vessels (377). It has been difficult,
in consequence, to isolate the epileptogenic mechanism, because
neuronal damage alone is often sufficient to initiate epilepsy, as
is instanced by the number of patients whose epilepsy is attributable
to cerebral trauma. Various authors have claimed that the effect of
the cobalt ion is the critical factor (371, 378), while others suggest
that the formation of the meningeal cicatrix is important in
developing epileptic activity (377, 376). It seems likely that both
factors, the cobalt toxicity and the general cell damage, contribute
towards the epileptic phenomena, the importance of the contribution
of each factor varying at different stages of the epileptic process.
However, it may well be that the crucial influence is that of the
cobalt ion; glass implants, for example, although capable of
inducing a degree of gliosis and meningeal damage, do not initiate
epileptic foci (374), while a recent paper by Willmore et_ al. (379)
demonstrated very clearly that •'"he cobalt ion does possess a potent
epileptogenic effect, when applied directly to cortical tissue. The
epileptic signs at later stages, for example at 10 weeks post-
implantation, may not be so closely linked to the presence of the
cobalt ion. At this later stage atomic absorptiometry studies,
reported in this thesis, show that the cobalt has been cleared free
all areas of the brain except the primary focus, where some of the cobalt
remains encapsulated in a calcified glial capsule. Epileptic
activity at this time probably reflects the cell damage, a large
degree of which may be permanent. This raises several problems
concerning the mechanisms of this form of epilepsy. Is the epileptic
behaviour of the first few weeks, possibly elicited! by the cobalt ion,
mediated by the same mechanisms as are involved in the later stages
of the cobalt model when tissue scarring and/or resolution may
predominate as the cause of the epileptic behaviour? If the
mechanisms are different, does this mean that different stages of the
development of an epileptic focus may be best treated using different
drugs? It may well be that, during the early stages of the cobalt
focus, metal ion chelators would be effective, or alternatively drugs
acting on those groups of neurones that are moat involved at this
stage: but this does not mean that the chelators or the specific
drugs will be effective during later stages when the epileptic
mechanism may be different. Certainly the studies reported in this
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Fig. 4. Development of abnormal epileptic spike activity in cobalt implanted rats. Each point is the
mean ± S.D. for the primary focus (© —®)and secondary focus (0 G). The number of animals
used were for days 2, 4, 5, 6, 7, 11, 12 and 28 — 12 animals; for days 8, 14, 18 and 21 — 24 animals.
thesis do suggest that the pattern of involvement of the different
neuronal types does vary at different times after the cobalt implant.
Considerable reservations must therefore be made when comparing
data from the cobalt model with clinical data; much of the work done
on this model has concentrated on a period of only 30 days after
the implant, and it is possible that this study may shed very little
light on the problem of long-term chronic human epilepsy. However,
it may be of aone value in unravelling the mechanism involved in
the developing stages of the human epileptic condition, and in
suggesting some possible avenues of research into the development of
early, possibly prophylactic, treatment in cases of cerebral trauma.
TIME COURSE OF DEVELOPMENT OF EPILEPSY IN THE COBALT-IMPLANTED RAT
Following unilateral implantation of cobalt into the frontal cortex
of the mat, a primary epileptic focus developed in the nervous tissue
around the implant zone, and a secondary focus formed in the corres¬
ponding area of the contralateral cortex, as measured in the animals'
EEC. Epileptiform waves, referred to ss 'spikes' because of their
typically small peak angle, appeared in both primary and secondary
foci at around 3-5 days post-implant and increased in frequency until
reaching a maximum in both foci at days 7-13 post-implant. The
frequency of spiking in the secondary focus is almost always greater
than in the primary focus. Very often the rate of spiking fell on
both sides to 20-30% of peak values by days 14-16, and remained at
approximately these rates for a period of 2-3 weeks, when a farther -
peak has been reported to develop (Fig. Al). Studies by Emson and
Joseph (466) have shown that the levels of glutamic acid decarboxylase
(GAD) and choline acetyltransferase (ChAC), enzymes associated with
\
r?iG. A2 Involvement of various enzymes in cortex of cobalt-implanted rats
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Fig. A comparison of amino acid and enzyme ciianges in cobalt epileptic rats relative to the
development of epileptic spiking (a) y-aminobutyric acid, (b) glutamate (c) aspartate (d) glutamic
acid decarboxylase (e) choline acety[transferase (f) spike development in the secondary focus
(O O) and primary focus (© ©).
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Fig. 5. The effects of cobalt implantation into the frontal cortex on amino acid levels in the lesion
( x x), primary focus (/_— A), secondary focus (O G) and glass implanted
controls (□- • - • -□). Each point is the mean of 4 animals. Calibration bars are the normal
range A S.D. for 6 control animals. Comparison with controls, Student's t-test, • P < 0.05; •• P <
O.OI; ••• P <"k0.002. (H6).
62.
gabaiainergic and cholinergic systems respectively (583), are reduced
in the primary focal area, that the reduction is maximal when
epileptic spiking is at its peak, and that the enzyme levels recover
rapidly as spiking declines (Fig. A2). In parallel with these
changes in enzyme activity, the concentrations of several putative
transmitter amino acids including glutamate, aspartate and gamma
aminobutyric acid (GABA) also fall in the primary focus area as the
spikes increase, and recover as spiking decreases (Fig. A3). These
changes are not consistently paralleled in the secondary focus.
ChAC and GAD activity show minor reductions, as does the concentration
of aspartate, while GABA levels are slightly elevated compared to
controls. This may mean that the changes found in the primary focus
are more a reflection of the trauma initiated by the cobalt implant
than a necessary concomitant of the epileptic process. Nevertheless,
Etason suggested (577) that these results might indicate that the
epileptic behaviour in this model represents a denervation response.
This pattern of recovery within 30 days is repeatedly referred to in
later sections on monoaminergic involvement in this model, as it
became apparent during the course of the work of this thesis that
catecholaminergic and serotonergic parameters followed different and
specific patterns of their own.
The behavioural responses after cobalt implantation are as follows;
animals typically develop clonic movement of the contralateral forelimb
at 4-10 days after implant, with bilateral whisker twitch. Ipsilateral
forellmb twitch occasionally occurs, associated with discharges in the
secondary focus (347). These traits are often still observable 3
months or more after the cobalt implantation.
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THE CONTRIBUTION OF DIFFERENT TYPES OF NEURONE
TO THE EPILEPTIC RESPONSE
CABAMINERGIC 3YSTEMS AND THE SEIZURE THRESHOLD
The first evidence establishing ^ -aiainobutyric acid (GABA) as
an inhibitory neurotransmitter was obtained from studies of the
crayfish neuromuscular junction (Otsuka et al.. 1966, 418). Later
iontophoretic studies by Krjnevic and Schwartz (419) suggested that
GABA might also function as an inhibitory neurotransmitter in the
mammalian CNS. This idea was supported by localisation studies (412),
finding that mammalian synaptosomal preparations were very rich in
GABA, and by perfusion experiments (410) finding that the amount of
GABA released into dog cortical perfusate or CSF was inversely
proportional to the degree of cortical arousal. Histocheoical
work (520, 521) showed that the activity of glutamic acid decarboxylase
(GAD), GABA'a synthesislng enzyme, correlated closely in the brain
with the distribution of inhibitory neurones. Today the existence
of inhibitory gabamlnergic neurones in the mammalian CHS is generally
agreed an, and they are thought to be involved in the epileptic
condition.
One would expect that raising the effective levels of a cortical
inhibitory neurotransmitter would raise the seizure threshold, and a
reduction of inhibitory tone to have the opposite effect. This is in
the main borne out by the experimental data. GABA injected intra-
cranially into the frontal lobe has been shown to protect mice from
Footnote I
Qabaainergic neurones are those neurones that employ GABA as a
neurotransmitter.
64.
electroahock and front pentylenetetrazols seizures (09). The pial
application of gamma-aminohydroxybutyric acid (a GA-3A analogue)
suppresses the activity of penicillin-induced foci in the mouse
(14,10). Conversely, bicuculline, a drug thought to act as a GABA-
receptor blocking agent, has been shown to act as a powerful convulsant
(444, 445).
The seizure threshold in various models has also been shown to
be affected by drugs that alter the synthesis en- catabolism of GABA.
In fact as early as 1959 Baxter et al. (410) had suspected that
several of the clinically useful anticonvulsants acted by altering
GABA levels; however, it is doubtful whether any anti-convulsent
acts solely via the gabaminergic system, as they have been shown
by other workers to exert effects on a number of other systems.
This point is discussed at greater length in the section dealing
with 5-hydroxytryptamine (p!33),
Gamma-aminobutyric acid transaminase (GABA-T) and glutamic acid
decarboxylase (GAD), respectively the catabolic and synthetising
enzymes which between them control brain GABA levels, are both
dependent on pyridoxal phosphate as a co-factor, as are all the
transaminases, decarboxylases, and certain other enzymes. The Km
of GAD, while high compared to most other known Km values for the co-
factor, is lower than that of GABA-T (446, 447). This means that a
decrease in the amount of available co-factor will tend to affect
GABA-T first, before GAD is affected - with a consequently biphasic
action on the seizure threshold. Amino-oxyacetlc acid, a drug
known to act as a pyridoxal phosphate antagonist, has been shown to
have a moderate suppressant effect on spiking in the cobalt-implanted
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rat at low doses and to be convulaant at higher doses (568). Various
other pyridoxin® antagonists, including 4-deoxypyridoxins and pyridoxal
phosphate-glutamyl hydrazone, have been shown to act as convulsants at
hi£h doses (115, 448). Their ability to lower the seizure threshold
correlated well with their ability to reduce GABA concentration in the
brain. Schlessinger and Schreiber (60) also compared the rate of
GABA loss with the lowering of the seizure threshold in mice on a
vitamin© IK deficient diet, and found a very close correlation between
o
the two trends. It seemed possible that 5-HT, NAd and DA, all of
whose biosyntheses include a pyridoxal phosphate-dependent enzyme,
might also be involved in this lowering of the seizure threshold.
However, Uchida et al., 1964 (449) found that the concentrations of
the monoamine species were relatively unaffected after convulsant
doses of pyridoxins antagonists, and therefore their contribution to
the lowering of the seizure threshold in this model is probably
unimportant.
Some workers have criticised attempts to relate seizure threshold
to any factor as vague as "total brain GABA levels"; for example
thiosemicarbazide, which blocks GABA synthesis, can still induce
with.
seizures in rata.jwfelsh artificially elevated brain GABA levels
(248, 249, 250). This apparent paradox can be resolved by the
suggestion that the effective inhibitory GABA is not a function of
the whole brain pool, but rather a function of the synaptic, newly
synthesized GABA (450), and that this may not correlate with total
brain GABA. Very recently di-n-propylacetate (sodium valproate),
a competitive inhibitor of succinic dehydrogenase (SDH), has been
used in clinical trials in the treatment of various human epilepsies.
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Thia drug increases cerebral concentrations of succinate, a compound
formed in the transamination of GABA, and subsequently causes a
reduction in the rate of the transamination of GABA in accordance
with Le Chatelier's principle. The results have so far been
encouraging <413, 481), in contrast to the earlier attempts at using
pyridoxins antagonists as anticonvulsants, which had failed because
of these compounds' lack of selectivity. Altering brain GABA levels
by interfering with SDH may turn out to be amongst the more fruitful
areas of anticonvulsant research, although it should be pointed out
that same doubt exists concerning the mode of action of di-n-propyl-
are
acetate. Therapeutically effective doses in nian/of the order of 5-10%
(in terms of mg/kg body weight) of the dose levels found to be
effective in raising rat brain GABA (Emson, P., private communication).
This is by no means conclusive evidence, however, as very little work
has been done on the possibly considerable species differences that
may exist in terms of the absorption, metabolism, distribution and
clearance of this drug.
SEIZURE THRESHOLD AND CENTRAL CATBCBOIAMINEBGIC NEURONAL SYSTBiS
Many workers have suggested that the seizure threshold in a wide
range of animal models of epilepsy is proportionally related to,
amongst other factors, central levels of the postulated catecholamine
transmitters.
The evidence has been mostly derived from studies of drugs, known
to act on central catecholamine systems, that have been found to alter
the seizure threshold. A second important category of data derives
from studies of various parameters of amine metabolism in a range of
models of epilepsy, including clinical cases. A third category
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includes the work that has attempted to unravel the mechanism of
action of the various canvulsant and anticonvulsant drugs,
documenting effects on the catecholamine systems amongst others;
this work is in general less clear-cut than is the information
provided by the first two categories, because the anticonvulsants
in particular have been demonstrated to have a wide spectrum of
effects only some of which involve the amine systems.
DRUGS AFFECTING CATECH0LAM1NERGIC NEURONAL FUNCTION
a) Drugs that reduce catecholamine levels.
Reserpine and tetrabenazine have both been used to examine the
effects of central amine depletion on the seizure threshold. Both
drugs reduce central concentrations of 5-HT as well as of NAd and
DA, and both dings lower the seizure threshold in a variety of
models, including pentylenetetrazols convulsions (38, 89, 90, 91),
electroshock (99), audiogenic shock (95, 96, 97, 98) and convulsions
induced by exposure to hyperbaric oxygen (92, 93).
Somewhat more specific amine depletora have also been examined|
the fall in HAd synthesis after dopamine p-hydroxylase inhibition
has also been reported to lower the seizure threshold in the audio¬
genic mouse model (44, 145, 146) and the actual destruction of central
catecholaminergic neurones using 6-hydroxydopamine, a fairly
selective catecholamineraic neurotoxin, has a similar but longer-
lasting effect (144). A reduction of monoaminerglc tone can also
be achieved by the use of specific receptor blockers. The anti¬
psychotic phenothlazines have been shown to exert a wide spectrum
of effects, including a central DA- and NAd-receptor block and this
range of drugs has been found not only to lower the seizure threshold
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in animal models (109) but actually to precipitate fits in certain
clinical cases of epilepsy (110, 147).
b) Drugs that raise catecholamine levels.
L-Dopa loading has been shown to raise the seizure threshold
in a number of models of epilepsy. It was found to raise the
threshold to audioshock in reserpinised, audiosensitive mice (120,
121), and intra-ventricular injections of L-Dopa have been used to
raise the seizure threshold to pentylenetetrazole in reserpinised
mice (54). However this last study reported a biphaslc action of
L-Dopa, namely a protective action at high doses but a facilitating
effect at low doses. Schlessinger et al. (59), using the mouse
audioshock and pentylenetetrazole models, demonstrated a seizure
threshold-raising effect of NAq, given intra-cranially into the
frontal lobe. Monoamine oxidase (MAO) inhibitors have also been
used to raise central amine levels; although the evidence here is
not so clear, as not only NAd and DA but also 5HT, and in fact levels
of all biogenic amines normally metabolised by MAO, are altered.
However, various workers (100, 101, 102) have suggested that the
anticonvulsant effects of MAO are mediated at least in part by the
increase in central levels of NAd and OA.
Another category of data concerns the use of various drugs
thought to increase effective, if not absolute, amine levels.
It has been suggested, for example, that the mode of action of the
tricyclic antidepressants is via an "amplification" of central
catecholaminergic neurones brought about by blocking amine re-uptake
at nerve terminals. It is of Interest in the present context that
imipraiaine has been reported to be effective in the treatment of some
cases of petit mal and minor motor epilepsy (100).
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Various studies have also looked at the effects of monoaminergic
receptor stimulators. Apomorphine, ergocornlne and piribedil, for
example, have all been shown to raise the seizure threshold in audio-
sensitive miee (121), and in related work it has been shown that
amphetamine, which stimulates central NAd and DA release, can protect
audio-sensitive mice from audio-shock (123), and can also reduce
spiking in the EEC of the cobalt-implanted rat (12S).
The data so far summarised support the original hypothesis that
the seizure threshold is linked to central catecholaalnergic
activity. This is also supported by microiontophoretic studies,
(75, 76, 77, 78), all of which indicate that NAd and DA act as
inhibitory neurotransmitters in the cortex. It must be admitted,
however, even those drugs which are thought to have the most specific
mode of action may well exert effects on more than one system. Some
of the treatments may act directly on 5HT systems - for example
reserpine and tetrabenazine. Others may affect the 5HT systems
indirectly. It has been established that functional links exist
between noradrenergic and serotonergic systems in certain animals)
in the eat, sectioning the noradrenergic dorsal bundle apparently
results in an increased cortical and raphe synthesis of 5HT (380,
511).
There is also reason to believe that drugs acting on NAd and
DA neuronal systems in the brain have an effect cm intra-cerebral
blood flow, and hence may alter regional metabolism not specifically
related to catecholamine systems; this is discussed in more detail
in the section on 5HT (Ref .437 ). It should also be pointed out that
L-Dopa loading techniques raise central levels of both NAd and DA,
but have also been reported to cause a reduction in whole brain 5HT
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in the rat (580). Many MAO inhibitors and monoamine uptake
blockers are too unspecific to permit differentiation of the
effects of the monoamine neurotransmitters.
There are available some studies that have attempted, in view
of the above criticisms, to provide more specific answers.
Navarro et al., (336) have shown that paentolamine and sotalol, a-
and p-adrenoceptor blockers respectively, have an anti-convulsant
effect in the mouse electroshock model despite their action raimicing
a reduced noradrenergic tone. Inversely, although MAO inhibitors
and monoamine neuronal uptake blockers raise monoamine levels
absolutely or effectively, both have been shown to precipitate, on
occasion, fits in epileptic patients (102, 103). Kellog et al. (139)
using the techniques of catecholamine synthesis inhibition and
catecholamine precursor administration, have found that the seizure
threshold in the audiosensitive mouse model can be raised by increasing
or decreasing central catecholamine concentrations. Some very
interesting work has also been done on the cobalt rat model.
Ashcroft et al. (354) demonstrated that, while OA-releasing agent amphet¬
amine and DA-receptor stimulator apomorphine reduced or abolished
epileptiform signs in the EEC, DA receptor blocker chlorprooiazine
and the NAd receptor stimulator clonidine had the opposite effect.
Another very clear study by Azzaro et al. (44) examined the
effects of manipulating levels of specific amines on the elesfeis*-
shock seizure threshold in the mouse* They found that inhibiting
either tyrosine hydroxylase or tryptophan hydroxylase could delay
the recovery of the threshold to control values after reserplne,
whereas a simultaneous inhibition of both hydroxylases could prevent
the recovery indefinitely. However, in the unreserpinised mouse,
the threshold could not be effected by either synthesis inhibitor
acting on its own, but only by e combination of the two. Similar
results have been published by Killiam and Frey (335).
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Kellog et al. (130) also found that, In a certain type of audio-
sensitive mouse, audiogenic seizures could be blocked using clonidine,
an a-adrenergic receptor agonist, but not by apomorphine, a DA-
receptor stimulator. These findings contrast with the opposite
pattern of results found in the cobalt-implanted rat, in which
clonidine aggravated spiking while aponorphine reduced it (354). This
may be related to the fact that morphine has a stimulatory effect in
mice but a sedative effect in rats (507). This suggests that the
neuronal substrate to epileptic behaviour is model-specific, or
species dependent, and that the involvement of monoaminerglc sub¬
systems (and presumably also gabaminergic, cholinergic and indeed
all neuronal sub-groups) may differ widely from model to model.
Iturrian and Fink (345) proposed a model of the convulsion
consisting of three separate but interdependent systems. Firstly,
an afferent link, requiring the operation of an oscillator within
which a substantial number of neurones must discharge over a limited
period of time. Secondly, a mediating link consisting of the
mechanisms responsible for the propagation of the seizure discharge
from the oscillator (this mediating link has been the target of
several neurosurgical techniques used clinically, and this is
discussed briefly in the summary of the thesis), and thirdly, an
efferent link, at which level mechanisms operate to produce a
generalised seizure. Although the last stage may be common to
all forms of tonic-clinic epilepsies (346), it seems logical to
suppose that the neuronal substrate for the first two stages is
model specific, and is not the same in, for example, electrical,
chemical and reflex epilepsies.
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Not many workers would now agree with the eart ier, unifying
hypothesis that sought to establish a coairaon biochemical denomin¬
ator whether serotonergic (330, 331, 332, 333) or catecholaminergic
(328, 329, 543) to all types of epilepsy. The concept of model-
specific patterns of neuronal involvement helps to explain and
reconcile much of the previously irreconcilable data.
Rudzik and Johnson (55) performed on elegant series of experiments
which also suggested that the various monoamine neuro-transmitters
played different roles in the different epilepsy models, and pointed
out very effectively the weakness of any general statement linking
seizure threshold with central monoamine levels. They examined the
effects of specific monoamine depletion in two different models, the
mouse electroshock model and the mouse pentylenetetrazols model, and
it became apparent that the two models involved two different raono-
aminerglc systems. The pentylenetetrazols threshold could be
elevated by raising effective 5-HT levels and lowered by reducing
central 5-HT, but it was insensitive to manipulation of central NAd.
Conversely the electroshock threshold was shown to be directly related
to central NAd levels but to be unaffected by altering serotonergic
tone. Similarly, in the rat, apomorphine has been shown to afford
protection against maximal electroshock seizures (569) and to reduce
epileptic activity in the cobalt-implanted rat (354), but it is also
reported to potentiate pentylenetetrazols seizures (570).
The circuitry of even one type of convulsive model may be species
dependent. Amphetamine has been reported to raise the threshold
to electroshock in rabbits (543) and mice (544), while lowering it
in the rat (545).
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To summarize, It must be admitted that some of the data referred
to in this action do not match very well. There are three main
reasons for this; first, some of the earlier work reported on total
brain monoamine levels, rather than on neurotransmitter turnover;
second, some of the drug treatments may not have been as specific as
they were thought to be, and third, the variety of models used makes
it difficult to compare data from different laboratories.
FINDINGS OF ALTERED AMINE METABOLISM IN EPILEPSY M0DEL8
One of the first studies by Schlessinger et al. (356) on the
neurochemistry of audiogenic reflex epilepsy described how the
seizure threshold in genetically susceptible mice varied with age,
and how this correlated with age-dependent changes in #rain amine
levels. They discovered that at the time of maximal vulnerability,
brain NAd and 3HT levels were respectively 40 per cent and 50 per
cent of values in non-sensitive mice while at later times when the
mice were no longer audio-sensitive their brain amine levels closely
matched values in other mouse strains.
There is a suggestion of similar NAd involvement in a related
mouse model, the rubidium chloride-treated audio-sensitive mouse (468).
Paradoxically this drug has been reported to cause an increase in NAd
turnover in rat brain (460). In the cobalt implanted rat, however,
studies by Colosanti and Craig (454) have failed to reveal any changes
either in whole brain NAd, DA and 5H7, or in NAd and DA turnover.
ALTERED CATECHOLAMINE METABOLISM IN CLINICAL EPILBPSV
In general, central catecholamine metabolism in human subjects
can only be followed fpdirectly. Usually only CSF samples are
available, and workers in this field have for the most part been
interested in measuring levels of the dopamine metabolite homovanillic
acid (HVA). The problems of interpreting the data from CSF-sampling
are discussed in more detail in the section on 5HT (pi 50).
Shaywitz (87) and others (32, 33, 34) found a 50% reduction of
HVA in the CSF of epileptic children, and a similar reduction was also
found in the CSF of a groupf of unmedieated epileptic patients (9),
suggesting that the low CSF HVA concentrations genuinely reflected the
disease process, rather than the effects of the patients' medication.
However, there are conflicting reports; Garelis and Sourkes (8)
report normal CSF HVA levels in lumbar and mixed samples taken from
grand mal and temporal lobe epileptics; and Chadwick et al. (29)
found CSF levels of HVA in unmedicated patients fairly close to
control values. They also reported a correlation between CSF HVA
levels and plasma anti-convulaant concentrations, and suggested
that various anti-convulsants raised CSF HVA levels - in fact that
the increase in HVA levels was a direct manifestation of the anti¬
convulsants' effectiveness.
THE EFFECTS OF ANTI-CCNVULSANTS ON CATECHOLAMINE METABOLISM IN BRAIN
Phenobarbitone has been shown to reduce DA and NAd turnover in
rat brain (61, 62, 63). This action of the drug is hard to square
with the conclusions of Chadwick at al. (29), (see above),
but apparently phenobarbitone (and diphenylhydantoin) also interfere
with the transport of organic acid metabolites from brain which would
tend to increase CSF HVA levels (36). In the mouse electroshock and
pentylenetetrazols models, NAd and DA depleting agent a-methyltyrosine
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and NAd receptor blocking: agent phentolamine were found to render the
anticonvulsants diphenylhydantoin and phenobarbitone ineffective,
while L-Dopa had an opposite, synergistic effect (41). This suggested
that these anticonvulsants acted at least in part via the central
catecholaisinergic systems. However, in conflicting experiments
(140, 141) the amine depletors, reserpine, tetrabenazine, a-
methyldopa, c-methyltyrosine and adrenergic blocking agents tolazollne,
nethalide and chlorpromazine, had little effect on the anticonvulsant
action of diphenylhydantoin in the mouse electroshock model. The
authors suggested therefore that diphenylhydantoin did not exert its
anticonvulsant effect solely by way of central monoamine systems.
This discrepancy may be explicable in terms of the specificity of the
monoamine depleting agents used, or degree of reduction of amines.
Amphetamines have also been used clinically in the treatment
of epilepsyjincluding petit mal seizures (942); they counter the
ataxia and drowsiness produced by phenobarbitone and diphenylhydantoin,
and have been reported to enhance the antl-convulsant action of
phenobarbitone clinically, (541), and the anticonvulsant action of
phenobarbitone and diphenylhydantoin in the mouse electroshock and
pentylenetetrazol models (55). The authors inferred that the action
of amphetamines in these models was in some way related to the central
NAd releasing effect of this class of drugs. They suggested that
this was probably not the only mode of action, as D-amphetamine was
capable of reversing the lowering effect of reserpine on the seizure
threshold to both pentylene tetrazole and electroshock, in other words
was still an anticonvulsant when central NAd stores were depleted.
It is worthwhile mentioning here that there exist theories of
the action of anti-convulsants which are completely divorced from
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any concept based on the biochemical sub-classification of neurones,
but concentrate instead cm the electrical properties of the neuronal
membrane. Swinyard (357) suggested that anticonvulsants might act
by stabilising the neuronal membrane, resulting in a reduced tendency
to hypersynchrony. This would disrupt the oscillator mechanism and
also result in a reduction of spread of the epileptic discharge,
which could be thought of as dampening down the mediating and efferent
links of Iturrian and Fink's model (345 (p72).
The disruption of the oscillator link, and the damping of the
mediating and efferent links could, therefore, be a reflection of
an alteration in the properties of the conducting nervous membrane,
rather than a result of interference with events localised to the
synapse. It might consequently be wrong to overemphasise the
biochemical findings referred to above.
INTRODUCTION TO THE BIOCHEMISTRY OF GABA IN THE COBALT-IMPLANTED BAT
Work already carried out in the M.R.C. Brain Metabolism Unit (466)
using the Finkheimer technique to examine the development of epileptic
foci in the rat after the implantation of metallic cobalt into the
frontal cortex, has shown that degenerating terminals, axons and cells
could all be clearly demonstrated to be present in the primary lesion
between the 4th and 29th day post implant; this was most marked in
the involved areas of sensori-motor cortex, but cellular damage was
also evident in the body of the caudate nucleus Inferior to the site
of Implant. There was also evidence of a lesser degree of damage
in the secondary focus and in the contralateral caudate nucleus.
During the same period spikes were present in the ECoG, appearing
3 to 4 days post-implant and increasing in frequency until reaching
peak rates between 7 and 12 days, and then falling off to 20 to 30%
of the peek rates during the third week. It was also shwon (466)
that glutamic acid decarboxylase (GAD) activity was reduced in the
area of the primary lesion between 4 and 8 days post-implant, while
levels of GABA in the same area were reduced at S days post-implant,
and were lowest at days 8 to 10f before recovering at day 25.
Involvement of both of these parameters in the secondary focus was
less conclusive. The degree of involvement of cholinergic neurones
as measured by assaying choline acetyltransferase (ChAc) activity,
was also mentioned, and this enzyme also showed reduced activity in
the primary focus between days 2 and 10 with a smaller, transient
fall at day 5 in the secondary focus. Lactic acid dehydrogenase
(LDH) activity was only reduced in the immediate lesion area,
suggesting that outside the area of necrosis, nerve terminals were
more specifically affected (Figs A1-A3). There appeared to be some
correlation between the reduction in amino acid concentrations and
enzyme activity and the developing epileptic signs in the ECoG,
over the first two weeks after the cobalt implant. The altered
gabaminergic parameters suggested that a permissive relationship might
exist between the viability of the gabaminergic system and the
tendency of the cortex to produce spike discharges. However, it was
Impossible to say from this evidence alone which was cause and which
effect, or whether both factors were a consequence of some other
change(s) occurring in the damaged tissue.
In the hope of throwing some further light on this problem it
was decided to measure gamma aminobutyric acid transferase (GABA-T)
activity in primary and secondary foci over the 30-day period already
examined. GABA-T estimations were carried out using the method of
Table Alb
Estimation of brain GABA-transaminase activity (n.mol. GABA trans-
a .
aminated/g protein/ hr) in rat frontal cortex at Intervals after
cobalt-implantation
A) Control values 365 378
(Unoperated littermates) 326 360
357 + 19(4)
B) Cobalt-implanted rats Leaion Contralateral
Day 3 post-implant 126 7 288 96
57 nil 138 298
nil 76 392 281
44 £ „ 47(6) 249 _+ 101(6)P1
Day 6 post-Implant 71 nil nil nil
6 6 nil nil
41 26
25 at 27(5) 5 + 10(5)
Day 9 post-implant 269 886 63 264
508 721 264 172
625 119
602 £ 207(5)P1 176 + 79(5)P3
Day 12 post-implant 239 286 126 138
435 152 50 125
553 nil
333 + 143(5) 88 + 54(5)P3
Day 30 post-Implant 237 185 511 534
229 344 435 504
249 _+ 58(4)P2 496 37(4)P2
Day 100 post-implant 384





1. All final values are given as the mean _+ standard deviation.
2. P-values refer to comparisons between experimental and control
data, made using Student's t-test with Bessel's correction.
PI = 0.1 >P>0.05; P2 = 0.025 ) P >0.02; P3 = 0.01 > P > 0.005
Hall and Kravltz <574, Methods Bl) in frontal cortex at different
times after cobalt implantation (Fig, All). GAHA-T activity fell
in both foci at days 3-6 post-implant; then increased to above
normal values in ipsilateral cortex at day 9 before stabilising at
day 12. The pattern of changing GABA-T activity in the secondary
focus was slightly different, remaining low until day 12, before
increasing to above normal values at day 30. The published data
on GAD activity and GABA concentrations (466) show no corresponding
increases at days 9 and 30 in primary and secondary focus, and it was
therefore considered unlikely that the GABA-T data might represent
any increase in the number or activity of gaba-containing nerve
terminals. It seemed more likely to be associated with the glial
reaction that develops around this time in the area of the cobalt
implant (466). This would provide an adequate explanation for the
increased GABA-T activity, as it has been shown that a large
proportion of GABA-T in brain is, unlike GAD, associated with glia
(597). The much smaller Increase in GABA-T activity in the
secondary focus at day 9 may reflect the much smaller glial reaction
on the contralateral side (466).
INTRODUCTION TO THE BIOCHEMISTRY OF THE CATECBQ1AM1NERGIC SYSTEMS
IN THE COBALT-IMPLANTED RAT
None of the results of the previous work had been directed to
examining the role of monoaminerglc neurones in this model. It was
therefore decided to assay enzymes involved in the functioning of
catecholaminergic neurones in the primary and secondary focus areas
at different times after cobalt implantation.
Tyrosine hydroxylase (TOH) is thought to be the most specific
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marker enzyme, being located in the CN8 only within catecholam-
lnergic neuronea (604). Monoamine oxidase (MAO) a mitochondrial
enzyme (403), and crtechol-Onsethyltransferase (COMT) a cytoplasmic
enzyme (404), were the other two enzymes studied, but although both
of these enzymes play an integral role in the function of central
monoaminergic systems the data they provided was thought to be less
unequivocal, as they are associated not only with monoaalnergic
neurones but also non-aminergic neurones (401) and with glia (402).
MAO in particular is rather evenly distributed in brain, with only
a three-fold difference in activity reported between areas of highest
and lowest activity, the hypothalamus and corpus csllosum respectively
(149). A recent paper by Ulmer et al., 1970 (67) casts further doubt
on the usefulness of MAO as a monoamlnergic cell marker; they found
that in undercut cortex preparations, i.e. in tissue presumably cut
off from extra-cortical innervation, MAO fell by only 10 per cent,
in marked contrast to the reduction, by almost 50 per cent, of acetyl¬
cholinesterase .
The reason for assaying MAO and COMT was therefore as support
for the TQH data, which on its own would have been open to various
criticisms, discussed in the following section, concerning the method
of assay used. To provide farther information on the involvement
of catecholaminergic neurones in the epileptic process, concentrations
of noradrenaline (NAd) were measured In the cortex, and metabolites
of dopamine (OA) hcmovanilllc acid (HVA) and of NAd, 4-hydroxy-3-
methoxyphenylglycol (IIMPG) were monitored in cortex and striatum.
ToH activity was also assayed in sections of mid-brain containing the
locus coeruleus to provide some indication of events at the cell
body level of the noradrenergic neurones projecting to the cortex.
Table A1
Protein content (me/fir wet weight of tissue) in lesion (1) and
contralateral (c) frontal cortex of the cobalt-implanted rat.
Days post-implant
Day 0 Day 3 6 9 12 30
_L c _L _L £_ _L L £.
113 98 114 94 09 92 03 112 106 107 120
108 103 108 97 103 101 101 93 102 113 109
121 94 110 92 103 95 103 92 113 115 112
112 97 102 107 04 93 99 102 95 110 117
106 106 117 98 97 100 114 96 92 103 112
104 101 111 105 102 97 107 06 103 116 107
Mean values ( + standard deviation)









6 9 12 30
98.83+5.46 97.83+6.25 98.5+6.82 110.66+4.57
99.66+3.34 102.8346.54 101.83+6.01 112.83+4.45
NAd concentrations were assayed using: the fluoroasaay of Schlumpf
©t al. (24), Methods CI. Metabolites HVA and IfiPG were assayed using
the methods of Hoos (21), Methods CII, and Walter and Eccleston (562),
Methods CIII respectively. The radiometric tyrosine hydroxylase
assay was based on the method of Hendry and Iverson (353), Methods
Bill.
INVESTIGATION OF THE CATECHOLAMINE SYSTEM IN THE COBALT MODEL
A.
All the enzymes referred to here were assayed in terms of enzyme
activity/g protein, rather than per g wet weight, to avoid the risk
that oedema developing at any stage might confuse the picture with
an increase in the fluid content of the tissues sampled. The protein
content of every sample was assayed using the method of Waddell
(572) (Methods Dla). The results show (Table Al) that a reduced
protein content/g brain develops around the primary lesion by day 3
post-operatively, and by day 6 in the secondary focal area. In
both cases the protein/wet weight ratio has returned to normal values
by day 30. The rapidity of the changes suggest that the altering
protein/wet weight ratio is more influenced by changes in fluid content
rather than by any actual changes in protein levels.
Levels of activity of all three enzymes, ToH, MAO and COIIT, fell
in both ipsi- and contra-lateral cortex as early as 3 days post-implant.
(Tables A2,3,4). Levels of all three enzymes were still low in both
cortices at 30 days, and had returned to normal values at 100 days.
These results differ in two Important ways from the published data
(466) already referred to, concerning the cholinergic biochemistry
and gahaminerglc biochemistry of this model. First, MAO and TOH
Table A2
Estimation of tyrosine hydroxylase (in n.iuol Dopa produced/g prot./h)
in ipsi- and contralateral frontal cortex of cobalt-implanted rats
A) Control values 5.0 3.6
(Unoperated littermates) 5.0 5.3
3.8 2.2
4.2 + 1.1(6)
B) Cobalt-implanted rata Legion Contralateral











0.42 £ 0.27(5) 1.57 + 0.49(6)










0.55 + 0.25(5) 0.58 £ 0.24(5)










0.27 £ 0.14(5) 0.61 £ 0.16(5)










0.24 ± 0.1(5) 0.73 £ 0.4(5)








1.23 £ 0.15(4) 1.36 £ 0.31(4)
Bay 100 post-Implant 3.42





1. All final values are given as the mean £ standard deviation.
Table A3
Estimation of catechol-O-methyltransferase activity (n.mol. 4-hydroxy-
3-r.tethoxyphenylglycol formed/# protein/h) in ipsi- and contralateral
















Day 3 post-implant 92 64 72 60
49 38 54 107
36 31 48 37
52 + 21(6)P3 63 + 22(6)P3
Day 6 post-implant 878 898 133 100
949 317 154 50
1742 253
957 + 455(5)P1 138 + 67(5)P2
Day 9 post-implant 151 582 97 150
389 144 94 87
132 52
280 + 179(5) 96 + 31(5)P3
Day 12 post-implant 97 68 106 120
230 281 179 233
625
260 + 199(5) 160 + 51(4)P2
Day 30 post-implant 137 95 418 85
126 222 165 213
145 + osu/■>»•<pwf»V 220 +123(4)
423 + 26(4)
Notes:
1. All final values are given as the mean + standard deviation.
2. P-values all refer to comparisons between experimental and control
data. Student's t-test was used, with Bessel's correction.
PI = 0.05> P> 0.025; P2 = 0.02> P> 0.01; P3 = P< 0.001
Table
Estimation of monoamine oxidase activity (p.mol. tyramine oxidis#d/g








B) Cobalt-implanted rats Lesion Contralateral


































Day 100 post-implant 23





1. All final values are given as the mean + standard deviation.
%.
activities did not return to normal by 20 to 30 days, remaining at
roughly 30% of normal values. Second, it appeared that these
enzyme activities were as much affected in the secondary focus as in
the primary focus, in contrast with the findings of relatively
minor alterations in the activity of cholinergic and gabaminergic
enzymes in the secondary focus. CCMT activity also fell in both
foci at day 3, but in this case, although levels remained low in
the secondary focus throughout the first 30 days. There was an
increase to over double normal iavels in the primary focus at
day 6, remaining substantially higher than secondary focus values
at day 9 and 12. However, by day 30, they were low again and close
to secondary focus values. It was thought that the increase in
the primary focus might be related to the gliosis that develops
around the cobalt implant at this stage (466), as CCMT is associated
with glia (402). This does not quite fit with the findings of
increases in GABA transaminase activity in the primary focus at day 9,
which was also tentatively ascribed to a glial reaction, because at
day 9 CCMT activity has already fallen from the peak values reached
at day 6. This could be explained theoretically in terms of a
sequence of biochemical events occurring in the developing
population of glia as the damaged tissue reacts to the trauma of
the implant. Another possibility is that there may be two distinct
populations of glia involved in the response; there is some evidence
for a biphasic glial response after injury, as described by Sumner and
Sutherland (364), developing in the hypoglossal nucleus after hypo¬
glossal axotomy. In this case, however, the transition occurred
rather more slowly, the microglial response peaking between 2 and 14
Table AS
Estimation of 4-Hydroxy-3-Methoxyphenylglycol (HMFG) in ipsi- and























































128 + 21 (4)
1. All final values are given as the mean + standard deviation.
2. Tissue from 3-4 rats was pooled for each analysis.
3. P-values all refer to comparisons between experimental and control
groups. Student's t-test was used, with Bessel's correction.
PI = 0.2 >P> 0.1; P2 = 0.1> P> 0.05; P3 = 0.02 > P > 0.01.
Table A6
Estimation of 4-Hydroxy-3-Methoxyphenylglycol (£MPG) in caudate nuclei,
ipsi- and contralateral to cobalt implant in rat frontal cortex
(ng JMPG/g wet weight brain)
A) Control values (Unoperated) 136
(Both caudate nuclei pooled) 152
193
160+24(3)
B) Cobalt-implanted rats Lesion Contralateral













Day 20 post-implant 114 190
98 165
135 201
116 + 15(3)P1 185+15(3)





1. All final values are given as the mean + standard deviation.
2. Tissue from 4-5 rats was pooled for each analysis.
3. P-values all refer to comparisons between control and experimental
data. Student's t-test was used, with Bessel's correction.
PI = 0.1 >P >0.05; P2 = 0.025 > P > 0.02; P3 = 0.01 > P > 0.005
day* after axotomy and the astrocyte response between 14 and 35
days. One possible reason for the apparent compression of the
time-scale in the cobalt rat gliosis may be a geometrical one -
o
cortical trauma can stimulate a glial response in a zone of 360
around the injury, whereas in the hypoglossal model it may take
some time for the gliosing stimuli to arrive at the nucleus after
damage at a distant site on the axon.
INVESTIGATION OF TODS CATECHOLAMINE afgTEH IN THE COBALT MODEL
B. Metabolites
Concentrations of KdPG (Table AS) in both ipsi- and contra¬
lateral cortex showed marked rises at 8 days post-implant, and
appeared to have returned to normal by days 15-30. The changes
in both ipsi- and contra-lateral caudate nucleus were fairly
similar (Table A6) ifttPG levels showing an Increase at day 8 but
returning to normal slightly more quickly, at day 15. Again* here
is a pattern of similar changes occurring around both primary and
secondary foci.
The assay used to estimate concentrations of HVA was insuffic¬
iently sensitive for a bilateral assay of striatal HVA, and samples
of both leaion and contralateral side from rats had to be pooled
for analysis. The results (Table A7) indicated that HVA concen¬
trations Increased by between 50 and 100% in the mixed caudate
samples between days 4 and 30 post-implant. Although one cannot
be sure, the size of the increase suggests that the changes in HVA
levels occurred bilaterally.
Table A7
Estimation of homovanilllc acid (HVA) in caudate nuclei of rats at
intervals after cobalt implantation (ng HVA/g wet weight brain)






934 + 131 (6)
B) Cobalt-implanted rats (Lesion & contralateral sides pooled)














1. All final values are given as the mean ± standard deviation.
2. To provide adequate tissue for analysis, samples of both lesion
and contralateral side caudate were pooled from 2-3 rats to
provide each datum included in the table.
3. P-values all refer to comparisons between control and experimental
rats. Student's t-test was vised, with Bessel's correction.
PI = 0.05 > P> 0.025; P2 s 0.005 > P > 0.001; P3 = P< 0.001.
Table A8
Estimation of noradrenaline (NAd) in ipsilateral cortex of cobalt-








(frontal cortex, lesion side)















1. All final values are given as mean + standard deviation.
Table A9
Estimation of mid-brain tyrosine hydroxylase activity (n.nol. Dopa



















































1. All final values are given as the mean + standard deviation.
2. Student's t-test with Bessel's correction was used to compare
the experimental data with control values. No significant
changes were found (P>0.2).
3. Mid-brain sections prepared as described in Methods Section, j\ Tv
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INVEST ICAT ION OF THE GATECHOLAMINERGIC SYSTEM IN THE COBALT MODEL
C. Further parameters
Noradrenaline (NAd) was assayed in the ipsilateral cortex, and
tyrosine hydroxylase (TOH) activity was measured in mid-brain
sections containing: the lpsl- and contralateral locus coeruleus.
(Tables A8, A9). The finding of unchanged levels of NAd in the
cortex is supported by fluorohistochemical studies of the cobalt-
implanted rat in which no alteration of NAd-attributable
fluorescence in the cortex was detected. (BJorklund and Emson,
personal communication). TOH activity also remained unchanged in
the ipsi- and contralateral midbrain sections of the epileptic rat.
DISCUSSION
The results presented above form a rather contradictory set
of data. The fact that the changes in enzyme activities and
metabolite concentrations occurred in -both primary and secondary
foci suggested that the catecholaminerglc system might be reacting
at the cell body level, but the fact that no bilateral or unilateral
changes in TOH activity could be demonstrated in the loci coerulei
argued against this, as did the unaltered cortical NAd concentrations.
This implied that the changes described above were a reflection of
local cortical events rather than aspects of a physiological response
in a discrete neuronal system. This is also suggested by the rate
of onset of the changes in the catecholamlne-related enzymes and
metabolites, which resembled fairly closely the overall pattern of
cellular degeneration in the cobalt model as described by Emson &
Joseph (466), and also appeared to coincide with the developing
changes in the EEG, although this in Itself does not distinguish
between the causative or simply associative mode. If the changes
in catecholamine-related parameters are not due to changes at the
cell body level, then the problem arises of how to explain the
rapid and dramatic changes in the secondary focus. As evidenced
by the changes in the primary focus, various processes occurring
within catecholaoinergic nerve terminals appear to be very
sensitive to cobalt. One only has to hypothesise some form of
fairly rapid transport of the cobalt to the contralateral cortex
to provide a putative explantation of the parallel changes occurring
in the contralateral cortex. If the cobalt ion is in fact
inhibiting the enzymes TOH, MAO and CCtST, then the fact that
decreased activities of these enaymes can be demonstrated using
in vitro assay techniques where the series of dilutions involved
in preparing the tissue for incubation would substantially reduce
the concentration of the cobalt ion, suggests that the Inhibition
is of the irreversible type, and that the cobalt in the cortex,
possibly concentrated in the region of catecholamlnergic nerve
terminals, effects a permanent alteration of the enzymes' structure.
This possibility is discussed in a later section.
The increased HMPG concentrations in cortex and caudate nuclei
Cipsi- and contralateral to the lesion) at day 8 can be explained
in terms of only two processes, one being an increase in NAd
catabolism and the other being a reduction in iftfPG transport from
the brain. In the light of the reduced tOH, MAO and COST
activities and unaffected cortical NAd concentrations already
described, it seems most reasonable to suggest an inhibition of
HMPG transport as the prime reason.
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Unfortunately the assay method used In this study measured
total HMPG concentrations, not distinguishing between free and
conjugated HiPG (MiPG-S04). Free HUPG is thought to be readily
diffusible throughout brain; some workers suggest that no 12.1PG
transport system exists (Korf et al., 469) and if it can indeed
diffuse so easily then teleologlcally there would appear to be no
reason for a transport system to have developed. This theory is
supported by the findings of low regional variation of HMFG; C* Yates
(personal communication) finds only a two-fold maximal regional
difference for total HfcfFG in areas of rat brain, the highest
levels occurring in brainstem and the lowest in cerebellum.
Ashcroft et al. (529) have published similar findings in the dog
brain, with a maximal variation of 400 per cent, and similar data
is being produced by the J4BC Brain Metabolism unit in on ongoing
project using post-mortem human brains.
This Is in marked contrast to the patterns of HVA and 5HIAA
distribution, which display up to ten-fold regional variation, and
it is also in contrast to the pattern of localisation of the mono¬
amine neurotransmitters. Although HMPG removal from brain is
different from HVA, 5H2AA and H^PG-SO^ excretion in that it is
relatively insensitive to probenecid, a recent paper by Barany (666)
has established the co-existence of two distinct transport
mechanisms in the rat choroid plexus. As well as the classical,
renal secretcry-llke system, he showed that another system, resembling
that of hepatic bile acid secretion, could be demonstrated, it being
less sensitive to probenecid. Although there is as yet no evidence
for MtlPG being a candidate for this second transport system, this
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possibility cannot be discounted.
The rise in total HMPG levels could be due to an interference
with the removal of HMPG-SO.. Eccleston and Ritchie (532) have4
shown that HUPG is readily esterifled in rat brain in vivo, and
there is some evidence for an HMPG-SO^ transport mechanism from
the brain in the rat (527, 528), which resembles 5HIAA and HVA
transport in that it can be inhibited both by probenecid and by
ischaemia (527). As already pointed out, the method of HMPG assay
used here does not distinguish between free and sulphated HMPG
(only total t&IPC was measured), so I do not know the contribution
of the two species to the rise. Jf it is true that free IMPG is
removed by diffusion, while the sulphate is removed by a transport
system, the increase in total HMPG content of cortex and caudate
at day 8 seems more likely to be a result of Jfc'PG-SO^ retention.
If inhibition of HUPG-S<>4 transport were indeed a factor, then one
might expect to find similar increases in HVA and 5H2AA. One of
the series of 5HIAA data did in fact display an increase in cortical
5HIAA concentrations during the first week after implant;
similarly, 5HIAA concentrations were found to be significantly
elevated in the caudate nuclei between days 4 and 15 post-implicit
(Tables A18,A19). These data are discussed in more detail in the
5KT section. The HVA data also displayed a significant rise (by
about 100%) in striatal concentrations at day 4 post-implant, but
this elevation appeared to be longer lasting than that of HMPG, as
it was still apparent at day 20. Although these changes do not
exactly match, they all suggest that a block of metabolite transport
was developing sometime between day 4 and up to day 20. This may
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be an affect of the cobalt ion, or a result of the general trauma
of the implant and subsequent epilepsy. Unfortunately the controls
used in this experiment were unoperated litter-mates of the
experimental animals, rather than glass-implanted, and in the absence
of further data it is Impossible to be more specific on this point.
It was decided to examine in more detail the possible
mechanisms involved in the rapid, bilateral reduction in cortical
TOH activity. The pteridine-sensitive hydroxylases are notoriously
sensitive to a wide range of factors, one important one being the
type of co-factor used. There is one commonly used synthetic
pterin, 5, d-dimethyltetrahydropteridin© (DMPH^), which has often
been used in place of the physiological eofactor, tetrahydrobiopterin.
Not only does the enzyme^ affinity for ths different cofactors vary,
(Km for EKFH4 Is three times that for the tetrahydrobiopterin) but
also when using the synthetic pterin the affinity of the enzyme for
its substrate is drastically lowered, the Km value being increased
twenty-fold (40S). Parallel results have been published concerning
the other pterin-dependent hydroxylase, tryptophan hydroxylase
(17,18). Tetrahydrobropterln has also been shvwn to increase Vteax.
values for TOH (406), and the chemical efficiency of the
hydroxylatlon reaction (400,407), in comparison with data derived
using DMFH .
4
The type of homogenising buffer used in the in vitro assay
technique is also important, as TOH has been shown to be sensitive
to a range of ions, notably the sulphate ion (406), which has a
stimulating effect. Sulphated mucopolysaccharides, especially
heparin, also stimulate the enzyme (540). Returning to the cobalt-
implanted rat, it is known that a general feature of tissue damage
is an initial fall in the level of sulphated mucopolysaccharides,
with a subsequent increase associated with scarring. This could
complicate the picture in the primary focus, but does not seem
likely to affect TOH activity measured in the secondary focus.
As the results generated by the particular assay used are dependent
not only on the activity of the enzyme but also on the availability
of endogenous substrate, the criticism lias been raised that a fall
in tyrosine hydroxylase activity could be partly caused by a fall in
tyrosine content of the sampled areas of brain. However, no
other amino acid assayed in this model (400) shows the decrease in
concentration in both foci necessary to explain the bilateral fall
in TCffI activity. It is perhaps more reasonable to suggest that
the cobalt ion is affecting a permanent inhibition of the enzyme,
perhaps by causing some subtle alterations of the enzyme structure.
The normal enzyme activity in the loci coorulei suggests that enzyme
synthesis is unaffected, but possibly transport of the enzyme to the
nervo terminals is inhibited. A reduction in the number of
noradrenergic nerve terminals to and around both foci would also
explain the reduced TOH activity, but the unchanged levels of
cortical NAd argue against this, unless one postulates a compensatory
increase in NAd concentration in the remaining functional neurones.
The picture then is of a greatly reduced activity of TOII in the
cortex, yet normal concentrations of NAd. This seems contradictory,
but can be explained by a redundancy factor - it is generally held
that levels of neurotransmitter synthesising enzymes are in excess
of what is requirod for normal functioning of the nervo, and in
particular Mackay (526) baa shown that in the sympathetic ganglion
preparation, no correlation whatsoever could be found between
potential TQH activity and NAd concentrations. The situation as
regards UAO and CGtST is very different. Unlike TGH, which is
restricted to a single nerve species, both MAO and CCtiT liavo been
shown to be associated not only with catecholaminergic neurones,
but also with non-catecholaminergic neurones and with glia (366,367).
To account for the changes in those two enzymes, therefore, either
<me has to postulate a degree of general cell damage which, again,
does not correlate ttt all with the unaltered cortical NAd concentrations
nor with histological studies of this model (466), or one has to
argue that the changes are specific. In that case one is faced
with two possibilities - either the cobalt ian interferes with the
synthesis of these two enzymes, or, due to a very high affinity of
the ion for the enzymesand/or their environs, a finite amount of the
ion continually inhibits the newly-synthegised enzymes.
The coincidence that the three enzymes should be affected in
such a similar way, in contrast to, for example, gabaminergic and
cholinergic enyymes, is so unlikely that common factors must be
looked for. Would the fact that all three enzymes are thought to
require the presence of a divalent metal ion cofactor render them
especially vulnerable to the effects of the cobalt ion? (TQH
-f | Hh-4-
requires Fe , CC&1T requires Ug and 2.IA0 is thought by some workers
to require Fe also (602)). If these enzymes have a high affinity
for cobalt, more so than, say, GABA-T, then this might explain the
long-lasting changes. Alternatively, if by one of the mechanisms
mentioned the cobalt ion first affects tyrosine hydroxylase activity,
the changes in MAO and COSfT may be compensatory phenomena, post-
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and pori-synaptlc responses to altering catecholaminergic tone.
These longer-term phenomena would probably not be important in
affecting the initial changes in enzyme levels, for example the
reduced activity of MAO and COW at day 3 in both ipai- and contra¬
lateral cortex.
It seemed necessary at this point to check on whether the
apparent reduction in tyrosine hydroxylase activity was a real
phenomenon or an assay artefact. It was therefore decided to
examine the effects of postulated enzyme inhibitors (including
the cdbalt ion) on the assay, and to measure concentrations of
cobalt in the rat brain at different times after implant.
Two possible enzyme inhibitors were examined. First, It had
been suggested that the cobaltous ion might compote with the ferrous
ion co-factor, so the effects of the ferrous ion on cortical
horaogenates from cobalt-implanted rats were examined (Table A10).
Enzyme activity in samples of contralateral cortex wen© unaltered
by the addition of Fe++ to a final concentrat ion of 50pM. Second,
it was decided to examine the effects of HMPG, in the light of the
large changes in the concentration of this metabolite in cortex
and caudate during the onset of the epileptic condition (Table 0 5 t).
This latter seemed a less likely candidate for the possible enzyme
inhibitor, as &.TPO concentrations have after all returned to normal
long before enzyme activities recover. IfctPG in a final concen¬
tration of ImM, the maximum concentration found in the striatum
in the earlier study, had no effect on tyrosine hydroxylase
activity in a homogenate of contralateral cortex from a cobalt-
implanted rat (Table A10). The sensitivity of the enzymes
(TQH, MAO, CCfcfT, GABA-T and tryptophan hydroxylase) to concentrations
Table A10
Effects of postulated inhibitora on tyrosine hydroxylase activity
A Control cortex











B Contralateral cortex from rats 15 days post-implant
Control Incubation Incubated with 60»M Fe~*
Animal No. 5. 0.52 5. 0.67
6. 0.97 6. 0.91
7. 0.43 7. 0.37
8. 1.02 8. 0.88
0.74 + 0.26 0.71 + 0.22
Notes:
1. All figures expressed as n.mol. Dopa produced/g protein/h.
2. All final values given as the tuaan + standard deviation.
3. Fe was added as Fe Cl0.
Table All
Sensitivity of pterin-dependent hydroxylase enzymes to cobaltous
ion concentration in vitro, tyrosine hydroxylase preparations being
obtained from frontal cortex and tryptophan hydroxylase preparations
from mid-brain
Tyrosine Hydroxylase Tryptophan Hydroxylase




3.6 + 0.4(4) 4.0 + 0.4(4)
B) Experimental data 3.8
lOpM Co** 3.2 4.1
4.0 3.4
3.3 3.3
3.3 + 0.3(3) 3.7 + 0.3(4)




3.1 + 0.2(4)P1 3.2 + 0.3(4)P1





1.3+ 0.4(4)P3 2.0 + 0.7(5)P2
Notes:
1. Figures show n.mol. Dopa produced/g proteln/h and n.mol.
5-hydroxyindoles produced/g brain/h for tyrosine and tryptophan
hydroxylase respectively.
2. Final values given as x + SD'(N).
3. P-values refer to comparisons between experimental and control
data. Student's t-test was used, with Bessel's correction.
PI = 0.1>P>0.03; P2 = 0.05 >P> 0.025; P3 = 0.005 >P > 0.001.
|
4. Co was added to the incubation media as the CoCl? salt, and
pre-incubated for 10 m. before the enzyme reactions were begun.
Table A13
Sensitivity of enzymes of rat frontal cortex to cobaltous ion in vitro,
i. Monoamine oxidase (MAO








































































36.5 + 5.5 P4 39.2 + 2.7(4)












13.2 + 2.7(5)P4193 + 15(3)
_
Notes:
1. Figures show n.mol. GABA transaminated/g protein/h (GABA-T),n.mol.
EMPG produced/g protein/h (COOT), and p.mol. tyramine oxidised/g
protein/h (MAO).
2. Final figures given as x + SD'(N).
3. P-values refer to comparisons between experimental and control values.
Student's t-test was used, with Bessel's correction. PI = 0.2 >P> 0.1;
P2 = 0^05 >P> 0.025; P3 = 0.005 > P > 0.001; P4 = P <0.001.
4. Co was added to the incubation media as the CoCl2 salt, and pre-
incubated for 10 min. before the enzyme reactions were begun.
of the cobaltoua ion was measured (Tables All,12), and an analysis
of this data is presented In the discussion of the next section,
dealing with the results of the assay of cobalt in various areas
of the brain.
ESTIMATION OF COBALT C0NCENIHATI0N8 IN THE BRAIN
OF COBALT-IMPLANTED RATS
It was decided to assay cobalt levels in different areas of the
brain of the cobalt-implanted rat to find out whether cobalt from
the implant had been transported in some way to the secondary focus
and could be contributing to its development. Were any of the
changes found in the cobalt-implanted rat related to an action of
cobalt outside the primary focus?
Cobalt was estimated In various brain regions by flaoeless
atonic absorptiometry (Methods Dili). The concentrations found in
the various regions at different times are given in Table A13.
At day C after implant, the substantial levels of cobalt in
ipsilateral occipital cortex and caudate indicated a lateral and
downward spread of the cobalt from the Implant zone. The figures
for contralateral cortex and occipital cortex (means 16.8 and 18.5
ng cobalt/ng tissue respectively) give some indication of the degree
of spread of the cobalt from the area of implant, and raise the
possibility that the secondary focus may not be a pure mirror focus,
but nay be instead simply a reflection of the cobalt that has in
aocie way reached the cortex contralateral to the site of implant.
The raphe region also contained small amounts of cobalt (4-S{%
cobalt/mg tissue). It is impossible to say in this case whether
this represents diffusion of the cobalt from the implant, or whether
Tabic A13






be detected in any samples
B) Rats 6 days post-implantation
Rat number 1 2 3 4 5 x+SD'(N)
Frontal cortex(l) 39 38 65 38 63 49+13
" (C) 14 14 28 10 20 17+6
Occipital cortex(l) - 10 37 19 35 25+11
" " (c) - 4 12 19 28 15+8
Caudate nuclei(l) 34 15 30 37 38 30+8
" (c) 10 2 17 17 30 15+9
Raphe nuclei(l) 4 1 7 1 11 4+3
" " (c) 11 2 4 7 4 5+3
C) Rats 21 days post-implantation
Rat number 7 8 9 10 11 12 x+SD'CN)
Frontal cortex(1) 59 47 6 29 4 44 31+20
" " (c) 4 6 0 5 1 6 3+2
Occipital cortex(l) - 25 5 10 10 17 13+6
" <c) - 4 2 6 5 6 4+1
Caudate nuclei(1) 5 23 12 8 2 12 10+6
" " <c> 5 4 2 5 2 2 3+1
Raphe nuclei(l) 1 2 5 1 4 15 4+4
" « (C) 0 2 4 1 1 9 2+3
D) Rats (4) 97 days post-implantation. No cobalt could be detected
in any area of the brain.
Notes:
1. All final values are given as the mean + standard deviation.
2. In all cases the glial capsule and any visible traces of cobalt-
galatine was removed from samples of the primary lesions.
However the concentrations of cobalt measured in these samples may
have been attributable in part to 'depot' cobalt metal.
3. (1) and (c) refer to lesion and contralateral sides respectively.
4. The minimum amount of cobalt that could be detected when added to a
samples of brain from an unoperated animals was l.Sng added to a
digest of 3mg wet weight brain.
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any retrograde transport of cobalt In serotonergic fibres might have
occurred. However, If cobalt in the contralateral cortex is
instrumental in forming the secondary focus, the finding that
sectioning the corpus callosunt can, if carried out within 4 days
post-implant, prevent the development of a secondary focus (817),
suggests that transport of cobalt intraneuronally may be an important
factor.
Using the figures of cobalt concentrations in brain, it is
possible to examine the possibility of the enzymes TOR, ?4AO and
COMT being inhibited in vitro in the assay procedure.
At day 6, cobalt levels in the secondary focus are a round
17 pg/mg tissue. In the preparation of homogonates of brain for
the enzyme assays the tissues were in effect diluted tern-fold,
giving an estimated concentration of l-2ng cobalt /pi horiogenate.
In the case of the assays for MAO and tyrosine hydroxylase t liere is
a subsequent two-fold dilution, and for the assays of GABA trans¬
aminase and cet.!T a ten-fold dilution, giving cobalt levels under
assay conditions of lOO-SOO pg cobalt/pl. The atomic weight of
cobalt is 59; the above figures therefore represent lOpM cobalt
in the tyrosine hydroxylase and MAO assays, and 2pM for the C'OblT and
GABAT assays. These four enzymes had already been investigated
as regards their sensitivity to the cobalt ion, and had all been
shown to be unaffected by concentrations of the order of 2-10pM
(Tables A11.A12).
This suggests that the to vitro enzyme assays were unaffected
by the presence of the cobalt ion; but it does not exclude the
possibility that the cobalt affects these and other enzymes in vivo,
as the cobalt ion may be concentrated locally in brain to levels
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that are sufficient to cause enzyme inhibition. Willmore et al.
(379) and Erason and Joseph (466) have demonstrated using histochetalcal
techniques that the regional distribution of cobalt in the brain
after cobalt iontophoresis or implant is very uneven indeed. At
21 days post-implant the cobalt concentrations in all areas of brain
sampled had fallen from the day 6 values by 90-75%, except in the
immediate implant area where levels had not fallen as rapidly.
No cobalt could be detected in any brain area at 97 days, and it
seems probable that a significant proportion of the cobalt has
been sequestered by the bone of the skull around the Implant (980).
Possibly at this late stage trace quantities of cobalt may still be
leaching out into the brain and contributing to the longer-term
epileptic activity.
It will be remembered that the three enzymes TQH, MAO and COMT
display very similar changes in the cobalt-implanted rat. All
three parameters of the central catecholamlnergic system are low
between 3 and 30 days post-implant, and are normal at 100 days.
The sustained reduction of T0H activity in both ipsl- and contra¬
lateral cortex suggests that the catecholamlnergic neurones do not
recover within the same 30 day period as previously described for
the cholinergic and gabaminergic systems (466). All the materials
for reconstruction of cortical monoarainerglc fibres must derive from
extra-cortical nuclei. The long period before recovery could
reflect a prolonged period of cell rapair, or even regeneration,
with the protein synthetic machinery of the cells being occupied
with the manufacture of structural proteins before any significant
synthesis of neuro-transmltter-related enzymes is allowed to occur.
This sort of sequential programming of the syntheses of different
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classes of protein (that is, structural before neuro-transmitter-
related) has been described during neuronal development by Seeds
<365).
An alternative explanation is that until a fairly late stage,
the amount of cobalt diffusing into the brain tissue from the
Implant may still present a zone of cobalt concentration too toxic
to permit any regrowth of noradrenergic nerve terminals} it is
possible that these neurones are more sensitive in this respect
than other types of neurone. There is hlstochemical evidence for
selective cobalt adsorption by specific cell types in the cortex
(notably the giant pyramidal cells, which are subsequently killed
in the tissue around the primary cobalt focus (295, 466), and it
has also been demonstrated that, while noradrenergic fibres regrow
into freeze-lesion foci (467), they will not regrow into cobalt
foci (BJorklund and Emson, personal communication).
A third explanation for the long>~delayed recovery would be
related to rates of axonal regrowth. The time course of axon
regrowth has been shown by various workers to be of the order of
75-100 days, for example the re-innervation of the tongue after
hypoglossal axotoray (364). Although the times fit, this is
hardly enough in itself to suggest an axonal regrowth and
regeneration of cortical innervation as a basis for the biochemical
findings* There is to date no evidence of cobrect re-innervation,
or fibre regrowth over any distlnce, in the CNS of the adult mammal
(368,369).
Another problem la how to distinguish an increase in manoamlne-
related enzymes due to re-innervation from that due to a compen¬
satory mechanism in the remaining intact neurones. For example,
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reserpine-induced uocoaiBine depletion, and cold stress, have been
reported to cause increases in tyrosine hydroxylase activity in the
stellate and superior cervical ganglia. If the stress of cortical
injury and the epileptic process affect central catecholaminergic
neurones similarly, this might contribute to the apparent normal¬
isation of enzyme activity at 70-100 days post-implantation.
EFFECTS QT AN INHIBITION OF CEREORAL PROTEIN SYNTHESIS ON
THE DEVELOPMENT OF THE SECONDARY FOCUS
The fact that cobalt could have contributed to the formation of
the secondary focus rekindled the question of whether the contra¬
lateral cortex becoming epileptic was due to a transfer of the
original epileptogen (in this case cobalt) or whether the secondary
focus "learns" to mimic the electrical activity of the primary focus,
a process involving perhaps the formation of new connections between
the Involved areas of cortex. In the case of other epilepsies,
that following 'freeze' lesions for example, it seems unreasonable
to postulate the synthesis of an epileptogen in the primary focus
and its subsequent transfer to the secondary. To resolve this
point it was decided to examine the effects of a protein synthesis
inhibitor on the development of the secondary focus, as it has been
demonstrated (596) that this type of drug can block part of the
learning process. The drug of choice for this experi sent seemed
to be acetoxycycloheximide, a potent inhibitor of protein synthesis
and, unlike puroraycin, a drug free from any gross effects on the
EEG (596).
The drug's effect on protein synthesis was first examined,
(Methods D,Ib), and then a series of rats was given gobalt implants,
treated with the drug, and recorded over a period of 3 weeks.
Table A14
Effect of acetoxycycloheximide on rate* of cerebral protein synthesis
in rat frontal cortex.
Control Acetoxycyclohexlnlde-treated
Left Right Left Right
1. 0.84 0.89 4. 0.67 0.63
2. 0.81 0.87 5. 0.64 0.53
3. 0.79 0.92 6. 0.60 o.id
0.86+0.04 0.63+0.03 0.57+0.1
Notes:
1. Each figure represents a ratio derived from TCA-insoluble (protein)
counts to TCA-soluble (amino acid) counts.
2. Acetoxycyclohexiiaide-treated animals were given an intracerebral
injection of 20 fig of the drug, made up in 10 pi mammalian
Ringers solution, into the right frontal cortex 48h prior to
killing.
3. Each animal was given a subcutaneous injection of 0.5 ml 0.0% NaCl
14
containing 1 pCi of a C-labelled protein hydrolysate lh.
prior to killing.
4. All final values are given as the mean + standard deviation.
Table A15
Effects of an intracerebral injection of 20 pg acetoxycycloheximide
into the contralateral frontal cortex of a cobalt-implanted rat on
the rates of spike formation/min. in a 10 minute ECoG recording.
Days post-implant
6 12 16 20
A 3/2 12/53 3/38 3/11
B 0/2 12/12 30/5 8/6
C 1/1 3/0 1/2 DIED
D 0/C 20/38 6/37 9/33
E 4/0 61/81 15/150 12/105
F 0/1 0/5 DIED
0 54/55 2/3 N.R. 0/0
H 23/25 32/31 N.R. 0/0
1 5/7 0/4 7/3 5/6
J 3/32 6/25 5/25 3/25
9.4+16.8/13.6+17.5 16.7+17.6/25.2+25.0 9.6+0.3/38.4+51.3 6.743.3/31.0+34.6
Notes:
1. x/y represents spikes in primary/secondary epileptic foci.
2. N.H. indicates no recording was made.
3. 20 pg of acetoxycycloheximide was given at days 1, 3 and 5
pos t- iiitplantat ion.
4. All final values given as the mean +, standard deviation.
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Acetoxycycloteximi.de has a long duration of action, reducing
rates of cerebral protein synthesis by around 53% at up to 2 days
after administration of the drug (Table A14). The cobalt-
implanted rats were given the drug at days 1, 3 and 5 post-implant,
to maintain a degree of inhibition of protein synthesis over the
first week. The results (fttble A15) suggest that a 55% inhibition
of cerebral protein synthesis may in some cases be associated
with subnormal rates of spiking in both foci at day 6 post-implantation.
These results are however difficult to interpret, because the effect
was not consistent, a significant minority of the experimental
animals displaying normal spiking rates in both foci.
As this degree (58%) of cerebral protein synthesis Inhibition
is similar to that found by Baroades and Cohen (596) to interfere
with the learning process, it was felt that, while various types
of protein synthesis may be associated with the development of the
epileptic foci, the question of the causation of the secondary
focus could be answered most satisfactorily in this model by
postulating the transfer of cobalt as the critical factor.
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THE ROLE (F THE 5-HYDRQXYTRYPTAMINERGIC (3-HT) NEURONAL SYSTEMS
IN THE COBALT- IMPLANTED RAT
After the studies of the catecholamine-related enzymes and
metabolites had been completed, a further series of experiments
was undertaken to investigate the involvement of the serotonergic
systems in the cobalt model.
It would be appropriate here to discuss first the evidence
for 5HT as a central neurotransmitter, and second the work that
suggests that the SHT systems are involved in certain states of
central nervous system malfunction, specifically the epilepsies.
Much detailed biochemistry has been done on animal models;
however, the situation in man is obviously less accessible to study,
and most clinical investigations are limited to the analysis of urine,
blood and CSF samples. In order to interpret the clinical data in
the light of the structure of evidence provided by animal models,
the functioning of the 5HT systems in the control and model animal
must first be clarified.
In the following section s brief summary of the present
knowledge of the role and function of central SHT is presented,
Including evidence supporting the three criteria of postulated
neurotransmitters: namely the appropriate presence or location
of the compound and its synthetic and catabolic enzymes, its release
on stimulation of the appropriate nerves, the ability of the
exogeneous compound when appropriately administered to mimic the
effects of the physiological release of the endogenous compound, and
finally, the ability of the exogenous compound to mimic the
endogenous compound in terms of its activity being appropriately
modified by drugs known to act on the endogenous system.
THE EFFECTS OF EXOGENOUS 5HT
A series of micro-iontophoretic studies has been carried out to
examine the action of 5HT neurones in the brain. The general
consensus is that 5HT is primarily inhibitory in effect, although
cells in certain areas of the brain have been demonstrated to be
excited by SHT.
In the cortex, Roberts and Straughan (178) reported that lonto-
phoresod 5HT inhibits one third of cortical cells, excites another
third and is Inactive on a further third. This study also
investigated the interactions between SHT and other drugs, establishing
that the excitatory action of 5HT could be blocked by methyaergide, a
drug known to block the peripheral actions of SHT. The inhibitory
acticm of SHT could not be blocked, however. This was later
verified by Krjnevic and Phillis (482) who, however queried the
findings of 5HTs excitatory action, and suggested that 5HT in the
cortex was almost entirely inhibitory in function. Jordan et al.
(483) published a paper in 1972 suggesting that the excitatory action
of SHT in the cortex described by Roberts and Stranghan (178) and others
was in fact artefactual, caused by pH effects rather than the SHT
The picture is by no means clear, though, because recently a report by
Boakes et_ al. (129) has described how the excitatory action of SHT on
cortical neurones can be blocked using lysergic acid diethylamide
(LSD) and 2-broiao-d-lysergic acid diethylamide (BOL-148), drugs
thought to act as 5ifT receptor blockers. This would support the
idea that the excitatory action of the iontophoresed 51IT is a
physiological response rather than an artefactualcone.
In areas of heavy serotonergic innervation, including the optic
tectum, amygdala and ventral lateral geniculate, iontophoreaed 5HT
has an inhibitory effect (484, 485). In the raphe nuclei too, 5HT
has been demonstrated to have an inhibitory action and it has been
suggested that this may indicate the presence of an auto-inhibitory
modulating >aechanism (484). Cells in the reticular formation which
may be fktvolved in the postulated reticular activating system, fall
into two classes, some being excited and others inhibited by 5HT (486).
CRITERION OF LOCATION
Fluorohistochemical work by Dahlstrom and Fuxe (168) showed 5HT
in the rat brain to be located solely in nerve cells whose bodies
lie in the mid-brain and brain-stem, primarily in the raphe nuclei.
The cells in the rostral raphe nuclei project mainly to the forebrain,
and the caudal nuclei mainly to the spinal cord (168, 160), in a
pattern similar to that found in other animals (170). Concentrations
of 5HT appeared to be greatest in the nerve terminals, and very much
lower in the cell bodies and axons (168,171). Sub-cellular
fractionation studies also showed that a substantial proportion of 5HT
(and NAd) in brain was to be found in the synaptosomal fraction (105,
196), associated with a population of dense-cored vesicles (If©,198).
Autoradiographic work by Aghajanian and Bloom (197) supplied corroborative
evidence, finding that tritium-labelled 5HT given intravontricularly was
mostly taken up by nerve-terminals, primarily those containing dense-
cored vesicles. These dense-cored vesicles, found in the varicosities
of terminal axons and not in the inter-varlcosal segments, (195), are
thought to be involved in the release of the neurotransmitters NAd and SOT
(176,198).
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The effects of electrical stimulation of the raphe were first
investigated by Aghajanian et al. (201, 202), who found that this
treatment resulted in an increase in 5-hydroxyindole acetic acid
(5-HIAA), the principal metabolite of 5HT together with a fall of 5HT
in the fore brain. Unilateral surgical lesioning of the medium
fore-brain bundle prevented these changes on the affected side; at
longer periods after lesioning, ipsilateral cortical 5IIT and 5HIAA
levels fell, reflecting the degeneration of the serotonergic nerve
terminals (203-208). Raphe stimulation has been shown to increase
5-HIAA release into cortical perfusate in the rat, and into cat CSF
(200, 210). As all these studies (203-210) with one exception (201)
found that stimulating the serotonergic system increased 5-HIAA
formation without affecting S-HT concentrations, it seems that such
stimulation increases 5-HT synthesis in such a controlled manner that
5-H1 concentrations remain constant.
More recently an elegant single-cell recording study by Bloom
fit al. (552) has indicated that the effects of raphe stimulation are
uniformly inhibitory on all identified post-synaptic cells, and the
authors suggested that the raphe has a general tonic inhibitory
influence on all the cells to which it projects. These observations
indicate again that the studies showing an excitatory effect of 5HT
did not reflect the physiological situation.
SYNTHESIS OF SHT IN BRAIN
Metabolism: The synthetic pathway of 5HT is illustrated in Figure AA.
The amine itself is thought not to pass the blood brain batrier
in significant amounts (Axelrod and Inscoe, 179), but recently it has
been demonstrated that traces of 5IIT given intravenously do in fact
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enter the brain, although thia is only of significance in the first
ten minutes after injection (587) because of the rapid clearance of
5HT from the blood, and equally rapid oxidation of 5HT in the brain.
It is generally assumed, therefore that any 5HT found in brain has
been synthesized In situ from a precursor in the blood, either trypto¬
phan or 5-hydroxytryptophan (5HTP). Normally 5HTP cannot be
detected in the blood (180), so the sequence of synthesis is thought
to commence with the uptake of tryptophan from the blood into the brain,
with all subsequent synthetic steps occurring in the brain.
Tryptophan hydroxylase activity has been demonstrated in brain
by various workers, including Grahame-Smith, 1964 (181), Green and i*1-1-
Sawyer, 1966 (182), Ichiyama et al., 1968 (193) and Gal et al., 1963
(184). It has been shown by Graham-Smith (480) and others (185,479) that
the distribution of this enzyme parallels the distributions of 5HT
and of 5HT nerve terminals as described by Dahlstrom and Fuxe (168).
Sub-cellular studies (183, 480) have found that, in rabbit hind-brain,
around half of the tryptophan hydroxylase activity was associated with
the synaptosomal fraction.
The second step in the synthesis of 5HT is the decarboxylation
of 5-HTP; the enzyme responsible is thought to be the relatively
unspeclflc L-aromatic amino acid decarboxylase (476); lmmunohistochemic-
ally the decarboxylase in serotonergic neurones behaves identically
to the unspecific decarboxylase, which is widely distributed throughout
the brain (476).
The rate-limiting step in vitro (in brain honogenates, 183) and
in viva (in dog and rat brain, 187) appears to be the initial hydroxy-
latlon. The K^, of the hydroxylase for its substrate, tryptophan is
reported to be of the order of 50pM, a value closely in line with
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published values for brain tryptophan concentrations (17,18). It
is thought that the rate of tryptophan hydroxylation is highly
sensitive to substrate levels in brain, and hence ultimately
influenced by plasma free tryptophan concentrations (180,188,190,199),
Theoretically the order of the two synthetic steps could be
reversed, but the affinities of the two enzymes for the respective
substrates rules against that possibility as a major pathway (183).
However, Marscion and Cisrzon (478) and others (479) have demonstrated
endogenous tryptamine in rat brain, and have also shown that a
proportion of brain tryptamine is formed in serotonergic neurones.
Other workers suggest that the hydroxylase and the decarboxylase are
in some way coupled; an in vitro synthesis of c^-sirr from C1-
tryptophan was reported to be so efficient (183) that no trace of C14
5HT9 could be found in the reaction medium containing unlabelled
carrier 5HTP, indicating that the labelled intermediate waa taken up
by the decarboxylase immediately after hydroxylation.
Gatabolism
5HT is oxidised by monoamine oxidase (MAO), forming 5-hydroxyin¬
dole acetaldehyde. This intermediate is further oxidised by aldehyde
dehydrogenase to form 5HIAA, 5-hydroxyindole acetic acid. An alcohol
dehydrogenase has also been demons trated in brain, and a small
proportion of the 5-hydroxyindole acetaldehyde is metabolised to
3-hydroxytryptophol (192, 193). It is also theoretically possible
for 5HT to be removed from brain as a conjugated sulphate; however
Korf and Sebens (194) were unable to detect endogenous SHT-O-sulphate
in rat brain, and Eccleston and Ritchie (832) have shown that 8H7 is
not a substrate for the sulphotransferase system in rat brain, although
the tryptophol might be.
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Regulation of 5HT synthesis
A regulation of tryptophan hydroxylase activity was first hinted
at in studies of the rates of 5HT synthesis in animals treated with
drugs to raise or lower central levels of 5lfT. Tozer ot al. (285)
demonstrated an increased rate of 5HT synthesis in reserpinised rats,
and, conversely, mice pre-treated with monoamine oxidase inhibitors
appeared to have subnormal rates of central 5HT synthesis (587).
Various experimenters attempted to study the phenomenon of an
end-product feed-back system in an in vitro situation, looking for a
reduction in tryptophan hydroxylase activity in preparations of mid¬
brain when incubated with high concentrations of 5HT. McCiear and
Peters (267) published negative results; and other studies (288, 289)
failed to demonstrate any inhibition of tryptophan uptake into brain
synaptosociie preparations. lloek and Fuxe (290, 435, 436) and others
(291) found that after MAO inhibition, the concentrations of brain 5HT
rose much more than tljose of central catecholamines and attributed
this to the lack of a serotonergic end-product inhibition but
Clowinski o_t al. (292, 293) reported that whan 5HT levels reached three
times normal, after MAO inhibition, a reduction of 5HT synthesis did
occur. They suggested that this regulation developed at the
hydroxylase level, since the synthesis inhibition did not affect the
3 3
conversion of H-5HTP to H-5HT. Homon et al. (294) used brain slice
preparations from rat striatum to demonstrate that a high concentration
of 5HT in the incubating medium did inhibit the rate of 5HT synthesis,
3
as measured by 5HT and 5H1AA formation from H-tryptophan. in this
elegant experiment the inhibitory effect depended on intraneuronal 5HT
levels, as the inhibitory effect of 5ITT was lost after chlorimipramine,
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of 5HT neuronal uptake blocker was added to the medium. Tryptophan
uptake waa not affected by the high OUT concentrations.
In summary, it would appear that an end-product inhibition
mechanism does exist, although it appears to be less sensitive than
the system operating in catecholaminergic neurones (202,293).
ANALYSIS <F THE BARAMETER8 TO BE USED IN THE INVESTIGATION Of
THE COBALT HAT
It was necessary to decide which of all the available parameters
of the serotonergic system would provide the most data on the cobalt
model. Those parameters chosen should preferably reflect central
events only, and remain unaffected by changes outwith the C.N.S.
Rates of tryptophan hydroxylation centrally, for example, are thought
to be influenced by plasma free tryptophan concentrations (180,188-
190) amongst other factors. This can be allowed for, under laboratory
conditions, by using a genetically uniform strain of animals in a
standardised environment, fed on a uniform diet and experimented on at
set times of the day.
Systemic changes in 5HT metabolism, on the other hand, do not
affect the central levels of 5HT and 5HIAA, as these compounds do not
cross the blood-brain barrier.
Concentrations of 5HT in the brain are not a good index of central
6HT turnover. Electrical stimulation of the raphe, as already noted
(203-210) results in increased 5HT turnover unaccompanied by any change
in 5HT concentrations. In the reserpinised rat, 5EFT turnover increases
while 5IIT levels are low (285).
In this respect an assay of 5HIAA provides more information.
5HIAA levels depend on two factors, one being the rate of oxidative
deamination of 5HT and the second the rate of removal of the
metabolite from the brain into the CSF and blood. There is same
degree of passive diffusion of 5H1AA from the brain, and there also
exists an excretory mechanism (213,214), which has been shown to
resemble/^excreticn of 5HIAA from the CSF to the blood in the dog
(215) and the renal tubular secretion of organic acids in the kidney
(215). Perez-Cruet et al. (216), charting the rate of 5HIAA
disappearance from brain after 1SA0 inhibition, found that it was
proportional to the levels of 5H1AA in the brain. This linearity
was lost at concentrations in excess of 180 per cent of normal
when the transport mechanism became saturated, and a change of
slope indicated that farther increases in the rate of 5HIAA removal
could only be achieved by diffusion. If 5HIAA efflux from brain is
normally proportional to its concentration, then continuous monitoring
of cerebral 5HIAA concentrations would provide an excellent indication
of rates of 5HT turnover. A single estimate does not furnish as much
information, as a datum so obtained can only reflect 5HT turnover in
the steady state condition. And it may well be that the steady state
is a vanishingly rare phenomenon. Work by Knapp and ?<iandell (218 and
231, 232, 234) shows that the administration of many, if not all, drugs
that act on the metabolism of aminerglc neurones results in a prolonged
series of adaptStive responses by the neurones to the new conditions
of function, rather than in a new steady state. Levels of 5II1AA
may be used as an approximate measure of 5HT turnover in a non-steady
state condition with more validity if 5IfT concentrations are also
measured, as one can then view the 5HIAA data in the light of the
nerve terminals' capacity to store 5HT. This might be of considerable
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in ,conditions
importance/of 5HT displacement, where measurements of SHIAA concen¬
trations could give a mialeadingly high indication of SHT turnover.
Cortical SHT and 5HIAA concentrations, and rates of
cortical SHT uptake, were therefore selected as an index of the
functional state of the serotonergic nerve-terminals, and tryptophan
hydroxylase was assayed in the anterior raphe nuclei to provide
information on the state of affairs in the cell bodies. All the
assays were fluorimetric; SHT and SHIAA were measured using the
techniques of Schlumpf et al. (24), Methods CV and the extraction
procedure of Roos (211), Methods CII. The tryptophan hydroxylase
assay uped was that of Baumgarten et al, (243), Methods BII: it
was insufficiently sensitive to measure enzyme activity in the
cortex.
ALTERNATIVE METHODS OF MEASUREMENT OF SHT TURNOVER
1. Accumulation of SHIAA in brain after inhibition of the metabolite
transport system
The drug generally used is probenecid. It effectively inhibits
the active transport of SHIAA from rat brain (214), and from CSF, in
the dog (214). After probenecid actainistration to rats, SHIAA has
been found to accumulate linearly for up to 8 hours, reaching 6 times
the normal level (598), and the drug has also been shown to almost
completely halt the decline in SHIAA after MAO inhibition (214).
This means that the active transport system must account for nearly
all the removal of SHIAA from brain. In addition, the fact that
SHIAA levels continue to rise linearly even when grossly above normal
(598) suggests that the build-up of SHIAA does not exert a feedback
inhibition on SHT synthesis, a possibility which might otherwise cast
doubt on the validity of this method of measuring 5HT turnover.
Probenecid itself does not appear to affect the rate of tryptophan
hydroxy1stion, as the rates of 5HT turnover calculated in this manner
agree with the results calculated by measuring rates of removal of
3HIAA after MAO inhibition (214).
2. Rate of removal of 5HIAA from brain after MAO inhibit ion
This method is based on the fact that removal of 5HIAA from the
brain is directly proportional, over a certain range, to its
concentration (216). As already pointed out, however, at elevated
5HIAA levels saturation of the transport mechanism occurs, and the
relationship between 5H1AA concentration and rates of 5HIAA efflux
alters. Saturation of the transport mechanism in the rat is thought
to develop when 5H1AA levels reach 180% of normal values (216).
One must also make the assumption that the metabolite transport system
is not affected by the MAO inhibitor, and that 5HIAA is the sole
metabolite of 5HT; this latter is probably not completely true, as
there is evidence of some formation of 5-hydroxytryptophol in vivo
(D. Eccleston, personal communication), but the amounts of 9RT thus
metabolised are insignificant.
3. Accumulation of 5HT after MAO Inhibition
This method has also been used to measure cerebral 5HT turnover,
and has given results similar to those obtained by the other methods
(212). It assumes that SHT is only catabolised by MAO, that a total
inhibition of MAO can be achieved, and that no 5HT is lost from the
brain by diffusion. It also assumes that the inhibitor used (toes
not affect tryptophan hydroxylase directly, and that the increasing
levels of 5HT do not exert a product-inhibition effect either.
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In fact thla laat assumption is not completely true, as there is
evidence of inhibition of brain tryptophan hydroxylase by high
concentrations of 5HI both in vitro (294) and in vivo (212);
however, calculations of 5HT turnover based on initial rates of 5HT
accumulation after MAO inhibition give data in line with the results
obtained using other methods (212).
4. Increases in brain SHT and 5HIAA after tryptophan loading
This method involves giving the experimental animals large doses
of L-tryptophan so that cerebral tryptophan hydroxylase becomes
saturated, and mesuring the subsequent changes in 5HT and 5HIAA in
the brain. The technique does not give an exact quantitative
estimate of 5HT synthesis, as SHT and 5HIAA are turning over all
the time; but it does provide an overview of the whole metabolic
pathway, indicating whether, in an experimental situation, synthesis
or breakdown of SHT is affected or 5HIAA excretion. The cerebral
distribution of SHT Mad SHIAA is the same after tryptophan loading
as under normal conditions (187), although the high concentrations
reached (up to 10 times normal in rat brain after doses of 400-800
mg/kg (180, 236) may trigger off a number of side-effects.
Aghajanlan (237) reported a reduction in cell firing rates in the
raphe, and suggested that this was due to increased SHT in sero¬
tonergic nerve terminals acting at post-synaptlc receptor sites
with a consequent compensatory reduction of raphe activity. He
found, however, that this raphe inhibition could not be prevented
by the use of a tryptophan hydroxylase inhibitor (p-chlorophenyl-
alanine), indicating that high concentrations of tryptophan may also
inhibit serotonergic neurones (237). High concentrations of 5HT
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have been shown to inhibit tryptophan hydroxylase, in rat brain
slices (294), and this phenomenon may also occur in vivo.
5. Methods using radioactive tracer compounds
5HT turnover has been measured by charting the rate of dis¬
appearance of labelled 5HT from brain after intra-ventricular
administration (009), and the rate of labelled 5HF formation after
intravenous administration of radioactive tryptophan either in an
infusion (600) or a single injection (601). The problem with the
first of these methods is that one cannot be sure whether 5HT given
intraventricularly is distributed and metabolised in the same way
as the endogenous amine. The other two methods also have their
disadvantages, and are not widely used. The Infusion technique
requires that the animals be immobilised, a stress factor which
could complicate the biochemical picture, and it has been found
that, with the single injection technique, very slight variations in
the technical procedure are capable of producing an unacceptably
wide variation in results (601).
CHOICE OF METHODOLOGY
When the investigations into the role of the serotonergic system
in the cobalt-implanted rat were begun, it was decided to simply
measure 0HT and OHIAA in various brain areas, and then examine the
effects of tryptophan loading on the 5HT and 5HIAA levels. Zt was
felt that, in view of the involvement of MAO in the cobalt-implanted
rat as already described (Table MA) and the possibility of a block
of metabolite transport after cobalt implantation (p $5 ), it might
not be wise to use methods of measuring BUT turnover using MAO
inhibitors or probenecid.
Table A16
Estimation of 5-hydroxytryptaoine (5HD (fig 5-JffT/g wet weight tissue)










































1. All final values are given as the mean + standard deviation.
2. None of the experimental data differ from the control results,
(P> 0.2); Student's t-test with Besael's correction was used.
In addition to the above, the following parameters of the
serotonergic system were also studied. Rates of 5HT uptake in the
cortex were measured, to give some idea of the number and viability
of serotonergic nerve terminals in samples of primary and secondary
focus, and other cortical areas. Tryptophan hydroxylase activity
was measured in mid-brain sections containing the anterior raphe
nuclei to give some Indication of the involvement of the serotonergic
system at cell-body level (unfortunately the assay used proved
insufficiently sensitive to measure cortical tryptophan hydroxylase
activity). The concentrations of tryptophan in the cortex were
also measured to examine further the possibility of alterations of
tryptophan metabolism in the cobalt^implanted rat. Finally, in view
of the results provided by these investigations, the effects of a
series of drugs known to act on the metabolism of 5HT was examined in
terms of their effects on the ECog of the epileptic rat.
THE INVOLVEMENT OF THE SEROTONERGIC SYSTEM IN THE COBALT- IMPLANTED RAT
The measurement of 5HT and 5HIAA in the cortex and striatum was
carried out using the fluoroassay of Schlumpf et al. (24, Methods CV).
The concentration of SHT in the cortex around the primary lesion
was apparently unaffected (Table A16). This was basically in
agreement with the findings of an unaltered intensity of 5HT-
attributable fluorescence in the cortex of the cobalt-implanted rat
(Bjttrklund and Emson, personal communication). However the concen¬
tration of 5HIAA in the same area of cortex showed a fall of about
25% developing between days 10 and 20 post-implant (Table A17). The
time- course of this reduction appeared to be of significance, because,
unlike any other parameter studied so far in the cobalt-implanted rat,
it did not develop in step with the onstt of non-specific cell
Table A17
Estimation of 5-hydroxyindolacetic acid (5HIAA) in cortex around the








bay 5 bay 10 Day 20 Day 30 Day 84
0.43 0.41 0.30 0.34 0.34
0.32 0.31 0.25 0.26 0.46
0.37 0.42 0.32 0.37 0.32
0.25 0.42 0.19 0.25 0.41
0.39 0.38 0.31 0.25 0.40
0.41 0.37 0.23 0.25 0.41
0.43 0.43 0.28 0.33 0.37
0.36 0.31 0.23 0.26 0.30
0.37.0.06(8) 0.38+0.05(8) 0.27+0.04(8) 0.29+0.03(8) 0.38+0.05(8)
P2 PI
Notesi
1. All figures refer to fig 5HIAA/g wet weight brain.
2. Final values are expressed as x + SD' (N).
3. I'-values refer to comparisons between control and experimental
data. Student's t-test was used, with Bessel's correction.
PI s 0.005 >P> 0.001; P2 = P < 0.001.
4. Assay method no. 2 was used to generate these data. Although
3H1AA levels thus measured appear slightly lower than those in
table 1, internal consistency is unaffected (Methods Cll).
Table A18
Estimation of 5-hydroxyindolacetic acid (fig 5-HIAA/g wet weight brain)
























Day 8 post-implant 0.38
0.33
0.36(2)
Day 15 post-implant 0.38
0.35
0.37(2)

















1. Final values given as x + SD* (N).
2. values refer to comparisons between control and experimental
data. Student's t-test with Bessel's correction sas used.
PI s 0.2 > P >0.1; P2 = 0.1 > P > 0.05} P3 = 0.02 > P > 0.01;
P4sP< 0.001
3. Assay method no. 2 was used to generate these data (Methods Cll).
Table A19
Estimation of 5-hydroxyindolencetic acid (5HIAA) (|ig 3-HlAA/g wet


























1. Final values given as x+ SD'(N).
2. Lesion and contralateral side caudate nuclei frow 2-3 rats
were pooled to provide sufficient tissue for assay.
3. P-values refer to comparisons between control and experimental
data. Student's t-test with Bessel's correction was used
PI » 0.1 > P> 0.05: P2 = 0.05 > P > 0.023.
4. Assay method no. 2 was used to generate these data (Methods CII).
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damage (466), or the appearance of the primary and secondary epileptic
foci (466).
To follow up this experiment 5H1AA concentrations were determined
in a second series of rats in ipsi- and contralateral cortex, and in
the caudate nuclei. It was decided to use a slightly different
assay method, this time using a separate extraction procedure (562,
Methods C,III). This second series of data also showed that the
concentrations of 5HIAA fell in both ipsilateral and contralateral
cortex with a maximum decrease of 50-60%, probably between days 15 and
24 post-implant (Table A18). The reduction of 5HIAA in the secondary
focal area appeared to develop more slowly than in the primary focus,
but in view of the small number of animals assayed the significance of
this was not clear. This greater reduction (50-60%) of cortical
5HIAA may have reflected the severity of the tissue reaction of the
cortex to the cobalt implant; different groups of implanted rats
did show variation in this respect, with the lesion in some cases
being confined to the cortex around the implant and in other cases
presenting with substantial erosion of the striatum below the cortical
implant. This particular group developed fairly severe lesions, and
the small number of experimental animals sampled was due to the number
of post-operative deaths in the group.
Changes in 5UIAA concentrations in pooled samples of ipsi- and
contralateral caudate did not parallel the changes in cortical 5HIAA
(Table AID). In fact, in complete contrast, 5HIAA concentrations
showed an increase of up to 50% from day 4 to 15 post-implant before
returning to normal values. A different type of test was initiated
to help to clarify these observations. Using tbe method of BJorklund
Table 20
Measurement of 5-PfT uptake In vitro into cortex of rata given cobalt
implants 20 days previously (Figures given as ratio of tissue counts
to medium counts, x 100. Methods DID.
A) Control values (glass-implanted littermates)
Animal no. 1 2 3 4 x+SD'
Frontal (left) 499 472 390 457 454+40
Frontal (right) 448 387 334 314 370+51
Occipital (left) 380 326 474 370 387+53
Occipital (right) 353 473 366 416 402+47
B) Cobalt-implanted rats
Animal no. 5 6 7 8 9 10
Frontal (Ipsilateral) 312 451 460 467 320 447
Frontal (contralateral) 430 336 325 359 318 349
Occipital(ipsilateral) 318 359 475 361 365 305






Animal no. 11 12 13 x+SD'
Frontal (ipsilateral) 53 87 58 60+14
Frontal (contralateral) 62 76 74 70+6
Occipital (Ipsilateral) 83 69 55 69+11
Occipital (contralateral) 55 70 57 60+6
Notes:
1, Experimental values did not differ significantly from control
values (F 0.25), as measured using Student's t-test with
Bessel's correction.
113.
et al. (304. Methods Oil), rates of 3HT uptake into various areas of
cortex were measured. The rate of 6HT uptake into a brain sample
is thought to be an indication of the number and viability of sero¬
tonergic nerve terminals in the sample (304). Rates of SHT uptake
were measured in rats 20 days post-implant in areas of ipsi- and
contralateral frontal and occipital cortex (Table A20). This was at
a stage when cortical 5HIAA had apparently fallen (Tables A17, A18),
yet experimental values for SHT uptake rates did not differ from
control values. This finding, taken together with that of the
unaltered SHT concentrations in the cortex, suggested that there was
little damage to serotonergic nerve terminals in the affected areas
of the cortex, and that the changes in 5HIAA concentrations might
therefore be due to changes in rates of SHT turnover and/or rates of
5HIAA transport, rather than a reflection of the breakdown of
serotonergic nerve terminals with subsequent increases in 5HT release
and oxidation.
In experim ental situations where marked degeneration of cortical
serotonergic nerve terminals is known to occur, for example after
lesioning the median fore-brain bundle, concentrations of both SHT
and 5HIAA are significantly reduced (203,204,206).
It seemed more feasible to postulate some degree of inhibition
of the 5HIAA transport mechanism. The increased striatal levels of
3HIAA at days 4 to 15 resembled the increases found in cortical and
striatal HMPG levels between days 8 and IS, and the increased striatal
HVA concentrations found between days 4 and 20 (Tables AS,6,7). But
it was difficult to reconcile the idea of a reduction of metabolite
transport with the findings of reduced cortical 3HIAA until it was
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realised that the reduction of cortical 5HIAA only developed between
days 15 and 24, that is, just after the apparent cessation of the
inhibition of metabolite transport. This complicates the picture,
because having made the assumption on the basis of cortical 5HIAA
levels that cortical 5HT turnover was reduced after 15 days* the
apparently normal 5HIAA levels before day 15 may have concealed a
combination of reduced 5HT turnover, together with an inhibition
of 5HIAA transport, the latter as we have seen posiibly developing
by days 4-8.
Why should 5HIAA concentrations in cortex and striatum have
changed in such different ways? How are these data reconcilable?
One possible explanation is that the serotonergic system differentiates
in its innervation to cortex and striatum, and is capable of exerting
a diffevent degree of tone on the two innervated areas. What is
known about the anatomy of the serotonergic system does not actually
rule this possibility out, as the cortical and striatal serotonergic
innervations develops from two distinct tracts (552), not is there any
a priori feason for thinking that the raphe nuclei should act in
parallel.
Recently it has been shown that the central dopaminergic
systems in this model may be comparably Involved. Eccleston ( D.
Eccleston, personal communication) has found a rise in striatal HVA
after cobalt implant, in step with a fall in HVA in the substantia
nigza. One possible explanation might be to postulate the existence
of an intermediate group of inhibitory neurones, operating so that a
reduction of tone in one system induces, via the inhibitory inter-
neurones, a local increase in activity in the other system. Could
Table A21








B) Cobalt-implanted rats (ipsi- and contralateral occipital
cortex pooled)









10.3+1.5(5) PI 44.0+10.0(4) P2
Notes:
1. Final values given as x + SO' (N).
2. P-values were derived using Students' t-test with Bessel's
correction. Experimental values were compared to control
data.
PI = 0.05> P > 0.025; P2 s 0.005 >P> 0.001
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cortico-artriatal inhibitory neurones explain the differing involve¬
ment of cortical and striatal 5HT systems?
To investigate further the apparent reduction in cortical 5HT
turnover, L-tryptophan was measured, using the method of Hess and
Udenfrlend (242, Methods C,IV), in a few animals to investigate the
possibility of reduced substrate availability being a cause of the
decrease of 5HT turnover. It was thought that minor changes in brain
tryptophan concentrations might cause large changes in the rates of 5HT
synthesis in brain (519), and therefore the possibility of changes in
substrate levels could not be overlooked. L-tryptophan concentrations
were therefore measured in the occipital cortex of a number of rats
whose frontal cortices were simultaneously sampled and used for SHIAA
estimation, as recorded in Table A18 (Table A21). L-tryptophan
concentrations were slightly reduced at 8 days post-implant, that is
at a stage when cortical SHIAA concentrations were unaffected, but
at day 30, when cortical SHIAA was low, L-tryptophan in the occipital
cortex appeared to be considerably higher than normal. The signif¬
icance of the latter datum is not clear (it is discussed further in
the following section) but it does at least suggest that any apparent
reduction in cortical 5HT turnover in this model cannot be explained
in terms of reduced substrate concentrations. These observations
could be criticised on the grounds that levels of tryptophan in
occipital cortex may not reflect conditions in frontal cortex; this
seems unlikely as Eccleston et al. (605) have found that the tryptophan
concentrations in most areas of brain are roughly similar.
To provide some information of involvement of the serotonergic
neurones at cell-body level, tryptophan hydroxylase activity was
Table A22
Tryptophan hydroxylase activity (n.mol. 5~IfT equivalents produced/g




































1. Final values given as x + SD' (N).
2. P-values refer to comparisons^ ..between control and experimental
data. Student's t-tost with Bessel's correction was used.
PI a 0.05 >P> 0.026.
Table A23
Tryptophan hydroxylase activity (n.mol. SOT equivalents produced/g
brain/h) in raid-brain sections of cobalt-implanted rats
A. Control animals




































2.8 + 0.6 (PI)
Notes:
1. P-values refer to a comparison between control and experimental
data, made using Student's t-test with Bessel's correction.
PI s P <0.001.
2. Final values given as x + SD*.
3. All samples described here were processed together to minimise
experimental error. The difference in base-line activity from
values reported in table A22 may be due to the different sample
of tetrahydrobiopterin co-factor used in the two experiments.
This shaould not affect the internal consistency of these two
experiments.
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assayed in sections of mid-brain containing the anterior raphe nuclei
(details of dissection, Methods A,IV; the assay used was based on
that of Baumgarten et al. (243), Methods B,XX).
In the first experiment (Table A22), mid-brain tryptophan hydroxy¬
lase activity appeared to show a reduction of approximately 10% between
days 20 and 30 post-implant. Due to the small numbers of animals
available, it was difficult to be sure whether the fall was significant
so the experiment was repeated using only rats at 25 days post-implant.
(Table A23). This second experiment seemed to indicate that a real
reduction in enzyme activity was developing during the 3rd to 4th week
post-implant, of around 35%. This last experiment had also been
designed to investigate whether the reduced enzyme activity might be
attributable to the cobalt that had been found to be present in the
raphe (Table A13). One might, for example, hypothesise that cobalt
in the cortex be taken up selectively into serotonergic axons and
nerve terminals and then transported within the axons to the cell
bodies in the raphe nuclei, with a subsequent effect either on the
raphe cells generally or possibly on tryptophan hydroxylase
specifically. There is evidence that cobalt is absorbed or taken up
selectively by certain cells in the cortex (295), so the possibility
could not be ruled out without investigation.
Tyrosine hydroxylase and tryptophan hydroxylase had both been
tested for their sensitivity to cobalt (Table All). As the two
pterin-dependent hydroxylases behaved similarly in this respect,
both enzymes were assayed in the cell bodies of the monoaminergic
systems that projected to the cortex. The locus coereleus projects
unilaterally to the fore-brain, and therefore if retrograde axonal
transport of cobalt had taken place in noradrenergic neurones,
sufficient to contribute to any deterloration in the metabolism of
the cells involved then one would expect a greater involvement on
the side of the lesion. Mid-brain sections containing the loci
were bisected, and each side assayed for tyrosine hydroxylase.
(Table A9). All results were negative, in the sense that no
changes in the enzyme activity could be detected, unilaterally or
bilaterally. The raphe system on the other hand projects bilaterally,
and one would not therefore expect any unilateral involvement in such
a system, as measured by comparing tryptophan hydroxylase activity
in ipsi- and contra-lateral raphe sections. These assays were
performed using the same tissue sapples as were used for the tyrosine
hydroxylase assays, and in this case also no difference could be
fovaid between the ipsl- and contra-lateral sections (Table A23) and
sections from control animals.
The atomic absorptiometry assay of cobalt in the brain showed
that at 21 days post-implant, levels of cobalt in the raphe were
around 3 and5pg/g wet weight of tissue in contra- and ipailateral
raphe sections respectively (Table A13). This represents a cobalt
concentrations of 45-75pM in the raphe section, assuming even
distribution. Both tyrosine and tryptophan hydroxylase were
unaffected by 10pM Co**, in the conditions of the in vitro enzyme
assay used, and showed a slight (around 10%) inhibition at concen¬
trations of lOOpli Co** (Table All). If the 3-5 pg cobalt per g tissue
in the raphe sections was not evenly distributed, then a local concen¬
tration of cobalt of only 3 or 4 fold might have been sufficient to
inhibit the activity of the pteridine—dependent hydroxylases. However
the fact that tyrosine hydroxylase activity in the mid-brain sections
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of cobalt-Implanted rata did not differ from control values means that
one either has to postulate that the cobalt in the raphe Is associated
primarily with the serotonergic cells, or look for a different
explanation of the reduction in tryptophan hydroxylase activity.
INVESTIGATIONS INTO THE MODE OF THE APPARENT REDUCTION OF
SEROTONERGIC TONE
These previous studies, showing a decrease in cortical 5HIAA
concentrations and in tryptophan hydroxylase activity in the raphe
nuclei, together with unchanged concentrations and rates of uptake
of 5HT in the cortex, seemed to suggest that the apparent reduction
of 5HT turnover in the cortex may have been due to a response of
the serotonergic system as a whole, rather than simply a local,
cortical response to the cobalt implant. It was hoped that one
might obtain information concerning the maximal turnover capacity of
the serotonergic system by giving experimental and control animals
loading doses of L-tryptophan (180, 236), and then measuring concen¬
trations of brain SHT and 5HIAA at set times after the administration
of the L-tryptophan. If the apparent reduction of SHT turnover
already noted reflected a pathological involvement of the SHT system,
then presumably the maximal turnover capacity would be lowered in
proportion to the apparent reduction; if the suppression mas
functional, then the stimulus of a tryptophan load would result in a
proportionately smaller difference between cobalt and control rats,
or even no difference at all. Ideally one would have wanted to
measure tryptophan hydroxylase activity in the affected cortical
areas, but unfortunately the method used was insufficiently sensitive.
The experiment was designed as follows: a large group of the
experimental animals was divided into two smaller groups, one of
Table A24
5~hydroxyindolacetic acid (ng/g wet weight of tissue) in frontal and
occipital cortex of control and cobalt-implanted rats in the absence


















































331 + 83(5) 278 * 13(5)



























1. Final values given as x + SD' (N).
2. Using Student's t-test with Beasel's correction, it was shown
that cortical SH1AA in unloaded, cobalt-implanted rats was
significantly lower (P 0.005) than control cortical values.
3. Tryptophan-loaded were given 400 mg/kg L-tryptophan
i.p., 2h before killing.
4. Assay method no. 1 was used (Methods CV).
Table A25
5-hydroxytryptaraine (ng/g wet weight of tissue) in frontal and occipital
cortices of cobalt-implanted and control rats in the absence or


















































































1. Final values given aa x + SD' (N).
2. Student's t-test with Bessel*s correction was used to compare
experimental with control dirta. In no case were 5HT values in
the experimental animals significantly different (P 0.2)
from the relevant control values.
3. Tryptophan-loaded animals were given 400 mg L-tryptophan/kg, i.p.,
2h before killing.
4. Assay method no. 1 used (Methods CV).
these sub-groups being given cobalt Implants and the other glass
Implants. At 25 days post-Implant, when the reduction in cortical
5HIAA levels and mid-brain tryptophan hydroxylase activity had been
found to be ongoing (Tables A17,18,22,23), each of these sub ^-groups
was again divided in two, and one half was given a loading dose of
L-tryptophan (Methods, D,IV). Two hours after the L-tryptophan
administration, all animals were killed, and brains were stored in
liquid nitrogen for subsequent assay.
The method of L-tryptophan administration and the dosage used,
were chosen to create conditions resulting in a plateauing of brain
5HT and 5HIAA concentrations at 2h after injection, using the smallest
possible dose to achieve this (180,236). In retrospect, this may
have been a wrong decision - it may have been better to use smaller
doses of L-tryptophan, because, with the dose used (400 mg L-
tryptophan/kg), minor differences in rates of 5OT turnover might well
have beaen swamped.
On comparison of the unloaded groups, the cobalt-implanted rats
again demonstrated reduced concentrations of 3HIAA and normal SOT
concentrations (as measured in cortical tissue) in comparison to the
control values (Tables A24,A25). This was in agreement with the
results already quoted (Tables A16-19). A comparison of the data
from the L-tryptophan loaded rats shows that, when stimulated by a
large tryptophan load, the serotonergic system in the cobalt-
implanted rat was apparently capable of increasing its turnover to
the same extent as in the control rat. This does not at first sight
appear to be reconcilable with the reduction in mid-brain tryptophan
hydroxylase activity found in this model (Tables A22,A23). However,
even if rates of 5OT synthesis are depressed in the cobalt-implanted
rat, this might not be uncovered by the tryptophan loading test for
the following reasons. Studies by Eccleston et al. (236) have found
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that levels of 5HT in brain plateau at 1 hour after tryptophan
administration in the control rat. Even a reduced level of
tryptophan hydroxylase activity might, in conjunction with the
reduced f.iAO activity found in this model (Table A4), achieve cerebral
SlfT concentrations at 2 hours after tryptophan administration
similar to those found in the control animals. Furthermore, a
block of metabolite transport as has been postulated in this model
would, by elevating 5HIAA levels, also contribute to concealing
the effects of a reduction of tryptophan hydroxylating capacity.
In this context, how can one reconcile the findings of raised
(occipital) cortical tryptophan at day 30 post-implant, and an apparent
reduction in frontal cortical 5IfT turnover, with the fact that a
tryptophan loading doe© can increase 5HT turnover in the same model?
There are various reports in the literature of tryptophan levels
in brain being altered by drugs that affect 5HT levels and/or rates
of synthesis. For example, reaerpine, d-amphetamine, lithium salts,
and other treatments such as electroconvulsive shock and heat stress,
have all been reported to raise the rate of 5HT turnover in mammalian
brain tissue (290,285,297-302). All of these treatments have been
shown to increase brain levels of tryptophan concurrently (300, 301,
302). Conversely, para-chloramphetamine (pCA) causes a reduction
in brain 5HT, and lowers brain tryptophan also (302).
More recently Knapp and Mandell (207) have demonstrated that,
after lithium administration in the rat, the high-affinity uptake
of tryptophan into GUT nerve endings in cortex increased in capacity
(i.e. the Vmax. value increases) together with a correspondingly
increased turnover of 5HT in the nerve-endings. 5HT synthesis at
first increased in step with the increased substrate levels, but
after a series of adjustments in the cell bodies involving a
reduction of the amount of tryptophan hydroxylase fox-mat ion, 5HT
turnover returned to normal, while the uptake mechanism was still
stimulated. If at any time during this series of adjustments
5HT turnover fails to keep in step with tryptophan uptake, concen¬
trations of tryptophan in the brain might well be affected,
depending on the amount of the amino acid that could be metabolised
via other pathways.
This may explain the findings in the cobalt rat. It is possible
for example, that the cobalt ion stimulates the uptake mechanism for
tryptophan in a way similar to lithium (267) and caesium (300), and
this effect, together with a reduction of 5HT turnover would probably
result in raised brain tryptophan levels. It must be added, however
that Van Gelder and Curtois (333) examined amino acid levels in the
primary and secondary foci in the cobalt-implanted cat, but found
no change in brain tryptophan. Colasanti and Craig (454) haver
also reported alterations of cerebral 5HT turnover in a cobalt-
treated rat. it must be stated, however, that their model is
probably fairly unlike the model reported on in this thesis; they
report applying 30mg of cobalt powder directly onto the surface of
the parietal cortex, approximately 50-60 times the amount of cobalt
used in our model, mid almost certainly producing gross lesions not
only in the cortex but also all sub-cortical structures. They
examined OUT turnover in whole brain, 6 days after cobalt adminis¬
tration, by measuring the rate of increase in cerebral 5HT levels
after MAO inhibition, and measuring the rate of decline in 5HIAA in
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parallel. Both of these parameters indicated that 5HT turnover was
significantly low in the cobalt-treated animal. They could not find
any evidence for similar involvement of NAd or DA systems, and also
reported finding no alterations in whole brain NAd, DA and 5HT levels.
Korf et al. (981) have reported a pattern of changes in serotonergic
metabolism after probenecid which appears to resemble in some ways
some of the data presented in this thesis. Using probenecid to
block metabolite transfer in the rat, they found that in this case
brain tryptophan levels and 5HT turnover appeared to be uncoupled;
total serum tryptophan fell, and brain tryptophan nearly doubled,
yet SHT turnover appeared to remain unchanged. They suggested that
the probenecid Inhibited the binding of tryptophan to serum albumen,
and that the resultant increase in plasma free tryptophan provided
for the rise in brain tryptophan, and also suggested that, at least
in certain cases, brain 5HT turnover may not always be linked to
brain tryptophan. If we postulate that rates of tryptophan hydroxy-
lation are proportional to tryptophan levels inside the serotoc&r^le
neurones, and that this intraneuronal pool of tryptophan, although
usually representative of total brain tryptophan concentrations, may
in certain circumstances increase or decrease in size relative to the
total brain tryptophan pool, we then have a model where intra¬
neuronal rates of tryptophan hydroxylation may appear to become
uncoupled from brain tryptophan concentrations. It is possible, for
example, that this model might explain the fact that in the cobalt-
implanted rat, an increase in cortical tryptophan at day 30 occurs
together with an apparent reduction of cortical 9HT turnover (Tables
A17,18,21). The increase in tryptophan levels, after all, could
include tryptophan non-specifically bound to protein, and unavailable
to the hydroxylase.
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INTERACTIONS BETWEEN SEROTONERGIC TONE AND THE SEIZURE THRESHOLD
The work that is relevant to this area falls into three basic
categories:
I The effects on the seizure threshold, of treatments that affect
the serotonergic system. This category includes pharmacological
and surgical techniques and also certain metabolic errors of
monoamine metabolism.
II Alterations of serotonin metabolism in various epilepsy models.
III The effects of known anticonvulsant and convulsant drugs on 5HT
metabolism.
SECTION I. THE EFFECTS ON THE SEIZURE THRESHOLD. OF TREATMENTS THAT
AFFECT THE SEROTONERGIC SYSTEMS
The mechanical or electrical lesioning of the raphe model or
ascending tracts by Jouvet, Pujol and others has yielded some
interesting data: However, there is a certain amount of controversy
surrounding this work, as the raphe nuclei are so diffuse that any
comprehensive lesioning almost inevitably involves the destruction
of other tracts (437). In addition, most of this work has been
directed towards an analysis of sleep rather than of epilepsy.
The use of drugs that alter 5HT metabolism is of more interest.
This can be divided into two groups of data, one concerning the
effects of an increased serotonergic tone and the other documenting
the effects of a lowered tone.
1(a) Drugs that lower effective centaal 5HT levels by receptor
blockade
Certain drugs thought to act as central 5HT receptor blockers
have been investigated in certain epilepsy models. The drugs
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generally used are lysergic acid diethylamide (LSD) and 2-bromo-d-
lysergic acid (BOL). LSD has been found to completely block the
behavioural and EEG signs of epilepsy in the photosensitive baboon
(127, 128, 112). However there is evidence that LSD (and BOL) only
block the excitatory action of 5HT (129, 178, 482), and if, as the
microiantophoretic studies imply, cortical 5HT is primarily an
inhibitory neurotransmitter (552), then one is led to suspect that
these drugs' anticonvulsant action may not be aediated via the
serotonergic system.
Meldrum et al. (127), screening various hallucinogens and 5H7
receptor blockers in the photosensitive baboon, discovered that the
anticonvulsant action of LSD and paylocybin could have been mediated
in part by the effect both drugs had on inhibiting transmission in
the afferent visual pathway. Methysergide, also an anticonvulsant
in this model, did not have this effect, and they concluded that the
anticonvulsant effect of these drugs was therefore primarily mediated
via the serotonergic system.
It is not completely clear whether LSD, BOL and methysergide act
as 5HT antagonists or whether they are partial agonists (129, 178,
482) at serotonergic receptors. Furthermore, LSD has been found to
have a dopamine-receptor stimulating action (324, 325), so it becomes
rather difficult to specify exactly what the mode of action of these
anticonvulsants is. One also cannot rule out the possibility that
the effects on the cortex of these drugs may be secondary to their
effects on sub-cortical structures. LSD has been reported to
inhibit cells in the raphe (127, 128, 259, 260), and altering raphe
tone on the cortex may have an effect on a cortical epileptic focus
quite different to that of a 5KT receptor antagonist or agonist, as
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the cortical distribution of such a drug may not parallel the map
of the cortical serotonergic innervation.
Of this group of drugs, raethysergide has been used clinically.
At least three clinical trials have been reported (135, 136, 137),
all finding that methysergide was effective in treating certain
cases of temporal lobe and other epilepsies.
Kb) Drugs that loser central 5HT levels by inhibiting 5HT synthesis
The two drugs most commonly used to reduce central 5HT levels are
para-chloramphe tarnine (PCA) and para-chlorphenylalanine (FCPA).
Only PCPA has been used in the study of epilepsy to date. An amino-
acid analogue, its irreversible inhibition of tryptophan hydroxylase
(488) can be prevented by pre-treatment with a protein synthesis
inhibitor (490).
PCPA lowers the seizure threshold in the mouse and rat electro-
shock and pentylenetetrazols convulsion models (45, 46, 134) and the
photosensitive baboon (113). However there are other reports that
PCPA elevates the seizure threshold in the audiosensitive mouse (139,
565), suggesting that the neuronal substrate in the mouse electroshock
and audioshock models may be different.
Unfortunately the biochemistry is not absolutely clear, as PCPA
also inhibits tyrosine hydroxylase, though not to the same extent as
tryptophan hydroxylase (491, 492, 493). This means that here again
one cannot be completely certain about the relationship between
serotonergic tone and the seizure threshold.
1(c) Diugs that Increase central serotonergic tone
Various workers have investigated the effects of directly
administered 5-hydroxytryptophan (5HTP) or 5-hydroxytryptamine (5HT)
on the seizure threshold.
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The intracranial administration of OHT in mice into the frontal
lobe has been reported to afford some degree of protection against
audiogenic and pentylenetetrazols seizures (59, 130). In rats,
repeated intracranial doses of 5HT have been reported to antagonise
the convulsant effects of pentylenetetrazols and picrotoxin (100),
although single intracranial doses were ineffective (100, 101, 430).
In an analogous fashion, the short-term OHT-releasing action of
p-chloramphetamine has also been shown to protect mice from audioshock.
(130, 131). There is also one reference (431) stating that the
systemic administration of 5HT has a clinically useful anticonvulsant
effect. This is difficult to evaluate in the light of evidence that
0HT does not pass the blood-brain barrier in significant amounts (179),
but possibly the anticonvulsant effect in this case is mediated by a
peripheral action of 5HT on sensory afferents. This possibility is
examined in the final discussion section.
As 0HTP is able to pass the blood-brain barrier, it can be given
systemically. Large doses of 5HTP have been found to raise central
5HT concentrations and the seizure threshold in parallel in reserpinised
mice (44,03). 6HTP administration has also been reported to partly
protect the methionine sulphoximine pre-treated rat from audiogenic
seizures (132), to depress EEG responses to photic stimulation in the
photosensitive baboon (40), and to depress the epileptiform after-
discharge in the chronically isolated cortical preparation in the
cat (0). Interestingly enough, this last effect could be blocked by
methysergide.
Pre-treatment with MAO inhibitors has been reported to enhance the
anticonvulsant effect of 5HTP in the photosensitive baboon (112) and
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audiosensit1ve mouse (130). However there are also available
reports of 5HTP inducing EEG abnormalities in the photosensitive
baboon (113), and precipitating epileptic behaviour in the
"alumina cream" focus in the cat and monkey (50).
Tryptophan administration, with or without an MAO inhibitor, has
also been used to raise central 5HT levels. The combination of
tryptophan plus an MAO inhibitor has been shown to raise the
seizure threshold in the rat electroshock model (6, 47), and these
are several reports of 5HTP, tryptophan alone, and tryptophan plus
an MAO inhibitor all being clinically effective in the treatment of
myoclonus and various other types of epilepsy (71, 420, 461, 462, 463).
There is seme evidence that these forms of anticonvulsant therapy are
most effective with those patients who present with low levels of
5HIAA in the lumbar CSF (420).
However there is at least one conflicting report (51), that
found that tryptophan actually activates epileptic foci in some
patients.
The contradictory results described above, some studies indicating
that an increase in central 5HT may be anticonvulsant in some instances,
but may precipitate EEG abnormalities in others, indicate that it
would be wrong to assume a first order relationship between central
5HT concentrations and the seizure threshold. This point is very
effectively demonstrated by Kellog et al. (130), who found that the
seizure threshold in audiosensitive mice was raised both by p-
chlorophenylalanine, an Inhibitor of 5HT synthesis and by 5HTP, given
in conjunction with an MAO inhibitor. There are several possible
explanations for this. First, one can postulate model and/or
species differences to reconcile some of the data. Second, one
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could hypothesise that there may be an optimal range of central 5HT
concentrations above or below which cortical malfunction may develop.
Although cortical 5HT is thought to be mainly inhibitory (552), when
present in excess it might also act as an excitatory neurotransmitter,
possibly at physiologically inappropriate receptor sites if overspill
occurs from normal storage sites, or when, for example, 5HTP is
decarboxylated by the unspecific aromatic amino&cid decarboxylase (AAD)
in ^^-serotonergic neurones.
Third, one can investigate the possibility that the apparently
contradictory results are due to the non-specificity of the drugs used
to manipulate the serotonergic system. For example, the side-effects
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of LSD and PCPA have already been mentioned. Even 5HTP, the immediate
precursor of 5HT, may act on central systems other than the serotonergic
one. It has been suggested that, as 5HTP and Dopa are probably
metabolised by the same decarboxylase (AAD) to form 5HT and DA
respectively, large doses of either substrate may, by swamping the
enzyme's decarboxylating capacity, inhibit formation of the other
amine (425). Until very recently, the MO inhibitors available have
not been sufficiently specific to differentiate between the 'A' and
•B' forms of MAO (606), so in those experiments where MAO inhibitors
were used one cannot completely disciminate between the possible
effects on any of the monoaminergic systems. There is also available
evidence that various types of neurone in the CNS work intimately
together, with effects on one system being followed by compensatory
changes in another. For example, an increase in cortical 5HT turnover
has been reported after sectioning the noradrenergic dorsal bundle (471),
and conversely an increase in central 5HT concentrations (after
129.
tryptophan administration) has been shown to be correlated with a
reduction of the threshold to acetylcholine-Induced EEG seizure
discharges (49). Furthermore, it now seems likely that drugs
thought to act specifically on a- and p-adrenoreceptors, and also
histamine receptors, may, by affecting blood-flow In certain brain
areas, alter local pO , pCO and pH values (437). These factors
« 4m
have been shown to alter gabaminergic and serotonergic tone (161, 163),
and thus again we have a situation where an apparently specific drug
my indirectly affect a range of neuronal systems.
SECTION II ALTERATIONS OF 5HT METABOLISM
Alterations of 5HT metabolism In models of epilepsy
Much of this work has been done on the audiosensitive mouse model.
An early paper by Schlessinger et al. (95), detailed the relationship
between age, brain amine levels, and seizure susceptibility in the
audiosensitive mouse and reported an inverse correlation between
seizure threshold and levels of central NAd and 6HT. More recently
the work from Schlessinger's group has concentrated on the serotonergic
system. Brain 5HT levels have been shown to follow circadian rhythms,
being greatest at noon and lowest at 20.0 to 24.0 hrs (308, 309).
Subsequently 5HT synthesis and turnover were shown to follow the same
pattern (310). Finally a study by Schlessinger and Schreiber (52)
established that the diurnal rhythm of the seizure threshold paralleled
the rhythm of the serotonergic system, being at its lowest at night
and highest during the day. No apparent involvement of NAd could be
established on this study.
Another model, the audiosensitive rabbit, has also been reported
to display aignlfleantly lowered brain-stem 5HT levels Muring the
period of maximal audioaensitivity (455), but at this date the model
has not been investigated further.
Various workers have looked at aspects of 5OT metabolism in
other models; there is one report of increases in brain 5HIAA during
seizures in the tungstic acid nodel (10), and another detailing
findings of raised brain concentrations of 5HT in rats immediately
after electroconvulsive treatment (428). Although there is
obviously no directly analogous clinical information, concentrations
of 5HIAA have been measured in the CSF of patients given ECT for depressive
illness (142), but in this case no significant changes were detected
after a.COurse of treatment.
Reports of altered 5HT metabolism in cases of human epilepsy
There has been a lot of work done Jn this area in the last decade.
Many of the data are contradictory. This is probably due in part to
the anticonvulsant drugs which many patients were receiving, which
have themselves an action on 5HT metabolism. Various aspects of
methodology are also suspect. Clinical research is hampered by the
limitations of sampling. Much of the work reported on in this
section on clinical studies is based solely an assaying for 5HZAA in
lumbar CSF samples. However, there is evidence that suggests that
this technique may be cf little value in monitoring central 5HT turnover.
It should be noted that any theory attempting to link CSF concen¬
trations of 5HIAA in a simple, first-order relationship with the
effectiveness of the serotonergic system, or with a biochemical
pattern of epilepsy, does not take into account the fact that there
are thought to be two pools of 5HIAA contributing to CSF 5H1AA levels
(SO, SI, 82). One pool represents 5HT that is released from sero¬
tonergic nerve terminals, is effective at post-synaptic sites and
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catabolised extraneuronally. The other pool la derived from 5HT
that la synthealaed in serotonergic neurones in excess to require¬
ments and storage capacity, and ia a substrate for lntraneuronal MAO.
Only the contribution of the first pool to CSF 5HIAA concentrations
represents the degree of serotonergic tone; overall rates of SHT
turnover as measured by assaying CSF 5H1AA do not therefore accurately
represent the activity of the central serotonergic system. The
importance of this concept is that MAO in serotonergic neurones can
thus uncouple serotonergic tone from brain tryptophan levels, and
ultimately dietary tryptophan, thereby strengthening the independence
of neuronal function.
Secondly, it has been shown that, in various experimental animals,
concentrations of 5IIIAA in lumbar CSF reflect changes in spinal cord
5H1AA, rather than concentrations of 5HIAA in cisternal CSF (258,
590-592). This may also be the case in the clinical situation; and
furthermore, the areas of fore-brain involved in epileptic
phenomena are innervated by the anteriorly-projecting rostral raphe
nuclei; the descending serotonergic systems, deriving from the
caudal raphe nuclei, may not always be affected in proportion to
the ascending serotonergic systems. It would be a mistake to assume
that a biochemical homogeneity (the neurotransmitter both systems
have in common) denotes a common physiological response. Various
workers have attempted to solve some of these problems by taking
samples of mixed CSF, and it has also recently been suggested (255,
256) that a parallel estimation of tryptophan with the 5HIAA in CSF
samples might provide more information, as to the central 5HT
turnover.
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If CSF tryptophan correlates with brain tryptophan levels, then
such a dual analysis could determine whether the reported decrease in
5HT turnover during depression or epilepsy is contributed to by changes
in substrate availability in the brain, or an effect on the rate-
liiaitlng hydroxylation step. Although correlations have been found
between blood and lumbar CSF tryptophan levels in patients receiving
tryptophan orally, (256), no such relationship between CSF tryptophan
and CSF 5HIAA has so far been found (257, 258). If the rate of
central 5HT turnover is directly related to substrate concentrations,
as some authors think (180, 188, 189, 190), and if CSF tryptophan is
linked to blood and/or brain tryptophan, then one would expect CSF
tryptophan and 5HIAA concentrations to be related. In fact the
only study reporting such a correlation was basdd on an experiment
using genetically standard animals in a controlled environment (25 5).
The value of such dual assays is therefore not yet ascertained.
CLINICAL DATA
One study (8) found significantly reduced 5HIAA (60% of control
values) in the lumbar and mixed CSF of temporal lobe and Grand Mai
epileptics. Levels of homovanillic acid (HVA) in the CSF were, in
this study, reported as normal. Two corroborative studies (9, 87)
indicated that, after the inhibition of CSF metabolite transport
(using probenecid), the accumulation of 5HIAA in the CSF of otherwise
unmedicated epilepsy patients was significantly lower than control
values. A third study (36) by the same authors found a 50 per cent
decrease in lumbar and mixed CSF 5HIAA levels in epileptic children;
however, in this trial they also found a similar decrease in CSF HVA
levels, in contrast to their earlier findings. The authors
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speculated that 5HT turnover in their patients might have been even
lower than these findings suggest, as most of the patients were being
treated with diphenylhydantoin, a drug which has been reported both
to increase 5HT turnover in brain (36, 42€, 427, 428) and to inhibit
5HIAA transport (36). There have been surveys by other workers
(32 , 33 , 34) also detailing findings of lowered 5HIAA and HVA in the
CSF of epilepsy patients.
It seemed relevant at this point to include in this section a
discussion of the effects of anticonvulsants on 5IfT metabolism, as
so many of the reports on CSF metabolite levels are based on samples
from patients who are receiving medication of some sort.
SECTION III EFFECTS OF ANTICONVULSANTS ON SHT METABOLISM
Already, before OUT had been established as a central neuro¬
transmitter , a fairly exhaustive survey had been carried out by
Boimycastle et al. (30) concerning the effects of various anti¬
convulsants on brain SHT concentrations in the rat. Phenytoin,
mothoin, troxidone, paramethadione, phensuximide, phenacemide,
primidone, phenobarbitone and sodium bromide were all reported to
cause significant increases in brain 5HT; and it was suggested that
the drugs exerted their anticonvulsant effect primarily by elevating
serotonin concentrations. However it was shortly afterwards
established that lower but still anticonvulsant (i.e. protective
against electroahock) doses of diphenylhydantoin did not alter rat
brain SHT (548), nor did meprobamate, another anticonvulsant drug (547).
Two non-anticonvulsant barbiturates pentobarbitone and hexobarbitone,
also raised brain 5HT concentrations (547), and there has been at
least one report (428) of a convulsant, pentylenetetrazols, raising
rat brain 5HT, so the relationship between anticonvulsant efficacy and
an effect on SHT levels became rather blurred.
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More recently an extensive study by Chadwick et al. (29)
attempted to explain the findings of altered SHIAA concentrations
in CSF from epileptics as a result of their medication, as well as
of the underlying pathology. They analysed the CSF of patients
suffering from various forms of epilepsy and found that in CSF from
untreated patients SHIAA and HVA values were close to normal.
Those patients who were being treated with anti-convulsants, notably
dlphenylhydantoin and phenobarbitone, appeared to have raised levels
of these metabolites. They also found that those subjects who had
been receiving subtherapeutic doses of the drugs did not have signif¬
icantly raised CSF values, and conversely Ifchose patients manifesting
drug toxicity, with very high blood levels of the drugs, had the
highest CSF metabolite levels. They did not, unfortunately, present
any data concerning the effects of diphenylhydantoin and phenobarbitone
on the concentration of SHIAA and HVA in the CSF of non-epileptic
control patients.
Although other workers have been unable to show this correlation
between plasma levels of diphenylhydantoin and CSF concentrations of
SHIAA and HVA in epileptic children (9,87), Chadwick'a paper seems to
show that the reduced CSF concentrations of SHIAA and HVA reported in
other clinical studies (8,9,32-34,36) could not have been a direct
result of their medication, as some critics had suggested. It
also suggested that the anticonvulsant drugs acted primarily cm
central 5HT and DA systems, although it is unclear whether the main
action is on amine turnover, release, uptake or transport mechanisms.
One group of workers (36) has found that diphenylhydantoin and
phenobarbitone slow down the rate of removal of SHIAA from the C8I in
the rat, and reduce the rate of SHT and NAd oxidation in brain slices.
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This first action would tend to raise CSF 5HIAA concentrations, the
second would have the reverse effect. If one or other action pre¬
dominates at different doses of the drug, this could explain some of
the conflicting results on 5HIAA levels in the CSF of epileptic patients
receiving anticonvulsant medication. The effect on dopaminergic systems
may be similar, as phenobarbitone has been shown to reduce DA turnover
in rat brain (37,61).
The action of diphenylhydantoin and phenobarbitone on functionally
reducing 5HT cat&bolism would explain the previous findings of these
two anticonvulsants raising 5HT concentrations in rat brain (30, 31,
162, 153).
There is available further evidence linking the anticonvulsant
effect of diphenylhydantoin to its action on the metabolism of 5HT;
the rate of 5HT increase in the brains of rats given diphenylhydantoin
has been found to parallel very closely the development of the anti¬
convulsant's effect on the seizure threshold to both electroshock
(155) and to hexafluorodiethyl-induced seizures (ISC). These
findings have, however, been disputed by other authors (167, 158,
159). It must be clearly stated that none of these pieces of evidence
can establish whether the apparent changes in serotonergic metabolism
are fundamental to the anticonvulsant effect or merely reflect a
cortical inhibition, which itself may not be primarily serotonergic
in origin.
The theory of a primarily serotcnergically mediated anticonvulsant
effect has had its supporters and detractors. Perhaps one of the
best studies in support of the hypothesis was one by Meyer and Frey
(41), who examined the effects of altered brain amine levels on the
ability of phenobarbitone to protect against electroshock and
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pentylenetetrazol convulsions. Depleting central SHT and NAd by
pre-treatment with p-chlorophenylalamine and a-methyltyrosine
rendered the anticonvulsant phenobarbitone ineffective. Cyprohep¬
tadine and phentolamine, 5HT and NAd receptor blockers respectively
had the same effect, while 5HTP and L-Dopa administration augmented
the anticonvulsant action of phenobarbitone.
Other authors contested these findings. Rudzlk and Mennear (140,
141) used a-methyltyrosine, a-methyldopa and a-methyltyrosine to lower
central NAd levels, but found them all ineffective in antagonising
diphenylhydantoin. Tftey suggested that diphenylhydantoin therefore
may exert a part of its anticonvulsant action through mechanisms other
than alteration of monoamine metabolism, although they only examined
one model, the audiosensitive mouse.
Bonnycastle et al. (429) cite evidence that pretreatment with
diphenylhydantoin can augment the increase in brain 5RT after 5HTP admin¬
istration, and can also reduct the extent of SOT depletion in rat
brain following reserpine. Green and Graham-Smith (80,81) have
published some very interesting data concerning the effects of
diphenylhydantoin on SHT turnover; after a dose of diphenylhydantoin
that had previously been reported to enhance the hyperactivity in the
rat after tryptophan loading and a MAO inhibitor (82), they established
that the same dose on its own did not increase SifT levels, nor did it
alter synthesis rates, 5HT uptake, or post-synaptic response to 5HT
agonists. They suggested that the drug's action at that particular
dose may have been to increase the amount of SHT available for release
at the nerve terminals, by effecting some redistribution of the
neurotransmitter between different 5HT pools. They also looked at
the effects of repeated doses of diphenylhydantoin and found that
after a short course of the drug the rate of 5IfT synthesis in brain
apparently doubled. There was no increase in 9HT levels, so that
catabolism was keeping in step with synthesis; the 5HIAA concen¬
tration in the CSF increased twofold, agreeing with the earlier
observation that diphenylhydantoin and phenobarbitane had the
ability to raise CSF 5HIAA levels.
It is of interest to note here that lithium-treated rats
display similar changes in 5HT synthesis, and the behavioural
effects may be comparable too (83). There are also papers available
<84, 89, 219) describing findings of a significant rise in concen¬
trations of 5HIAA in the lumbar CSF of lithium-treated manic patients*
The fact that lithium appears to act on 5HT metabolism in a manner
resembling that of diphenylhydantoin, yet is not an anticonvulsant (86)
tends to detract from the theory of anticonvulsants as primarily
acting by altering serotonergic nerve function.
It may also be critical to know not only the type and amount of
medication a patient is receiving, but also for how long that treatment
has been going on. Goodwin et al. (262,263) have reported finding
elevated SHIAA levels in the CSF of patients receiving lithium for
8 days, and sub-normal levels of 5HIAA at 21 days. They postulated on
adaptatlve mechanism, which tended, after the primary action of lithium,
to return the neurophysiological balance to normal.
Poitou and Bohuon (347) have examined the action of Li+ on cate¬
cholamine metabolism in the rat, and found a similar blphasic pattern
here. After 3 days of Li+ treatment, NAd synthesis had Increased
above normal, but was at normal or subnormal rates at 13 days; OA
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synthesis was also reduced. They suggested that even if HAd synthesis
was increased at day 5,this was associated with a reduction in effec¬
tive NAd levels, because Li* stimulates intraneuronal catecholamine
release, with a subsequent increase in the metabolites produced by
deaminative oxidation by MAO. This is backed up by two earlier
papess, a report (344) that Li* reduces the extra-neuronal release
of NAd after electrical stimulation, and a clinical paper (348)
recording findings of raised MAO metabolites of catecholamines in CSF
after lithium therapy.
Knapp and Mandell (264, 265, 267) have suggested that a whole
array of adaptive mechanisms exist whereby a neurone or neuronal system
can absorb a stimulus; adaptations that affect the system in such a
way that receptor stimulation always tends to return to normal levels.
For example, after amphetamine administration in the rat, they find
decreased tryptophan hydroxylase activity in the raphe after 30 minutes,
and in the cortex after 60 minutes* The drug does not inhibit the
enzyme in vitro, but it does increase receptor stimulation by increasing
neurotransmitter release and blocking re-uptake (266). It was
suggested that the rapid reduction of tryptophan hydroxylase activity
was due to a compensatory mechanism called into play by the increased
receptor stimulation, and consequent neuronal feedback. The mechanisms
which may be involved include substrate uptake, the activity of the
synthetic enzymes, and possibly other factors such as availability
of reduced co-factor. In the case of the adaptive responses to Li*,
the paper by Knapp and Mandell (267) reports the following sequence;
after 3 to 5 days of Li* administration, first the high affinity uptake
mechanism for tryptophan in the striatum was increased; second, the
tryptophan was metabolised more rapidly to serotonin in a striatal
synaptosome fraction; third, soluble tryptophan hydroxylase
activity in the raphe decreased. After 21 days of lithium admin¬
istration the synthetic rate in the synaptosomea dropped to normal,
even when the high affinity uptake of tryptophan was still being
4-
stimulated by the Li . In other words, after a stimulation of
substrate uptake and 5HT synthesis in the nerve terminals a
compensatory decrease in synthetic enzyme occurred in the cell
bodies, which was eventually mirrored in the nerve terminals.
In practical terns this meant that in the attempt to elucidate
the Involvement of the serotonergic circuitry in the cobalt rat, it
would have been unsufficient to record any one parameter of the
neurones' viability. Simply measuring raphe tryptophan hydroxylase
would not necessarily have indicated how the cortical serotonergic
connections were functioning, and similarly any assay of cortical
5HT would not have given sufficient indication of the possibility
of an altered state of affairs in the cell bodies.
Metabolic Errors and the Seizure Threshold
There is one last category of work available concerning relation¬
ships between amine levels and seizure threshold, and this refers to
studies on patients with inborn errors of metabolism, some of which
affect levels of various neurotransmitters directly or indirectly.
However, most of this data is rather confusing as in most cases the
spectrum of effects on the overall metabolism is too wide to permit
any one-to-one relationship to be picked out. The best-studied
disorder is phenylketonuria. Approximately 50% of patients with
this disease display epileptiform abnormalities, and overt epileptic
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behaviour (268-271), including petit mal and grand mal. The primary
lesion is an absolute or relative deficiency of phenylalanine
hydroxylase. Phenylalanine ia instead converted to phenylpyruvate
and then to phenylacetate and phenyllactate.
The effects on the various neurotransmitters are as follows;
first, the increased concentrations of phenylalanine in the blood
inhibit the transport of other amino acids into the brain, including
tryptophan (272, 273), with the result that central OUT turnover is
depressed in these patients, as indicated by the low CSF 5HIAA
concentrations (275) they present with. Second, the synthesis of
the catecholamine neurotransmitters NAd and DA is also affected by
the deficiency in phenylalanine hydroxylase (276, 277).
Unfortunately the story does not end here; for the phenyl¬
alanine metabolites, phenyllactic and phenylacetic acid, which are
present in abnormally high levels in the brains of phenylketonuria
patients, are very potent inhibitors of glutamic acid decarboxylase
(GAD) (278, 279), and the consequent reduction in GABA synthesis is
also a probable factor in the low seizure threshold. If phenyl¬
ketonuria patients are given a phenylalanine load, all the metabolic
abnormalities mentioned above are exacerbated, and often fits and
convulsive behaviour are precipitated (280). A phenylalanine deficient
diet may return the amino acid and amine patterns to normal; for
example a return to normal levels of free serum 5IfT has been reported
(274), but this is not always associated with behavioural or EEG
improvement (281) as permanent damage may have already been done to
the neural substrate.
To summarise the proceeding three sections, it can be stated
broadly that CNS concentrations and turnover of 5HT, NAd and
possibly DA are affected in various forms of epilepsy. Changes
in the central availability of all three amines alter the seizure
threshold; the effects of all three systems are inter-related, and
there is reason to suggest that certain anticonvulsant drugs exert
at least a part of their action by modifying the raonoaminergic
neuronal systems.
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INTRODUCTION TO THE PHARMACOLOGY SECTION
From a thorough survey of clinical and experimental literature two
broad and contradictory trends had emerged. First, the physiological
increase in the activity of the serotonergic system occurring during
non-REM sleep appears to facilitate the appearance and spread of
discharge behaviour in the EEG (314, 313, 316, 317). Second, a
completely non-physiological increase in brain levels of 3HT such
as is caused by 3HTP loading (469, 44, 130, 131, 132, 40, 112), or
the combination of tryptophan loading and an MAO inhibitor (6, 47, 7,
420), is very effective in reducing or suppressing epileptic behaviour
in a variety of models. A third body of data refers to the effects
of a leas extreme, but still unphysiological, amplification of the
serotonergic system as caused by tryptophan loading alone. Those
workers who have examined the effect of this treatment on the
seizure threshold have published conflicting data. Some reports
suggest that tryptophan loading is effectively anticonvulsant, (461,
462), while others find that tryptophan loading actually activates
existing epileptic foci (50, 51). It would have been possible to
construct some bridging theory around the non-specificity of the
drugs used to manipulate the serotonergic system, but this seemed
unsatisfactory.
It is generally accepted that 5HT acts in the cortex as an
inhibitory neurotransmitter (482). This, and the hypothesis
regarding the specificity of the circuitry of hypersynchrony, forms
the basis of the following attempt to co-ordinate the above findings.
When the cortical serotonergic circuitry is activated, as in
non-REM sleep, a specific population of cortical neurones upon which
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the serotonergic nerve terminals project, is inhibited; the removal
of this population of cells permits, or is associated with the
development of the synchrony of sleep in the remaining active
neuronal matrix. This state, which displays such synchrony, has
also an increased vulnerability to the hypersynchrony of epilepsy.
(Theoretically it is just as possible to precipitate an oscillating
state by the removal of active elements from a matrix as by adding
active components.)
If the non-sleeping animals can be treated in such a way as to
mimic the action of the serotonergic projections, and consequently
removing the same specific nerve population from the pre-synchronous
nerve matrix of the cortex, then one would expect a similar reduction
of the seizure threshold. Tryptophan loading may achieve this.
Because tryptophan hydroxylase is only located in serotonergic
neurones, the increase in central 5HT after tryptophan loading is
restricted to physiological sites, i.e. serotonergic nerve terminals,
suggesting that the same cells in the cortex will be affected by
this treatment as are affected during sleep. Moir (464) established
that after tryptophan loading, the increased levels of brain 5H7
were proportionately closely related to the normal regional distribution
of the amine.
3HTP loading induces a raising of the seizure threshold, although
in this case the underlying factors are not identical; as aromatic
amino acid decarboxylase is widely located in the CNS, the rise in
cortical 5HT after 3HTP loading does not parallel normal 5KT
distribution, being considerably less differentiated (464).
Grahame-Sraith (82) found that tryptophan administration in the rat
144.
could only initiate a state of hyperpyrexia and stereotyped hyper¬
activity when given in conjunction with an MAO inhibitor, and suggested
that MAO might play an important part in determining the functional
response of serotonergic neurones to changes in the rates of 8-HT
synthesis brought about by altering substrate concentrations. He
suggested that 9-HT symthesised in excess of demand and storage
capacity would normally be catabolised intraneuronally; only after
MAO inhibition would an increase in 5-HT synthesis, after all storage
sites had been filled, "spill over" into extra-neuronal release and
functional activity. The importance of $hia idea is that it provides
a hypothetical structure of uncoupling serotonergic neuronal activity
from substrate concentrations and rates of 5-HT synthesis. However,
the fact fehat tryptophan administration alone can affect the seizure
threshold (50, 51, 461, 462) would seem to indicate that this uncoupling
may, in certain situations, not be completely effective.
Using tryptophan administration in conjection with an MAO inhibitor,
one might then arrive at a situation where an increase in the amount
of 5-HT released from serotonergic nerve terminals could be sufficient
not only to inhibit the critical population of cortical neurones, but
also neighbouring neurones. Alternatively, receptor desensitisation
of the critical cortical neurones might develop, which one would also
expect to result in a raising of the seizure threshold.
A good illustration of the different effects of serotonergic
manipulation is described in a series of papers cm the photosensitive
baboon, by Meldrum et al. (509, 510), although no explanation is
offered. 200-600 mg/kg L-tryptophan, given i.p., slowed background
rhythms and simultaneously increased spontaneous paroxysmal activity
in the EEC, resembling in these two instances the effects of sleep.
Table A27
Effects of L-tryptophan administration on cortical S-HT and S-HIAA
(fig/# brain) in unoperated, 3^ month old PVG rata
5HT 5HIAA
A A Controls .45 .42
.39 .35
.42 .38
8 Experimental; animals given 600 mg/kg L-tryptophan i.p., mad










Large doses of an MAO inhibitor were very effective at suppressing
spontaneous paroxysmal activity in the EEG, and also the myoclonic and
EEC responses to photic stimulation. Sub-effective doses of the MAO
inhibitor, in conjunction with tryptophan loads of 100-150 mg/kg,
were equally effective in suppressing epileptic behaviour, as were
5OTP loads.
It is interesting to note in this context that clorgyline, an
MAO type A preferential Inhibitor, has also been used on the cobalt-
implanted rat aodel and has been shown to suppress epileptic signs
in the EEG (J. McQueen, personal communication). I anticipated from
the observations reported in the literature and referred to above
that by manipulating the serotonergic system in the cobalt-implanted
rat a biphasic response would be Obtained, namely an increase in
spiking associated with increased but still physiological serotonergic
activity, followed by a reduction in spike formation associated with the
non-physiological synthesis and release of 5HT, and subsequent non¬
specific cortical inhibition.
EXPERIMENTAL RESULTS
In a preliminary experiment, the effects of a loading tryptophan
dose (600 rag/kg) on levels of 5HT and 5-HIAA in the cortex of control,
unoperated rats were measured at 1 and 2 hours after loading (Table A27)
It had already been established that cobalt-implanted rats responded to
a tryptophan load similarly to glass-implanted controls (Table A24, A25)
Subsequently an Identical dose of tryptophan was given to 30 day cobalt-
implanted rats. The BCoG of these rats were recorded before and after
the tryptophan administration, and a group of these animals was then
given clorgyline (2-4 mg/kg) before a final ECoG recording was made.
Table A28
The effects of clorgyline on cortical 5-HT, 5-H1AA and NAd.
8-HT 5-HIAA NAd
A. Controls 1 .39 .33 206
2 .42 .34 188
.41 .34 197
B. Clorgyline 3 .34 .20 217
4 .59 .14 195
5 .54 .23 199
.56+.02 .19+.04 204+10
Notes:
1. Figures given fig 5-OT or 5-HIAA/g brain, and ng NAd/g brain.
2. Final values given as x + SD',
3. Clorgyline given lh. before killing, 2 mg/kg l.p.
4. Each group of 3 data represent a sample of frontal cortex
from 1 rat.
Table A29








x + SD1! Control: 55 + 41/139 + 54
Clorgyline-treated: 25 + 20/58 + 40
Notes:
1. All figures represent spikea/tain., averaged from a 10 n in.
recording.
2. x/'y represents spike counts from primary/secondary foci.
3. Rats used 10 days post-implant. They were recorded once
before clorgyline administration, and again lh. after
2 aig/kg clorgyline, i.p.
4. Using the paired T-test, it was found that the reduction of
spiking in the primary focus was significant at the .05-.025
level, and in the secondary focus at the >.001 level.
Table A30
Spike counts in 10 rain. recordings of ECog in cobalt-implanted rats,
before and after L-tryptophan and clorgyline










All controls warn given 0.5 ml 0.9% NaCl i.p. after each recording
to allow for stress induced in the experimental animals by drug
administration and handling.
B. Effects of L-tryptophan, 600 rag/kg p.i., given directly after
recording at time zero.
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98 289 303 248
115 212 350 272
138 274 311 316
34 146 185 181
131 223 276 329
ia MB N B 533
87 * * * * 304 508
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195 424
C. Effects of clorgyline, 2mg/kg i.p. on tryptophan-loaded rats.
Tryptophan, 600 mg/kg i.p. given after 1st recording.
Clorgyline given immediately after recording at lh and 3h./...
Table A30 (contd.)
C. Effects of clorgyline, 2mg/kg i.p. on tryptophan-loaded rats.
Tryptophan, 600 tag/kg i.p. given after 1st recording.
ClorByline given immediately after recording at lh and 3h.






































1. Figures given represent spike counts from primary focus (x)
y
and secondary fostus (y).
2. In table C, all figures to right of double line represent
rats recorded lh after clorgyline administration.
The ECoG of a control group of animals was also recorded, these being
30 day cobalt-implanted llttermates of the first group, given
subcutaneous injections of 0.9% NaCl instead of the drug injections.
This was to allow for any ECoG effects in the experimental animals
due to the stresses of injection and handling. The control group
did not display any significant variation in spike counts over the
period of observation (Table A30, pt.A).
All rats given a 600 mg/kg dose of tryptophan responded at 1 hour
after loading by a 50-100% increase in the spiking rate in both primary
and secondary foci. This increase was maintained at 2 h. after
tryptophan, and the 4 rats which were recorded at longer times (4 and
5 h.) also showed a consistent elevation of spike counts above normal
in both foci (Table A30, pt.B). Then a group of these animals was
given clorgyline at a dose that had been previously found to increase
levels of S-HF in the cortex of unoperated control rats by about 30%
while leaving NAd concentrations unaffected. (Table A28). This same
dose had also previously been found to reduce spike counts in both
primary and secondary foci in rats at X> days post-implant (Table A29).
The clorgyline in this experiment caused a sharp fall in the
spiking rates in both foci to levels between 50-90% of the first,
pretryptophan recordings. Using the paired t-test, the post-
clorgyline spiking rates were significantly lower than the pre-
tryptophan rates at the 0.025 probability lavel (in the primary focus)
and at the 0.001 probability level (in the secondary focus). To
examine further the effects of manipulation of the central serotonergic
systems on the seizure threshold, a group of cobalt-implanted rats was
treated with a persistent central 5-HT depleting afront, 5,7-
dihydroxytryptamine. At 1 day post-implantation, the experimental
Table A31
Effacta of desKethyllnipramine and 5,6-dihydroxytryptamine on levels





























1. Figures given as fig 5-HT or 5-HlAA/g brain, and ng NAd/g.
2. Final values given as x + SD •.
3. 10 days before killing, rats were given 5 mg/kg deamethylimipramine
i.p., and 1 h. later 50 fig of the free base 5,7-dht. in 20 |il
mammalian Ringer's solution i.v.
4. Each group of 3 data represent a sample of frontal cortex from
one rat.
Table B32
Effects of deamethylimlpraalne and 5,7-dlhydroxytryptamine on ECog
of cobalt-Implanted rata.
Days post-Implant
Day 4 Day 10 Day 18 Dav 25
A 1/10 6/30 6/12 0/23
B 4/34 3/9 8/13 7/31
C 1/18 2/21 2/10 5/14
D 12/97 3/32 5/9 2/26
E 3/68 0/4 8/53 3/28
F 10/49 7/40 12/13 8/20
0 16/62 15/63 5/27 9/12
H 29/35 67/137 2/2 1/0
1 0/18 5/55 6/31 0/14
X + SD•: Day 4s 8.4+9.0/43.1+27.0
10: 12.2 + 19.7/43.4 + 37.7
18s 6.0 + 2.9/18.8 + 14.7
25s 3.8 + 3.2/18.6 + 9.1
Notes:
1. All figures represent apikes/min., averaged from a 10 min. recording.
2. x/y represents spike counts from primary/secondary foci.
3. 5,7-dihydroxytryptamine and desmethylicipramine given 1 day
post-implant.
animals were pre-treated with desiaethylimipramine (5 tag/kg, i.p.)
a selective blocker of catecholamine uptake, and then at 1 h. given
an intraventricular injection of 50 pg 5,7-dihydroxytryptamine, the
free base, in 20 pi mammalian Ringer's. Treatment with this
combination of drugs has been reported to have a very specific and
persistent 3-HT depleting effect in the brain, with only transient
changes in catecholaminergic parameters (503, 508). The group of
experimental animals was then divided into two, one subsequently
being used for biochemical analyses and the other for ECoG recordings.
Cortical levels of 5-ITT and 5-HIAA were approximately 40% of
normal at 10 days after treatment, while NAd levels were unaffected
(Table A31). The effects of central 5-HT depletion on the ECoG
proved, however, difficult to evaluate (Table A32). At first sight
it would appear that spiking rates are low in the primary focus at
days 10, 18 and 25 post-implantation, but the figures quoted here axe
not outside the wide range of variation of the cobalt-implanted
rat model when the ECoG is recorded only for a short (10 minute)
period on different days. The absence of any parallel effect on the
secondary focus suggested that the reduction of cortical 5-HT levels
by some 40% did not markedly alter the epileptic condition. This
finding was somewhat unexpected in the light of the theory, already
presented, linking raphe tone to the seizure threshold. Possibly
the reduction was not large enough to affect the cortical epileptic
foci; this seems however hard to reconcile with the observed degree
of involvement of the serotonergic system in this model, as instanced
by the 30-40% reduction of cortical 6-HIAA (Tables A17, A18, A24).
Table A33












1. All figures refer to spikes/min., averaged from a 10 min. recording.
2. x/y refers to spike counts in primary/secondary foci.
3. x/y—> a/b denotes changes in spike counts before and after
tolazoline; tolazoline was given i.p., 5ng/kg in saline,
inmediately after the first recording and 30 min. prior to
the second recording.


















In a subsequent experiment, a group of cobalt-implanted rats were
recorded before and after the administration of tolazoline (5mg/kg i.p.)
at days 5, 10-11, and 19-20 post-implantation. Tolazoline has been
reported to be a very potent central 5-HT receptor blocker
(Dr. D. Franz, personal communication). This drug did not display
any definite effect on apiking rates in either primary or secondary
epileptic foci (Table A33), at any stage recorded after implantation.
In retrospect tolazoline may not have been the drug of choice for this
experiment, as it is also an <x~adrenergic receptor blocking agent,
and an H -type histamine receptor agonist (606). A more specific
central 5-BTT receptor blocker, N-dimethyltryptamine, has been found
to aggravate spiking in the cobalt-implanted rat (Dr. J. McQueen,
personal communication).
At this stage the criticism was raised that the changes in spiking
rates observed during the tryptophan loading experiment may have been
a reflection of diurnal fluctuations in the seizure threshold, this
experiment differing from previous ones in that the animals were
recorded at different times throughout the day. Schreiber and
Schlessinger (52) had already demonstrated diurnal fluctuations
of the seizure threshold in the audiosensitive mouse, developing in
parallel with the circadian rhythms governing the central serotonergic
system. To ascertain the degree of diurnal fluctuation of the
seizure threshold in the cobalt-implanted rat, a group of operated
rats, 7 weeks post-implant, was recorded at 3 different times during
the day. (Table A26). The figures show an apparent decrease in
spiking rates in both foci at the two later recording times, but these
changes are not significant. (Using the paired t-test, the prob¬
ability of this reduction being significant are 0.2>P>0.1, for
both foci).
Table A26
Mean spike counts/min. in 10 min. recordings of ECoG In cobalt-
implanted rats when recorded at different times on same day
(50 days post implant)
Rat 9.00-10.30 a.m. 12.00-13.30 p.m. 15.30—17.00 p.m.
A N.R. 0/36 2/5
B N.R. 7/43 18/37
C 5/23 15/41 N.R.
D 2/7 5/5 N.R.
E 11/13 N.R. 10/11
F 2/21 N.R. 2/39
G 4/8 1/2 2/3
H 25/83 0/3 0/1
1 9/10 6/5 2/10
J 20/27 1/15 2/4
9.8+8.0/24.0+23.4 4.4+4.8/13.8+17.0 4.8+5.7/13.8+14.4
Notes:
1. x/y represents spikes in primary/secondary epileptic foci.
2. N.R. indicates no recording: made.
3. Final values given as x _+ SD* (N).
4. The paired t-test was used to compare the recordings; no
significant changes were noted (P 0.25).
 
These results are a little surprising in view of the diurnal
rhythms found in the audiosensitive mouse (52), but i* may simply
be the case that the variation in seizure threshold, if it occurs at
all in this model, develops before 9.00 a.m. and after 6.00 p.m.
They do suggest, however, that the changes in spiking rates fowd in
the drug-treated animals being recorded for periods of up to 3 to 4
hours (Table A30, pt. A and B), could not be ascribed to diurnal
changes in the seizure threshold as the experiments were all carried
out between 9.00 a.m. and 6.00 p.m.
In a final attempt to link developments in the ECoG of the
cobalt-implanted rat with the biochemical findings, a group of 10 male
PVG rats, 2.5 months old and weighing 226-273g, was given cobalt-
implants and subsequently recorded once weekly for just over 3 months.
In an attempt to reduce the degree of experimental variation, care
was taken to standardise recording conditions as follows; all animals
were recorded in a set sequence at a standard time of day, and to allow
for the stress induced by handling the animals and placing them in
the novel environment of the recording cage, a period of 10 minutes
was allowed between electrode connection and recording.
The ECoG recordings were processed simultaneously onto paper
print-out for visual inspection, and onto recording tape for subsequent
computer analysis by the program of Hill and Townsend (567). Two
distinct peaks of spiking appeared over the 3 months, the first
developing luring the first week post-implant and falling off to
20-25% of peak values between 14 and 21 days post-implant, and the
second peak developing at weeks 4-7 (Figure A5). After the second
peak the rates of spiking appeared to stabilise.
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The first increase in spiking1 develops at roughly the same time
as the reduction in the activity of cortical catecholamine-related
enzymes discussed in this thesis, and the fall in the activity of the
synthetic enzymes of acetyl choline and GABA (466). The next phase,
a major reduction of spiking rates between 14-21 days, develops
while concentrations of 5-HIAA in the cortex and the activity of
tryptophan hydroxylase in the raphe are also becoming reduced.
Between weeks 3-5, some of the rats display a relatively
quiet ECoG, and there is evidence that during this period some recovery
of cortical cholinergic and gabaminergic fibres is taking place (466).
Beyond this time correlations between events in the ECoG and bio¬
chemical changes appear more tenuous. One can only formulate
hypotheses as a basis for further experimentation. For example,
the second increase in spiking at 6 weeks may be due to denervation
hypersensitivity phenomena as the injured fibres compensate and/or
regenerate in the affected areas, while the period between weeks 7-13
could represent a 're-wired* steady state subsequent to the recovery
of the catecholamlnergiv and serotonergic parameters.
SUMMARY OF THE PHARMACOLOGY SECTION
We are left with a series of data that do not match completely;
but after allowing for variabilities introduced by factors such as
species differences and the non-specificity of certain of the drugs
used to manipulate the serotonergic systems, certain broad tendencies
emerge. The relationship between serotonergic activity and the seizure
threshold appears to be triphasic. In general, a reduction of sero¬
tonergic tone is associated with a lowering of the seizure threshold.
A slight increase in serotonergic tone may have the same effect, and a
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large increase is associated with an elevated seizure threshold.
It should however be stated that the data genez-ated by the
tryptophan loading and clorgyline experiment is open to other
interpretations than the one offerred above, that of excess
cortical 5-HT causing a general cortical inhibition. It is also
possible that the excess 5-HT causes a desensltisation of the
cortical cells that the raphe projects to, thereby preventing the
"damping" elements from being removed. Another alternative is that
a build-up of tryptamine and/or other amines normally catabolised
by MAO type A may contribute to the reduction in spiking after clorgyline.
If it is true that a moderate stimulation of the serotonergic
system can exacerbate epileptic behaviour, then it becomes apparent
that the clinician using drugs designed to elevate levels of 5HT in
the brain (as in the treatment of myoclonus), may be faced with the
problems of dealing with two thresholds in his titration of the
patient. A rise too small may be counterproductive, and an excessive
increase causes non-specific sedation. As dietary tryptophan is
difficult to monitor outside the clinical or laboratory context, it
may prove difficult to maintain optimal tryptophan levels in non-
hospitalised patients. However, the success of various clinical
trials, already discussed, suggests that the room for manoeuvre
between the two thresholds is great enough to make this form of anti¬
convulsant therapy useful. And it is not as if the sedative side-
effect at high doses is too high a price to pay, as it is in any case
a side-effect of standard anticonvulsant overdose; indeed the long-
term problems of serotonergic manipulation are probably less ominous
than those of, for example, diphenylhydantoin, where there are
reports of Purkinje cell fall-out after chronic use of the drug (586),
although these findings are disputed (585). Nor does the risk of
drug habituation seem likely, as can occur with the chronic use of
phenobarbitone.
In addition to the biochemical and pharmacological approaches,
another method of analysing events in the cobalt model would be to
study those aspects of behaviour in the rat which are thought to be
influenced by serotonergic tone. For example, it might prove
rewarding to examine sleep patterns in the cobalt-implanted rat,
for a loss in serotonergic tone may be reflected here as a reduction
in sleeping tine. Alteration in body temperature control might
also be worth studying.
CONCEITS OF NEURONAL SYNCHRONY
A hypothesis is developed concerning the role of the raphe in
epilepsy.
A summary of the available data linking 5HT metabolism to the
seizure threshold has already been presented. To develop the
hypothesis concerning the role of the raphe system in epilepsy, it
is necessary to disgress a little and include a short section on the
effects of 5HT on cortical arousal, indicating what this means in
terras of the behaviour of individual neurones in the cortices, and
of the overall functioning of the cortices themselves.
Let us begin by describing all states of the CNS in terms of the
efficiency of data handling; several concepts at once follow. In
the alert individual EEG tracings display complex and shifting wave
forms. If the eyes are closed and the mind relaxed, characteristic
rhythms develop over different areas of the cerebral cortices, the
well-known alpha-rhythm appertaining to the occipital areas* for
example* and the 11-12 Hz p-riiythm of the motor cortex. These
rhythms appear to denote the resting state of the cortical areas
involved. If cortical input is increased by opening the eyes* or
if intracortical activity is increased such as by the request to
carry out mental arithmetical operations* these resting rhythms are
disrupted and the EEG again returns to the more varied waking form.
We can examine the other end of this scale by monitoring the EEG
of a patient being brought under anaesthesia. Excepting the initial
excitatory phase, the deepening stages of anaesthesia can in fact be
characterised by the gradual reduction of information, or variation*
in the recording. This presumably reflects both the decrease in
cortical input* and also in intra-cortical activity. Consciousness
returns as the data-handling capacity of the brain, primarily the
cerebral cortices* increases to normal values. In the context of
the developing argument I would like to define consciousness here as
a parameter of date-handling.
One would expect that there must be a constant evolutionary
pressure on animals to develop rapid and efficient machinery for
handling the data in the input from a varied and varying environment.
One of the limiting factors of the capacity of a neuronal machine is
the velocity of neuronal conduction* and it is of Interest to note here
that this factor is found to correlate well with the degree of
evolutionary advance in many species. The speed of maximal information
flow in nerve cells in the jellyfish is of the order of lOcm/sec* the
best figures for worm nerve cells is around lOOcm/sec, while insects
and anthropoda display rates of conduction of up to 1 wtre/secocd.
The anthropoidal neurone can conduct at rates of up to lOta/sec* and
in man the fastest neuronal rates are around 30 m/aec. (326),
Other Uniting factors would include the degree of neuronal
arborisation and the actual nuiaber of neurones. These determine
the width of information channels and the possible ranges for
information coding and permutation. A further factor would be the
temporal density of signals that can be transmitted throughout a
circuit before interference and loss of signal develops. This is in
turn derived from the conduction velocity, the refractory period,
and under certain circumstances the time-scale of synaptic chemistry.
The state of alertness or arousal may be regarded as the
resultant state, or system, of a number of sub-systems in dynamic
equilibrium. These sub-systems could be specified biochemically,
anatomically or functionally: these three types of classification
may overlap, but are not necessarily synonymous.
The working brain can be manipulated in terms of any of the
above types of sub-system; biochemical sub-systems may be manipulated
pharmacologically, anatomical sub-systems by the use of local
lesioning or stimulating electrodes, and functional sub-systems by
the technique of manipulating physiological input.
At this stage I wish to introduce a further concept, "electrical
fluidity". Electrical fluidity describes the extent, as measured
in terms of the nuiaber of neurones involved, to which a neuronal
event occurring in a neuronal matrix will spread within that matrix,
in a given time.
We can also define the range of this factor in terms of
electrical behaviour of a nerve net. At very low, or zero, values
of electrical fluidity each neurone becomes Isolated; no information
passes from cell to cell, and the data handling capacity of the
system is zero. At pathologically high values of electrical
fluidity, an electrical event occurring at any point in a nerve
matrix is transmitted throughout that matrix, and every cell will be
stimulated by every other cell. It is then impossible to separate
groups of neurones in terms of specific function, all compartmentation
of information has broken down, and the data handling capacity of the
system is again zero. At intermediate values of electrical fluidity,
we have a state wherein one neurone can communicate with another, and
the co-ordinated functioning of groups of nerves is possible, while
at the same time the degree of corupartmentation is such as to afford
the processing of unrelated data concurrently.
This intermediate state is that of the normal working brain
during arousal; the hypothetical state of hypofluidity is in fact
found in the case of barbiturate intoxication, and a hyperfluid
state is displayed for example in epilepsy with its typical breakdown
of cowparteentat ion of function, or in the state of spreading
depression, and possibly in the states of aynaesthesia and hallucination.
The electrical fluidity of a nerve network can also be manipulated by
such techniques as kindling, where the seizure threshold is gradually
reduced by a course of sub-convulsive thalamic shocks (327). It may
also be the case that the learning process and memory consolidation
are the result of a controlled increase of electrical fluidity in
specific circuits, but this is outwith the scope of this thesis.
There is, therefore, a degree of electrical fluidity optimal
to cortical function, above or below which data handling is impaired.
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It is also appropriate here to discuss some of the prevailing
theories of neuronal interaction, specifically the category of
neuronal synchrony.
Various mathematical models have been constructed in attempts to
explain aspects of the behaviour of the CNS. One project, perhaps
the earliest, was developed by Selfridge (311). His model consisted
of a network of units all possessing the following characteristics;
first, a uniform speed of conduction, second a refractory period, and
third an "all-or-none" type of firing response. His model was in
fact designed to investigate the transmission of electrical information
in the myocardium, but could equally be applied to the study of the
brain. He found that in such a conducting network, certain types
of stimulus could initiate rhythms of electrical activity
synchronising the firing of large groups of units. These rhythms
could be damped by the introduction of new inputs, provided these
were not in phase with the standing rhythms, and strengthened by a
reduction of input, or by further in-phase input. The procedures
tending to strengthen standing rhythms could be exemplified by the
effects of eye-closure on a-rhythms already mentioned, and the form
of spilepsy known as flicker-epilepsy induced by specific rhythms of
visual input. These could be taken as representing a decrease in
input, and the superposition of an in-phase input respectively.
The stimulation of various sub-cortical areas, including the
nucleus tractus solitarius (513) or raphe nuclei, and certain thalamic
nuclei, can also induce cortical synchrony. The cortical synchronies
developed in the four stages of non-REM sleep, and which are used to
characterise each stage, are partly generated by a direct synchron¬
ising" tone of the raphe itself; howover, the reduction in cortical
input is also critical. Koella and Czicman have demonstrated that
raphe activation causes an Inhibition of activity of the reticular
activating system (HAS) (307), so the raphe exerts a dual effect on
the cortex's tendency to synchrony. in addition, the abolition of
visual input is probably also important. The HAS itself generally
exerts a desynchronising tone on the cortex; stimulation of the HAS
in cats has been reported to cause increased vigilance, with an
increase in sensitivity to stimuli of all sorts (424). Conversely
lesions of this system result in a state of hypersomnia and cortical
hypersynchrony (Lindalay, 422). The actions of the raphe and HAS on
the cortex then appear to be diametrically opposed, and the state
of cortical arousal at any one time will be a reflection of, amongst
other things, the balance of raphe and HAS tone.
It is also interesting to note here that the RAS, in
desynchronising the cortex, increases the data-handling capacity.
A novel stimulus, which arrives at the cortex, is firstly recognised
as novel, and then a train of events develops known as the
orientating reflex; the cortex sends information to the HAS which
responds by amplifying this signal and relaying it back to all areas
of the cortex resulting in the general arousal which can be caused by
apparently non-intense stimuli CiUfl* «
Flicker epilepsy has been mentioned above as an example of
reinforcing input creating synchrony in a neuronal matrix. Strobe
illumination is not only effective at awakening existing epileptic
foci, but also elicits epileptiform EEG abnormalities in 4 per cent
of am-epileptlc subjects (546). This has been Interpreted by some
workers to mean that the safety margin between normal and epileptic or
oscillating modes of brain function may be relatively slight (549).
in the design of complex serve-mechanisms, unintended and
destructive oscillation is recognised as a significant hazard. The
brain is by its complexity vulnerable to this type of malfunction,
as oscillatory behaviour could in theory develop at any level from
the simple circuit to three-dimensional nerve matrices. If this
view is valid, it indicates that attempts to isolate one malfunctioning
unit as the cause of the oscillation are doomed to failure, as the
oscillation is rather the property of the oscillating system.
Analogously, as epilepsy could refer to oscillations in any of an
infinitely wide range of levels of circuit, this would seem to
indicate the inadvisability of attempting to manipulate sub-systems
selectively. It is interesting to note here that the most potent
anti-convulsants, as mentioned earlier, have a very wide range of
effects; indeed their efficacy may depend on their spectrum of
actions on a wide range of sub-systems. Alternatively, one could
postulate that all the anticonvulsants exert, amongst their other
effects, one action on seme property common to all sub-systems, for
example the transmission of the action potential.
In situations where the overall system is the product of a dynamic
equilibrium of sub-systems, any relationship between the functioning
of the system and that of one of the sub-systems need not be a first-
order one. Each sub-system may operate over a wide range, only
certain values of which are optimal in terms of the functioning of
the system, performances above or below this range resulting in a
deterioration of performance of the system. This may explain
findings by Kellog (512), that both increasing or reducing central
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amine levels bad the effect of raising seizure threshold.
The more complex the arrangement of sub-systems, the greafe-jr
the redundancy in those sub-systems, the greater become the possibilities
of absorbing and adjusting to changes in the input to, and via, the
various sub-systems. However, this is offset by another rule of
systems behaviour derived by Aahby (323), Mho stated that a system
tends to be dominated by its least stable sub-system. And this
suggests that in certain epilepsies a specific therapy may in fact
be useful - for example, in the model of the audiosensitive mouse,
where the low seizure threshold has been associated with a deficient
serotonergic system, treatments to raise centra1 5HT levels have
proved very effective at raising the seizure threshold. Interestingly
enough the diurnal fluctuations of the threshold in this model have
been shown by Schneider and Schlessinger (52) to follow the clrcadlan
rhythms of the 5HT system; of all the known central arainergic
neuronal systems this appears to be the least stable, NAd and DA
systems showing no such involvement.
I would like to suggest that the neuronal behaviour involved in
generating the epileptic condition can be described as a consequence
of a pathological increase in the electrical fluidity of the areas of
brain involved. Again let me cite the case of kindling, where the
epileptic condition appears to be a result of the gradual increase of
electrical fluidity during the kindling treatment.
If rats are given daily shocks in the amygdala at current levels
high enough to produce an after-discharge but too low to elicit any
motor response, this procedure over a period of 1-2 months encourages
the progressive development and exacerbation of stimulus-induced
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epilepsy. As the procedure continues the electrical resistance to
spread decreases until, at 6-7 months, a condition is produced
characterised by spontaneous motor seizures (327).
At this stage in the discussion it becomes ecossary to return
again to the relationship between central 5HT systems and the state
of cortical arousal, or the data handling capacity of the cortices,
a parameter which I have already suggested is linked to the factor,
electrical fluidity.
Jouvet and Pujol (511) have shown that intracaretid injections
of 5HT in the cat cause a marked cortical hyperaynchrony, and sedation.
The increased synchrony, as we have already explained, indicates a
reduction of the temporal and spatial variation in the neuronal
matrices of the cortices, and therefore a reduction in data-handling
capacity - hence the sedative effect.
The hypersynchrony is probably mediated by cells in the area
postrecta, as the hyjx?rsynchrony and sedation can also be elicited by
topical application of 5HT to this area (337, 338, 511). Fibres
can be demonstrated leaving this area, entering the nucleus tractus
solitaries; appropriate stimulation of this tract will also cause
cortical hypersynchrony and sedation (339, 513). A severe state of
insomnia can be precipitated in the rat by the tryptophan hydroxylase
inhibitor, para-chlorophenylalanine: this insomnia is reversed by the
oral or Intravenous administration of 5-HTP, which is metabolised
centrally to 5-HT in the depleted but otherwise undamaged serotonergic
neurones (594).
Some delicate electrophysiological studies have shown that






































































































































inactive during waking and REM sleep (340). Further evidence of the
role of 5HT systems in determining the state of cortical arousal is
provided by cortical perfusion studies; sleep, or states of cortical
depression are associated with increases in cortical 5HIAA production,
and increased cortical 51TT levels (52).
These data all suggest that the activity of the serotonergic
system has a direct influence on the degree of cortical synchrony,
and the data-handling capacity of the cortices. It must be admitted
that it is not always possible to guarantee the specificity of various
pharmacological treatments; for example para-chlorophenylalanine (PCM)
as has already been described, also inhibits tyrosine hydroxylase, and
may in consequence lower the tone of NAd and DA systems as well as of
5-HT systems. Furthermore, it would probably be a mistake to think of
the serotonergic system (namely the raphe nuclei and their projections)
as either biochemically or functionally homogenous. For example,
certain nuclei within the raphe are more sensitive than others to the
5-HT-depleting action of para-chloroataphetamine (PCA), notably nucleus
B0 (282). There is also a report (283) of preferential degeneration
of the B9 nucleus after PCA. Similarly, although the projections of
the various anterior raphe nuclei reach all areas of the cerebral
cortices, the degree of involvement of each nucleus may determine the
areas of cortex involved. Although the effect of raphe stimulation
on all identified poat-aynaptic cells has so far been found to be
inhibitory (552), the selective withdrawal of specific units from a
nerve matrix could exert a wide range of effects.
A part of the data presented above is assembled in figure A7 and
A8-10. The pictures are not complete - for example, NAd systems are
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also involved, as sectioning the noradrenergic dorsal bundle has been
shown to increase cortical and raphe 5HT synthesis, with consequent
hypersynchrony and hypersomnia (511). Other systems may be involved.
Figure A10 shows how the factors cortical synchrony, data-handling
capacity, and electrical fluidity (E.f.) are related.
The following further comments regarding these figures may be made.
0. Hill (personal communication) finds that analyses of EEC
recordings of cobalt-implanted rats show that spikes develop most
frequently from the rising (surface negative) phase of synchronous
events, thus indicating that the pathological synchrony is in some
way facilitated by specific aspects of apparently normal synchronous
behaviour.
The basic form of figures Ag and A9 is obtained as follows:-
at the theoretical value of zero E.f., when all neurones are effectively
isolated, no information can be processed by the nerve net. At
maximal values of E.f. when all electrical events are transmitted
through the entire net, compartmentation breaks down and again data-
handling is reduced. The state of optimal data handling must
represent therefore a value of E.f. somewhere between these two
conditions, and the factor E.f. has been defined with this in mind.
Using the above definition of E.f., it becomes possible to
justify the inclusion of manic and hallucinatory states in the graphs.
Hallucinations if one accepts a circuital basis for information storage,
represent an abnormal processing of data, an activation of inappropriate
and normally unrelated circuits, and therefore an alteration in the
spatial co-ordinate of the E.f. value.
Mania and depression on the other hand are also represented in
these figures as states associated with altered E.f. values, but in
these states the temporal co-ordinate of E.f. is probably more
important.
Of the two states depression is perhaps the better documented.
Firstly there is some electrophysiological evidence that at least
certain types of information processing are slowed; Shagass and
Schwartz (555) have found that the refractory period between stimuli
in the sensory evoked response model is significantly greater in
depressed patients, indicating a reduced temporal component, and
this is perhaps one of the factors underlying the findings of a
decrease in mental and psychomotor speed in bipolar depressives (556).
and the subjective feelings of slowness, retardation and inhibition
associated with depression. Bipolar depressives also appear to
display a more highly synchronised EEC when in the depressed pbase
(557).
The literature concerning mental and psychomotor performance in
mania is contradictory. Kraepelin (558) reported an increase in
work and mental performance in the early stages of mania, with
performance falling as the mania increased; this is similar to
improvements found by Weiss and Laties (559) after small doses of
amphetamine. However Blackburn (056) found no significant increase
in mental and psychomotor performance in manic patients. The
available neurophysiological evidence is scanty. Dr. A.I.M. Glen
(personal communication) has found that the rate of peripheral nerve
conduction is slightly elevated in manic patients, and returns to
lower, normal values if lithium is administered, the change occurring
in step with the clinical improvement.
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Again assuming the circuital basis of information storage, this
suggests that the temporal co-ordinate of E.f. may be elevated in mania.
The manic phase is associated with a relatively desynchronised EEG (557).
Not only the extent of synchrony, but also the particular rhythms
involved, are apparently associated with various states. The two
factors are probably connected; G. Hill (personal communication) has
suggested that the frequency of a synchronous field is in part deter¬
mined by the number of active units in that field, such that an inverse
correlation exists between frequency and number of neurones involved.
In mania the reduced synchrony is associated with a downwards
shift in the dominant a-rhythm frequency (557), and this has also
been found in ethanol-induced stupor (560). Conversely, an
elevated a-rhythm is found in depression (557) and the hallucinatory
state elicited by LSD (561).
It must be noted that, like the electrical fluidity factor,
the 'synchrony' axis as used here is only quantitative, and cannot
distinguish between the normal synchrony of sleep and the
uncontrolled synchrony of epilepsy. These two states are patently
different with respect to both the underlying biochemistry, and
circuitry. The diagrams are therefore merely descriptive, and
not suitable material to base predictions cm.
In the condition of epilepsy it is generally assumed that the
•spike' represents the aummated response of a large population of
damaged or affected neurones firing in pathological synchrony. In
the healthy animal, as we have seen, the tendency for cortical cells
to develop synchrony is affected by various factors including the
activity of the raphe with its wide-spread projections to all parts
of the cortex. The cobalt rat for example, when placed in the
recording cage, displays an initial phase of exploratory behaviour.
Then if left to itself, it becomes quiet, sleepy, may even fall
asleep, and it is during this stage that spikes tend to appear, or
become most prominent. If the rat is aroused the incidence of
spiking falls. This may be analagous to that group of patients who
display an increased tendency to developing fits when drowsy, just
before sleep (30S, 306), another' argument that tendency to cortical
pathological synchrony is affected by raphe tone. In fact 'sleep'
epileptics are reckoned to constitute 45 per cent of all Grand Mai
patients (308, Janz) although other workers find smaller percentages
(516). The site of the focus appears to be important in determining
whether the epilepsy is 'sleep', 'awake' or 'random'. Frontal foci tend
to be
/associated with ' epilepsp, )D&rietal foci are associated with
'random' epilepsies (308). In fact the degree of raphe tone appears
to be quite critical; sleep epileptics display two peaks of fits during
sleep, the first just after falling asleep, the second occurring during
early morning sleep (390, 400).
Even more specifically, an analysis of the incidence of fits
during different stages of sleep reveals that fits tend to develop
only in stages 2 and 3, not in stages 1 and 4; in other words some
synchronies are more prone to epileptic triggering than others.
A few experiments have also been done in epilepsy models which
broadly agree with these findings. For example, Cohen et aJL (535)
have established that the electroconvulsive threshold in the cat is
at its lowest during slow-wave sleep; and in the cobalt focus in the
rat, Colasanti et al. (536) demonstrated that, with the exception of
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the period of continuous spiking, seizure activity was maximal at the
beginning and at the end of non-REM sleep episodes. Wyler et al.
(591) have reported an elegant series of individual cell recordings
in the chronic alumina focus in undrugged monkeys and have shown that
cells that behave as epileptic cells by firing in bursts do so for
longer and at a higher frequency during sleep, and that sleep spindles
which are associated with doublet or triplet firing in normal cortical
neurones, were shown to elicit exaggerated bursts in the epileptic
neurones.
Finally, and very significantly in the light of the description
of epileptic behaviour as a pathological extension of synchrony,
G. Hill (personal communication), after performing various types of
analysis of EEG recordings from cobalt-implanted rats, finds that the
spike is most likely to occur from the rising component or the peak
of a minor synchronous event.
In many patients synchronised sleep acts as a convulsant; as
the cortex develops slower rhythms, the appearance of generalised
bilateral hypersynchronous behaviour increases (314, 315, 316).
Some focal epilepsies are also aggravated (314, 317). Oesynchronised
REM sleep, on the other hand, is associated with the abolition or
reduction of various focal and generalised bilateral epileptic discharge
patterns (318). It is also suggestive that workers in this field
have established that the tendency of discharges to spread, in other
words the spatial component of electrical fluidity, is also affected
by the different types of sleep synchrony. Ferria et al. 1966 (328)
and Schwartz et al., 1964 (317) both established that during synchronized
sleep, the interictal discharges from focal epilepsies extended over a
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wider area of the cortex than during wakefulness, spreading in some
cases to the secondary focus. Conversely, during desynchronised REM
sleep, interictal discharges display maximal localisation. In this
case therefore electrical fluidity appears to vary directly with the
degree of synchrony. Other workers have noted the similarities
between the EEG activity of sleeping brain and epileptiform discharges.
Both are considered to be manifestations of widespread, synchronous,
episodic neuronal activity (Creutzfeldt et al. 1966, 382), possibly
sharing brain mechanisms for diffuse distribution. Skinner and
Lindsley (383) and Juko et_ al. (384) showed more recently that it was
possible to suppress sleep spindles unilaterally by ipsilateral
lesions of the rostral thalamus and underlying inferior thalamic
peduncles. If these lesions exert their effect on sleep spindles
by reducing the propensity of thalamic and cortical neurones to
become involved in synchronous discharge, they may also influence
epileptic behaviour.
Feeney and (Jullotta, 1972 (381) used a similar preparation of a
unilateral rostral thalamus lesion to examine the effects of such
treatment on the seizure threshold. They found that after infusing
pentylenetetrazole to the point of seizure, the frequency of discharges
in the cortex ipsilateral to the lesion was significantly lower than
on the contralateral side. This was not apparently due to a general
cortical depression as evoked stimuli to light were not altered.
Focal epilepsy in penicillin-induced foci was also inhibited on
the cortex ipsilateral to the lesion; and there are tsaa reports in
the literature on the clinical use of this operation, both of which
report improvement and some cases of complete suppression of clinical
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seizures in Petit Dal and Grand Mai. (Mullen et al., 1967, (386),
Spiegel et al., 1951 (386)).
These lesions may act by altering the functional state of the
remaining thalamo-cortical circuitry; they suppress the excitability
of non-specific thalamic nuclei which are considered important for
the wide-spread co-ordination of synchrony (Anderson and Manson, 1971,
(387), Purpura, 1970, (388)). More recent work by Feeney and
Gullotta (534) has centred around the use of high frequency stimulation
of the caudate nucleus and they find that this treatment in the cat
has a generally deaynchronlsing effect on cortex and suppresses sleep
spindles and also lnterictal discharges froia cortical penicillin-
induced foci.
The cortical recruiting response, another index of cortical
electrical fluidity, produced by the stimulation of various thalamic
nuclei, is also abolished by the desynchrony of KEN sleep (319 to 321).
The concept of different cortical states being more or less
conducive to epileptic behaviour may have clinical implications.
Sterman et al. (537, 538), using biofeedback techniques, have trained
cats to develop sensori-motor rhythm (SMR) (12-16 Hz), and shown that
these animals have a significantly raised seizure threshold to
hydrazine with respect to control animals; cats trained to suppress
the SUR displayed a reduced seizure threshold. A clinical follow-up
has been published; Sterman et al. (639) showed that various epilepsy
patients, who were selected on the criterion that they were unamenable
to drug chemo therapy, developed a significant reduction in fits
after using biofeedback operant conditioning to increase STR activity.
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CONCLUSION
The raphe is, as we have seen, capable of exerting both directly
and Indirectly, a powerful synchronising tone on the cortex. It can
also vary this synchronising tone; it is not just an on/off control
but a range of control which is displayed in the four stages of sleep.
It seems not unreasonable to suppose that the raphe can also respond
to the degree of cortical synchrony, for in all physiological situations
of an effector link operating between an effector organ or system and
a target organ/system, a feed-back loop operates, involving a monitoring
apparatus that feeds information back to the effector so that it has
some way of maintaining its output at an efficient or physiologically
appropriate level. If the raphe can respond to the varying degrees
of cortical synchrony, can it also respond to the pathological
synchrony of epilepsy?
The results discussed in the 5ITT section indicate that the raphe
might be doing just this. The changes in cortical 5-HIAA concentrations
and in tryptophan hydroxylase activity in the raphe appear to develop
at too late a stage in the cobalt-Implanted rat to be associated with
the development of the epileptic foci, and in this respect the response
of the serotonergic system differs from that of all the other systems
so far examined in the cobalt-implanted rat. The fact that the
cortical changes develop bilaterally also suggests a response of the
serotonergic system as a whole, rather than a local involvement of
serotonergic nerve terminals associated with the foci.
To examine the possibility of the raphe acting "protectively" in
the cobalt-implanted rat, and possibly in other forms of epilepsy, it
would seem logical to continue the work reported in this thesis by
examining the effects of electrical stimulation of the raphe, and
surgical lesions of the raphe, on the tendency of the cortex to
develop epileptic signs.
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Changes in Monoamine-Related Enzymes in Cobalt-Induced Epilepsy
PAUL R. CLAYTON and PIERS C. EMSON
MRC Brain Metabolism Unit, University Department ofPharmacology,
1 George Square, Edinburgh EHS 9JZ, U.K.
The evidence that points to the involvements of aminergic neurons in epilepsy can be
divided into two sets. First, the work that indicates that drugs acting on amine metabo¬
lism can modify seizures, including data on the use of reserpine to lower brain amine
concentrations in animals (Schlessinger et al., 1968) and man (Pallister, 1959), and
p-chlorophenylalanine to decrease brain 5-hydroxytryptamine in rats (De La Torre &
Mullan, 1970). These studies all demonstrated that a general decrease of amines tended
to increase susceptibility to epileptic seizures. This has been the subject of a review by
Carlsson (1974).
Conversely, drugs that potentiate the activities of brain amines, including monoamine
oxidase inhibitors (Prockop et al., 1959) or tricyclic anti-depressants (Lehmann, 1967),
have at least moderate protective effects. Recently this series of data has been refined into
an analysis of the roles of the different amines; dopamine (3,4-dihydroxyphenethylamine)
and noradrenaline are now thought by some workers to exert opposing influences on an
epileptic focus, inasmuch as dopamine and its agonists can be shown to decrease
'spiking' in the cobalt model, whereas noradrenaline agonists have the reverse effect
(Ashcroft et al., 1974).
The second set of information consists of work that indicates that an alteration in the
concentrations of brain amines, presumably parameters ofa functional change in specific
cortical circuits, occurs in the development of audiogenic seizures (Schlessinger et al.,
1967) and in cobalt epilepsy (Emson & Joseph, 1975). However, other workers have
found no changes in brain amines related to epilepsy (Hansen et al., 1973), so the case
cannot be said to be by any means complete.
In an attempt to clarify the problem of amine involvement in epilepsy, a study was
undertaken of the following amine-related enzymes in the cobalt model (Dow et al.,
1972): tyrosine hydroxylase, catecholamine O-methyltransferase and monoamine oxi¬
dase. y-Aminobutyrate aminotransferase was also investigated. The purpose was to use
these enzymes as cell markers to study the integrity of aminergic circuitry in the cortex
around a cobalt focus, and to ascertain whether these specific neurons could be demon¬
strated to react differentially.
Tyrosine hydroxylase was assayed by the method of Hendry & Iversen (1971), it
being assumed that this would be the most specific marker for noradrenaline neurons,
and the catechol O-methyltransferase (Axelrod & Tomchick, 1958) and monoamine
oxidase (McCaman et al., 1965) assays were mainly corroborative. y-Aminobutyrate
aminotransferase was examined (Hall & Kravitz, 1967) in the hope that it would
provide data on the integrity of local inhibitory gabaminergic fibres and their postulated
role in the eventual suppression of a focus, and also as an index of the glial reaction
that is associated with the cobalt implant.
Histological studies of the cobalt model done in our laboratory (Emson & Joseph,
1975) by using the Fink-Heimer (Fink & Heimer, 1967) technique have demonstrated
degenerating terminals, axons and cells around the primary lesions after 4 days,
extending to the 29th day after implant, at which time spikes are still present in the
electrocorticogram. Other enzymes so far studied, including glutamate decarboxylase,
choline acetyltransferase and aromatic amino acid decarboxylase, tend to follow a similar
pattern, reaching their lowest activities in the primary (1°) focus at around day 8 and re-
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covering at 24 days. It is probable that these changes, which are reflected in the secondary
(2°) focus to a lesser extent, represent a specific neuronal involvement; lactate dehydro¬
genase, a cytoplasmic enzyme, is only decreased in the lesion area, and is not a part of
the pattern of 2° focus development at all. The rate of spiking is inversely correlated
with these findings, reaching a peak at days 8-12 and decreasing towards day 24, and
probably reflects the enzyme picture (Emson & Joseph, 1975).
Of the enzymes studied, only y-aminobutyrate aminotransferase returned to normal
activity at around day 30 (Fig. la); the peak activity of y-aminobutyrate aminotrans¬
ferase occurring in the 1° focus, and to a lesser extent the 2° focus, at around day 9, prob¬
ably indicates the intense glial reaction that is developing at this stage.
The pattern of changing y-aminobutyrate aminotransferase activity agrees well with
those studies ofenzymes already carried out, and with the general time-course of cellular
degeneration (Emson & Joseph, 1975). However, tyrosine hydroxylase activity (Fig. 1 b)
is still low at 30 days, at only 30% of control values. Monoamine oxidase and catechol¬
amine O-methyltransferase activities are also low, at 20% and 40% respectively of con¬
trol value. All these enzymes appear to have returned to normal by days 75 and 100, and
the fact that they all share a similar time-course, and at 30 days are proportionately
very similarly affected (20%, 30% and 40%), could indicate that noradrenaline neurons
do not regrow into the area of an epileptic focus at the same rate as, for example, cholin¬
ergic neurons or cell regeneration in general (Emson & Joseph, 1975).
These results could be due to either an increased susceptibility to Co2+ or a genuinely
slower rate of repair; the fact that this pattern is also found in the 2° focus, where Co2+ is
probably not involved, tends to support the latter.
The rate of spiking in a 1° or 2° cobalt focus, followed over a period of some months,
tends to form a distinct pattern. Firing rates reach a peak at 8-12 days and then decrease
over the next 20 days, until at day 30 they are at 10-15 % of the peak values. After day 30,
spiking continues to decrease, though less rapidly, over a period of several months. It
could be that this apparently biphasic response represents an initial intracortical
phenomenon during the first month, involving cholinergic and gabaminergic fibres in
the suppression or resolution of the focus, followed by a slower regrowth of aminergic
Fig. 1. y-Aminobutyrate transaminase (a) and tyrosine hydroxylase (b) activities in the
frontal cortex of cobalt-treated rats
t, Primary focus; •, secondary focus.
3 6 9 12 30 75 0 3 6 9
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fibres from outside the cortex. The time-course for central-nervous-system regrowth has
been found by many workers to be of the order of 50-100 days, for example, the re-inner-
vation of the tongue after hypoglossal axotomy (Sumner & Sutherland, 1973). This
correlates reasonably well with the rates of return to normal of the aminergic enzymes.
To extend these results, data on cortical and striatal concentrations of noradrenaline,
dopamine and 5-hydroxytryptamine are being collected.
P. R. C. is a Medical Research Council research student, and P. C. E. is a Beit Memorial Re¬
search Fellow.
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The Effect of Neurotransmitter Release upon Phospholipid Composition
and Fatty Acid Turnover in Synaptic Vesicles of Torpedo marmorata
Electric Organ and Guinea-Pig Cerebral Cortex
R. ROY BAKER, MICHAEL J. DOWDALL and VICTOR P. WHITTAKER
Abteilung fur Neurochemie, Max-Planck-Institut fur Biophysikalische Chemie,
D-3400 Gottingen-Nikolausberg, Am Fassberg, Postfach 968, West Germany
It has been reported that lysophosphatidylcholine can promote the fusion oferythrocytes
and fibroblasts in vitro (Poole et al., 1970) and, further, that high concentrations of this
lysophosphoglyceride exist in chromaffin granules isolated from adrenal medulla
(Blaschko et al., 1967). Thus it has been proposed that this lysolipid may be involved in
exocytosis, the mechanism whereby compounds stored in intracellular vesicles or gran¬
ules are released to the extracellular medium (Poole et al., 1970; Winkler et al., 1974).
Some support has been given to this proposal by the demonstration of phospholipase A
activities in synaptic-vesicle fractions isolated from brain (Heilbronn, 1972; Gullis &
Rowe, 1973). Yet a number of other types of vesicle have only low concentrations of
lysophosphatidylcholine [as cited by Winkler et al. (1974)], and an enhanced turnover
of [32P]orthophosphate and [l-14C]glycerol has not been demonstrated in lyso¬
phosphatidylcholine of adrenal-medulla slices stimulated by acetylcholine (Trifaro,
1969).
The present communication is based on a more detailed investigation of the possible
involvement of lysophosphatidylcholine or other lysophosphoglycerides in synaptic
vesicles during the release of neurotransmitters. For this purpose we have analysed
synaptic vesicles from Torpedo marmorata electric organ and guinea-pig cerebral cortex.
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In the first part of these investigations the electric organ was stimulated electrically in
vivo, and crude synaptosomal fractions from cerebral cortex were incubated in vitro in
the presence of 50mM-KCl, a treatment known to cause the release of transmitters (de
Belleroche & Bradford, 1972). Synaptic vesicles were then isolated (Whittaker et al.,
1964, 1972) and their phospholipid compositions compared with those of controls. In
further studies, crude synaptosomal fractions from cerebral cortex were incubated in the
presence of labelled fatty acids and glucose and 50mM-KCl to determine if an enhanced
turnover of radioactivity could be demonstrated in vesicles during neurotransmitter
release.
The percentage compositions of the phospholipid fractions extracted from synaptic-
vesicle preparations from electric organ and cerebral cortex are given in Table 1. It was
found that electrical or 50mM-KCl stimulation did not significantly alter the phospho¬
lipid compositions of the vesicles. Lysophosphatidylcholine was the only lysophospho-
glyceride demonstrable and its low concentration did not increase as a result of
stimulation. Thus we conclude that there is no demonstrable generation of lysophospho-
glyceride in synaptic vesicles as a result of neurotransmitter release.
Control experiments assessed the activities of enzyme markers in the vesicle fractions,
the release of acetylcholine during stimulation and respiratory rates of the incubated
samples.
To pursue the possibility of a rapidly turning over lysophosphoglyceride which is
maintained at a very low concentration in synaptic vesicles, the labelling of vesicular
phospholipid by radioactive fatty acids and radioactivity derived from glucose was
studied by using the synaptosomal fraction from cerebral cortex. Generally, as measured
by the specific radioactivities of phosphatidylcholine, phosphatidylethanolamine,
phosphatidylinositol and phosphatidylserine, the presence of 50mM-KCl in the incuba¬
tion medium did not result in a significantly enhanced incorporation of [l-14C]oleate,
[l-l4C]arachidonate, [9,10-3H]palmitate or radioactivity derived from [l-3H]glucose
into vesicular phospholipid. Thus we conclude that there is not an increased turnover of
Table 1. Phospholipid compositions ofsynaptic vesicles and the effect ofneurotransmitter
release
Results are expressed as percentages of total phospholipid phosphate and as means±s.D.
There were three separate determinations for each analysis. Guinea-pig synaptosomal
fractions (P2) were incubated with (Stimulated) and without (Unstimulated) KC1 (50 mM)
for 15min in vitro after a 15min preincubation period. Torpedo electric organ was stimu¬
lated electrically in vivo (Stimulated) at 5/s for 30min through electrodes placed on the
electric lobe (Zimmermann & Whittaker, 1974); a denervated organ served as control
(Unstimulated).
Percentage of total phospholipid
Torpedo vesicles Guinea-pig vesicles
Unstimulated Stimulated Unstimulated Stimulated
Lysophosphatidyl¬ 0.4 ±0.3 0.3 ±0.2 0.6 ±0.2 0.5 ±0.1
choline
Sphingomyelin 5.1 ±1.6 5.6 ±1.5 6.2 ±0.6 6.6 ±0.6
phosphatidylcholine 46.6 ±3.2 44.9 ±1.0 38.8 ±0.2 39.2 ±0.4
Phosphatidylinositol 5.1 ±1.1 4.6 ±0.3 3.8 ±0.3 3.5 ±0.3
Phosphatidylserine 12.6 ±2.3 11.5 ±0.7 12.8 ±0.8 12.6 ±1.2
Phosphatidylethanol¬ 29.5 ±2.6 32.8 ±3.5 37.1 ±0.8 36.7 ±0.6
amine
Phosphatidic acid 0.6 ±0.1 0.5 ±0.2 0.8 ±0.3 1.1 ±0.3
//mol of phospholipid 0.025 ±0.006 0.018 ±0.004 0.61 ±0.15 0.58 ±0.14
phosphate/g of tissue
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Spread of Cobalt from a Cortical Epileptic Lesion Induced by a Cobalt-Gelatine Implant into the
Frontal Cortex of the Rat
P. R. Clayton and P. C. Emson1
MRC Brain Metabolism Unit, 1 George Square, Edinburgh (Scotland), 7 May 1976.
Summary. The spread of cobalt ions from cobalt induced epileptic foci in rats has been investigated. Atomic absorption
spectrophotometry and heavy-metal histochemistry reveal cobalt ions spread very widely from the focus. Biochemical
and physiological consequences for this model of epilepsy are discussed.
Kopeloff et al.2 first reported that the application of
powdered cobalt metal to the frontal cortex of the monkey
produced epileptiform spikes in the electroencephalogram
(EEG). Since Kopeloff's original observation the ap¬
plication of cobalt powder to the cortex or the insertion
of cobalt gelatine pellets into brain has been used to
produce reproducible epileptic foci in a variety of ani¬
mals3. In the rat, application of cobalt to the cortex
produces a distinct secondary focus in the contralateral
cortex4'5. Because of the use of cobalt salts to trace
axonal pathways6 we were interested to know if the
secondary focus, formed in the contralateral cortex of
the rat did contain significant amounts of cobalt. If this
A) The distribution of sulphide silver positive material (heavy metals)
in the frontal cortex as revealed by the Timms method. Note the
uneven distribution of staining in the cortical layers.
were so then the value of this model would be reduced.
Previous workers using this model4'5 have suggested
that the secondary focus in this model arises as a response
to the spread of electrical signals from the primary focus
across the corpus callosum and represents a response
similar to the kindling phenomenon described by God-
dard'. The presence of significant amounts of cobalt in
the secondary focus would mean that it is probably solely
caused by the presence of cobalt ions.
Cobalt-gelatine pellets prepared as described by
Fischer et al.8 of standard size 1 mm diameter and max¬
imally 0.5 mm thick (representing at most 1 mg of cobalt
metal in gelatine) were inserted into the right frontal
cortex of male PVG rats as described in detail by Dow
et al.4. The histochemical distribution of cobalt ions
after this implant was investigated using the Timm9
staining method at 4, 28 and 60 days after implantation.
The rats were anaesthetized with an overdose of barbi-
1 Beit Memorial Fellow, MRC Neurochemical Pharmacology Unit,
Hills Road, Cambridge CB2 2QD, England.
2 L. M. Kopeloff, S. E. BaRRera and N. Kopeloff, Am. J.
Psychiat. 98, 881 (1942).
3 P. C. Emson, in Biochemistry and Neurology (Eds. H. F. Brad¬
ford and C. D. Marsden; Academic Press, New York 1976),
p. 163.
4 R. C. Dow, J. K. McQueen and H. R. A. Townsend, Epilepsia
13, 459 (1972).
5 R. S. Dow, A. Fernandez-Guardiola and E. Manni, Electro-
enceph. clin. Neurophysiol. 14, 399 (1962).
6 R. M. Pitman, C. D. Tweedle and M. J. Cohen, Science 176, 412
(1972).
7 G. V. Goddard, Nature, Lond. 214, 1020 (1967).
8 J. Fischer, J. Holubar and V. Malik, Physiologia bohemoslov.
16, 272 (1967).
9 F. Timm, Dt. Z. ges. gericht. Med. 46, 706 (1958).
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B
B) The effect of a cobalt-gelatine implant on the TiMM-staining
pattern of the frontal cortex. The rat was sacrificed 4 days after the
operation to implant the cobalt. Note the marked increase in stain¬
ing around the lesion, extending even in to the underlying caudate
nucleus. In the secondary focus (contralateral cortex) the staining
pattern seems more intense than in control sections incubated for the
same time (Figure A). However it was not possible to be certain that
there was definite increase in staining in the contralateral cortex.
C
1 • 5mm
C) A section through the centre of an established cobalt-epileptic
focus (28 days survival). Note the definite calcified glial capsule sur¬
rounding the lesion, seeming to act as a barrier to further diffusion
of cobalt. There is no longer any evidence of increased staining around
the lesion and in contrast there is a decrease in Timm positive material
outside the glial capsule.
Key to symbols on Figures B and C. d, area of cobalt diffusion;
i, cobalt implant; g, glial capsule.
turate and perfused transcardially with phosphate buf¬
fered sulphide solution. Cryostat sections of the frozen
brains were serially mounted and impregnated by phys¬
ical development as described by Haug10. The results,
of applying the TiMM-staining method to the frontal
cortex of rats 4 days after implantation revealed a marked
increase in the density of histochemical staining around
the cobalt-gelatine implant (Figure B) up to 2-3 mm in
each direction from the original implant. Increased
staining was evident in the cingulate cortex, corpus cal-
losum and caudate nucleus below the lesion. We could
demonstrate no unequivocal increase in staining in the
contralateral cortex or secondary focus and the staining
pattern in the contralateral cortex does not differ signif¬
icantly from control sections (Figure B). The laminar
pattern of stainable material agrees with previous ob¬
servations10 but the significance of the staining pattern
is not understood. By 28 or 60 days (Figure C) the primary
focus has become surrounded by a calcified glial capsule
and no histochemical evidence of cobalt spread outside
the glial capsule is evident. In fact by 28 days the glial
capsule seems to provide a barrier to further spread of
cobalt and this may account for the regression of the
epileptic focus2'11. At no time during the development
and regression of the cobalt focus could we be certain
from histochemical staining that there was a spread of
cobalt ions into the contralateral cortex, although we
suspected this was occurring.
In order to further investigate the possible spread of
cobalt we used atomic absorption spectrophotometry.
This method would allow unequivocal demonstration of
cobalt ions in the contralateral cortex if these were
present. A Perkin-Elmer atomic absorptiometer, model
HGA 360 was used and samples were read at a wavelength
of 240 nm. Weighed pieces of brain were digested in con¬
centrated HNOs and 20 p.1 of digest representing 1 mg of
tissue was injected into the furnace. Using this program
no loss of cobalt was detected during either the evapora¬
tion or ashing stages. No traces of cobalt were found in
the reagents or incubation vessels. Known amounts of
cobalt 1-50 ppm were taken through the procedure to
provide a standard curve against which tissue data could
be evaluated.
The results of these determinations are shown in the
Table. Notice particularly the atomic absorption results
show clearly that cobalt spreads extremely widely from
the lesion site. At day 6 cobalt is found in significant
amounts in the secondary focal area, in the occipital
cortex both ipsi- and contralateral to the lesion site and
also in the raphe nuclei some 1.5 cm from the cortical
lesion site. The results are consistent with cobalt ions
diffusing or being transported away from the original
lesion to establish a gradient of cobalt through the brain.
The amount of cobalt which spreads by diffusion is not
likely to be very extensive outside the original lesion and
it is probable that the majority of cobalt is spread to the
rest of the brain by axonal transport. In agreement with
this suggestion the levels of cobalt in the contralateral
caudate follow closely the levels in the overlying frontal
cortex with which it has connections. By day 21 the
cobalt levels in the contralateral frontal cortex are signif¬
icantly lower (1.8 ± 1.4 ppm) than the cobalt levels in
the contralateral occipital cortex (5.3 ± 4.7 ppm) prob¬
ably as a result of the extensive degeneration of neurones,
axons and terminals in the ipsilateral frontal cortex and
consequent reduction in transport. At day 21 there is
10 F.-M. S. Haug, Z. Anat. EntwGesch. 145, 1 (1974).
11 P. C. Emson and M. H. Joseph, Brain Res. 93, 91 (1975).
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Cobalt concentrations in ppm (dry matter) F SD of the mean
Cortex Caudate nuclei Raphe nuclei
Frontal Occipital
Lesion Contralateral Ipsi- Contralateral Ipsi- Contralateral
Day 6 >50 ppm 10.5±5.5 16.8±7.5 12.1±6.2 19.9±5.3 10.0±6.6 3.0±1.9
Day 21 >50 ppm 1.8±1.4 7.9±4.7 5.3±4.7 6.1±3.9 1.98F0.8 2.4±1.6
Day 97 No detectable cobalt
There were 5 rats in each group. In all cases the glial capsule and any visible traces of cobalt-gelatine were removed from primary lesion
samples. It was often not possible to remove all traces of the cobalt-gelatine, however, and therefore physiologically inactive cobalt may
well have been assayed in the primary lesion. Excess values referred to represent values of over 50 ppm and were not quantified. Control
rats and 97 day rats were assayed under the same conditions as the day 6 and 21 rats (see text) and under these condition no cobalt could
be detected.
still significant cobalt in the brain outside the implant.
However by day 97 there is no longer detectable cobalt
in brain areas outside the glial capsule.
The implication of these results, for this and related
models of epilepsy, are profound. Although the in vitro
levels of cobalt (2-10 \±M) which would be obtained in
preparing a conventional brain homogenate (e.g. 1 mg
brain tissue in 10 jxl buffer) from an animal with a cobalt
implant would not be sufficient to inhibit in vitro the
enzymes we have previously studied (e. g. tyrosine hydrox¬
ylase choline acetyltransferase, glutamic acid decar¬
boxylase) 12. However, the levels in vivo (20-100 \j.M) will
undoubtedly interfere with a wide range of metabolic
process. In fact the wide spread of the cobalt ions and
the possibilities of their concentration in different cel¬
lular compartments, such as nerve terminals suggests
that a large area of the brain may become epileptogenic
rather than just a small area around the original implant.
These results indicate the need for caution in using heavy
metal implants as models of epilepsy and suggest that
the basis for cobalt induced epilepsy probably lies in a
certain selectivity of cells, terminals and enzymes to
the toxic effects of this ion in vivo. Certainly the second¬
ary focus produced in this model of epilepsy although
very interesting biochemically cannot be regarded as
being untouched by the toxic effects of cobalt.
12 P. R. Clayton and P. C. Emson, Biochem. Soc. Trans. 3, 261
(1975).
